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ABSTRACT 
The human immunodeficiency virus type-1 (HIV-1) is the leading cause of 
acquired immunodeficiency syndrome (AIDS) in the world. As there is no cure currently 
available to treat HIV-1 infections or AIDS, the major focus of drug development efforts 
has been to target viral replication in an effort to slow down the progression of the 
infection to AIDS. The aspartyl protease of HIV-1 is an important component in the viral 
replication cycle and thus, has been an important anti-HIV-1 drug target. Currently there 
are nine protease inhibitors (PIs) that are being used successfully as a part of highly 
active antiretroviral therapy (HAART). However, as is with all HIV-1 drug targets, the 
emergence of drug resistance substitutions within protease is a major obstacle in the use 
of PIs. Understanding how amino acid substitutions within protease confer drug 
resistance is key to develop new PIs that are not influenced by resistance mutations. 
Thus, the primary focus of my dissertation research was to understand the molecular 
basis for drug resistance caused by some of these resistance substitutions.   
Until recently, the genetic diversity of the HIV-1 genome was not considered to 
be important in formulating treatment strategies. However, as the prevalence of HIV-1 
continues, the variability of the HIV-1 genome has now been identified as an important 
factor in how the virus spreads as well as how fast the infection progresses to AIDS. 
Clinical studies have also revealed that the pathway to protease inhibitor resistance can 
vary between HIV-1 clades. Therefore, in studying the molecular basis of drug resistance 
in HIV-1 protease, I have also attempted to understand how genetic variability in HIV-1 
protease contributes to PI resistance.  
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In Chapters II, III and Appendix 1, I have examined how clade specific amino 
acid variations within HIV-1 CRF01_AE and clade C protease affect enzyme structure 
and activity. Furthermore, I have examined how these sequence variations, which are 
predominantly outside the active site, contribute to inhibitor resistance in comparison to 
clade B protease. With the results presented in Chapter II, I was able to show that 
sequence variations within CRF01_AE protease resulted in structural changes within the 
protease that might influence enzyme activity. In Chapter III, I focused on how sequence 
variations in CRF01_AE influence protease activity and inhibitor binding in comparison 
to clade B protease. Enzyme kinetics data showed that the CRF01-AE had reduced 
catalytic turnover rates when compared to clade B protease. Binding data also indicated 
that CRF01_AE protease had an inherent weaker affinity for the PIs nelfinavir (NFV) and 
darunavir (DRV). In work described in Chapter III, I have also examined the different 
pathways to NFV resistance seen in CRF01_AE and clade B protease. Using x-ray 
crystallographic studies I have shown the molecular mechanism by which the two 
different pathways confer NFV resistance. Furthermore, I provide a rational for why 
different resistance pathways might emerge in the two clades. In Appendix I, I present 
results from a parallel study carried out on clade C protease. 
In Chapter IV, I have examined the role of residue 50 in HIV-1 protease in 
modulating inhibitor binding. Patients failing amprevavir (APV) and DRV therapy often 
develop the I50V substitution while the I50L substitution is often observed in patients 
failing atazanavir (ATV) therapy. This indicates that by making subtle changes at residue 
50 the protease is able to confer differential PI resistance. With binding data presented in 
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this chapter I have shown that substitutions at residue 50 change the susceptibility 
profiles of APV, DRV and ATV. Furthermore, from analyses of protease-inhibitor 
complexes, I have described structural insights into how substitutions at residue 50 can 
modulate inhibitor binding. 
 This thesis presents results that reveal mechanistic insights into how a number of 
resistance substitutions within protease confer drug resistance. The results on non-B clade 
proteases demonstrate that clade specific sequence variations play a role in modulating 
enzyme activity and influence the pathway taken to confer PI resistance. Furthermore, the 
results provide structural insights into how amino acid substitutions outside the active site 
effectively alter inhibitor binding. 
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1CHAPTER I 
Introduction 
2 Since first identified in 1981, the Acquired Immunodeficiency Syndrome (AIDS) 
has become a serious public health concern and has resulted in major worldwide socio-
economic consequences. While the causative agent for AIDS was identified as the human 
immunodeficiency virus (HIV), there is no cure available for the treatment of HIV 
infection and AIDS at present (Barre-Sinoussi et al., 1983; Popovic et al., 1984). 
However, over a period spanning nearly three decades, a vast body of knowledge has 
been gathered on the biology of HIV and has lead to the discovery of a number of 
therapeutics and treatment procedures which have been successful in slowing the 
progression of HIV infections to AIDS. However, until a proper cure for HIV infections 
is available, continued study of the virus and the disease is essential to formulate proper 
treatment strategies and thereby improve the life expectancy of infected individuals.  
HIV and the AIDS pandemic 
 Over a span of nearly thirty years, HIV infection and AIDS have reached 
pandemic proportions with over 33 million people currently living with HIV (UNAIDS, 
2009). With the lack of a cure for HIV/AIDS over 2 million AIDS related deaths are 
reported annually making HIV/AIDS a major global health concern (UNAIDS, 2009). 
Currently available highly active anti-retroviral therapy (HAART) has proved to be 
effective in improving the life expectancy and quality of life of individuals infected with 
HIV. With the increased accessibility to anti-retrovirals across the world, the number of 
new HIV infections have stabilized over the past few years (UNAIDS, 2009).  
While HIV/AIDS statistics appear to have stabilized across the globe, the effects 
of the disease continue to be more prominent in resource poor settings of the world with 
3Sub-Saharan Africa and South and South-East Asia being the regions of highest 
HIV/AIDS prevalence in the world (Asamoah-Odei, Garcia Calleja, and Boerma, 2004; 
UNAIDS, 2009). Given that these regions are resource poor, setting up proper 
infrastructure to provide infected individuals access to affordable and continuous 
treatment is essential in order control the disease. Moreover, global efforts to educate 
people on disease prevention are vital to reduce the number of new HIV infections. 
Furthermore, a continued global effort is required to study and monitor the disease in 
order to develop better treatment strategies until a cure for HIV infections becomes 
available.  
Biology of HIV  
HIV was identified to be the causative agent for AIDS in the early 1980s (Barre-
Sinoussi et al., 1983; Popovic et al., 1984). It is now widely accepted that HIV has its 
origins in the simian immunodeficiency virus (SIV) found in west and central Africa and 
crossed species at some point in time (Sharp, Robertson, and Hahn, 1995). To date, two 
types of HIV have been identified: HIV-1 and HIV-2. Evidence has been presented to 
show that HIV-1 is closely related to SIVCPZ that infects chimpanzees while SIVSM, 
which infects sooty mangabey monkeys, is thought to be the closest relative of HIV-2 
(Gao et al., 1999; Hirsch et al., 1989; Huet et al., 1990). 
The HIV-1 genome is categorized into groups and clades that include subtypes, 
sub-subtypes and circulating recombinant forms (CRFs) based on phylogenetic analyses 
of envelope, gag, and pol regions of the retroviral genome (Los Alamos Laboratory, 
2010; Robertson et al., 2000). Through the course of HIV-1 infection in humans, three 
4distinct lineages have been identified. Group M (main or major) is the predominant form 
throughout the world while Group O (outlier) and Group N (non-M-non-O) are rare 
forms identified only in western-central Africa (Figure I-1A) (Kuiken et al., 2000; 
Robertson et al., 2000). Recently, a new group termed as group P, was described with the 
virus thought to be closely related to SIVGOR that infects gorillas (Plantier et al., 2009). 
To date, nine genetically distinct clades (A, B, C, D, F, G, H, J and K) and 43 CRFs have 
been identified within Group M (Los Alamos Laboratory, 2010).  Clade B, which 
accounts for about 12% of HIV-1 infections globally, has been the focus of the majority 
of HIV-1 studies over the years. However, the majority of global HIV-1 infections are a 
result of non-B clade viruses with clade C being the most prevalent form (Figure I-1B) 
(Osmanov et al., 2002). Clinical observations in patient populations with different clades 
have indicated that the HIV-1 clade plays a role in viral transmission, progression to 
AIDS as well as viral susceptibility to anti-retrovirals (Ariyoshi et al., 2003b; Grossman 
et al., 2004b; Holguin et al., 2006; Hu et al., 1999; Kanki et al., 1999a; Kiwanuka et al., 
2008). 
HIV is a lentivirus belonging to the Retroviridae family. A mature HIV virion 
carries two copies of a single stranded positive-sense RNA genome that contains at least 
ten viral genes: gag, pol, env, vif, vpr, tat, rev, vpu, nef and tev (Kuiken et al., 2008). Of 
these genes, the gag, pol and env genes code for viral structural proteins and viral  
5FIGURE I-1 
6FIGURE I-1 A. HIV-1 genomic classification (Los Alamos Laboratory, 2010; Robertson 
et al., 2000). B. Global distribution of the most prominent HIV-1 clades.  
.
7enzymes while the other genes code for accessory viral proteins (Kuiken et al., 2008; 
Subbramanian and Cohen, 1994; Wang et al., 2000). The virus primarily infects  
CD4+ T-lymphocytes, macrophages and dendritic cells (Alimonti, Ball, and Fowke, 
2003; Chan and Kim, 1998; Knight, Macatonia, and Patterson, 1990; Koenig et al., 1986; 
Orenstein, 2001). The infection is initiated by the virus fusing with the host cell and is 
followed by the release of viral components into the host cell cytoplasm (Figure I-2). The 
initial fusing of the virus with the host cell is mediated through the viral surface 
glycoprotein gp120, which interacts with a CD4 molecule and a co-receptor molecule, 
CCR5 or CXCR4, on the host cell surface (Chan and Kim, 1998; Dimitrov, 1997; Wyatt 
and Sodroski, 1998). However, a number of recent studies have observed that HIV 
particles can enter cells through receptor mediated and non-receptor mediated endocytic 
pathways (Fackler and Peterlin, 2000; Miyauchi et al., 2009; Pauza, 1991).  
 Once the viral components enter the cell the viral reverse transcriptase (RT) 
reverse transcribes the positive-sense RNA genome into its complementary DNA 
sequence. The HIV RT is extremely error prone and with the lack of a proof reading 
mechanism, accumulates a high number of mutations in the newly synthesized DNA 
strand (Bebenek et al., 1993; Preston, Poiesz, and Loeb, 1988; Roberts, Bebenek, and 
Kunkel, 1988; Takeuchi, Nagumo, and Hoshino, 1988). Thus, the error prone reverse 
transcription of the viral genome results in the high degree of genomic variability 
observed in HIV. 
 The reverse transcribed viral genome is then translocated into the cell nucleus 
where it is integrated with the host genome by the viral enzyme integrase (IN). The  
8FIGURE I-2 
 
9Figure I-2. A. Basic structural organization of an HIV-1 virion. B. Components of the 
HIV-1 viral genome. C. HIV-1 replication cycle (Flexner, 2007).  
10
integrated viral genome is transcribed into mRNA that is then translocated in to the 
cytosol. The mRNA transcripts are translated into Gag and Gag-Pro-Pol polyproteins, 
Env and other accessory proteins. These viral proteins, along with copies of the 
transcribed viral genome, are assembled at the host cell membrane and get packaged into 
immature virions that then bud out from the cell membrane (Navia and McKeever, 1990; 
Wang et al., 2000). While complete details of when the viral maturation process begins is 
not clear, there is evidence to show that once the immature virion has budded off, the 
viral protease (PR) cleaves the Gag and Gag-Pro-Pol polyproteins to release the structural 
components that then form the mature virus particle (Navia and McKeever, 1990).  
A number of host factors, such as TRIM5α and APOBEC3G, that are capable of 
counteracting HIV infections have been identified (Lama and Planelles, 2007; Sheehy et 
al., 2002; Zheng, Lovsin, and Peterlin, 2005). However, action of these host factors are 
either insufficient to suppress infections in humans or are counteracted by HIV viral 
proteins. Thus, targeting the HIV replication cycle has been a key focus in anti-HIV drug 
development to slow down the progression of the infection to AIDS.   
The HIV-1 reverse transcriptase and protease are two viral proteins to be 
successfully targeted by inhibitors very early in the HIV infection and AIDS pandemic. 
At present, there are thirteen reverse transcriptase inhibitors (RTIs) and nine protease 
inhibitors (PIs) that are being used successfully to prevent viral replication. Furthermore, 
in recent years, work on the fusion and integration stages of the viral replication cycle has 
resulted in two fusion and entry inhibitors and an integrase inhibitor that are now used in 
combination with RTIs and PIs. All currently available anti-HIV inhibitors are used as a 
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part of highly active antiretroviral therapy (HAART) where a combination of two or 
more inhibitors from different inhibitor classes is used to treat patients. HAART has 
proved to be a potent method to prevent viral replication as well as to suppress the 
emergence of drug resistant viral strains (Bonfanti, Capetti, and Rizzardini, 1999; Shafer 
and Vuitton, 1999).  
HIV-1 protease 
 The aspartyl protease of HIV-1 is an essential component in the replication cycle 
of the virus (Debouck and Metcalf, 1990; Kohl et al., 1988). HIV-1 protease is a homo-
dimeric aspartyl protease with 99 amino acids in each monomer (Figure I-3A-B). The 
catalytic active site is formed at the dimeric interface with aspartic acid residues at 
position twenty-five in each monomer catalyzing the cleavage reaction (Berg, Tymoczko, 
and Stryer, 2007; Liu, Muller-Plathe, and van Gunsteren, 1996). While the complete 
details of the mechanisms by which HIV-1 protease cleaves substrates is not very clear, a 
general acid-base catalysis mechanism has been proposed based on a number of structural 
and enzyme kinetics studies (Brik and Wong, 2003; Hyland, Tomaszek, and Meek, 1991; 
Hyland et al., 1991; James et al., 1992; Parris et al., 1992; Pearl, 1985; Silva et al., 1996; 
Suguna et al., 1987; Veerapandian et al., 1992). The proposed mechanism suggests that 
only one aspartic acid residue is protonated within the active site while the other is 
deprotonated (Adachi et al., 2009). The mechanism also involves a water molecule that is 
coordinated within the active site by the catalytic aspartates. The charged aspartic acid 
residue is thought deprotonate the water molecule to activate it. The activated water 
12
FIGURE I-3
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FIG. I-3. HIV-1 protease is homodimeric with 99 amino acid residues in each monomer. 
A. Amino acid sequence from HIV-1 clade B protease. B. Structure of HIV-1 protease. 
Each monomer in the dimeric complex is colored in cyan and magenta. The active site is 
indicated at the dimer interface and the side chains of the catalytic aspartic acid residues 
are also displayed. C. Cleavage mechanism proposed for HIV-1 protease. 
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molecule then disrupts the scissile bond through a nucleophilic attack on the carbonyl 
group (Figure I-3C). 
The HIV-1 protease cleaves at eleven asymmetric and non-homologous substrate 
cleavage sites within the Gag and Gag-Pro-Pol polyproteins and the Nef precursor protein 
(Table I-1) (de Oliveira et al., 2003). In addition to these cleavage sites, at least three 
auto-proteolysis sites are recognized within the protease (Rose, Salto, and Craik, 1993a). 
The active site of the protease has distinct pockets, S4 to S1 and S1’ to S4’, which 
accommodate substrate side chains P5 to P1 (towards the N-terminus from cleavage site) 
and P1’ to P5’ (towards the C-terminus from cleavage site) (Wlodawer and Erickson, 
1993). Analysis of the substrate cleavage sites has revealed that the protease does not  
recognize a specific amino acid sequence (Debouck, 1992). Structural analyses of HIV-1 
protease in complex with decamer substrate peptides have revealed the presence of a 
conserved shape taken by the substrates, termed the “substrate envelope” (Figure I-4A 
and 4B) (King et al., 2004a; Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002). Structural 
data has further revealed that substrate recognition is mainly through conserved hydrogen 
bond interactions between the protease molecule and backbone atoms of the substrates 
(Prabu-Jeyabalan, Nalivaika, and Schiffer, 2002). 
Given the crucial role played by HIV-1 protease in the viral replication cycle, it 
has been an important drug target in the effort to slow down the progression of HIV 
infections to AIDS (Debouck, 1992). Currently, there are nine FDA approved protease 
inhibitors (PIs), amprenavir (APV), atazanavir (ATV), darunavir (DRV), indinavir (IDV), 
lopinavir (LPV), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV) and tipranavir  
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TABLE I-1. HIV-1 protease substrates within the Gag and Gag-Pro-Pol polyproteins and 
Nef. The cleavage sites are indicated by the red lines. 
 
 P5 P4 P3 P2 P1 P1’ P2’ P3’ P4’ P5’ 
MA/CA (p17/p24) V S Q N Y P I V Q N 
CA/p2 (p24/p2) K A R V L A E A M S 
p2/NC (p2/p7) S T A I M M Q K G N 
NC/p1 (p7/p1) E R Q A N F L G K I 
NC/TFP E R Q A N F L R E N 
p1/p6gag R P G N F L Q S R P 
TFP/p6pol E N L A F Q Q G E A 
p6pol/PR T S F S F P Q I T C 
PR/RT C T L N F P I S P I 
RT-RH( RT/p66) G A E T F Y V D G A 
RH/IN (p66/IN) I R K V L F L D G I 
Nef P D C A W L E A Q E 
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FIGURE I-4 
 
Reprinted from Chemistry & Biology, Vol. 11, “Combating Susceptibility to Drug 
Resistance: Lessons from HIV-1 Protease”, Pages 1333-8, © 2004, with permission from 
Elsevier.  
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FIGURE I-4. A The substrate envelope calculated with GRASP (Nicholls, Sharp, and 
Honig, 1991a) from the overlapping van der Waals volume of four or more substrate 
peptides. The colors of the substrate peptides are red, matrix-capsid; green, capsid-p2; 
blue, p2-nucleocapsid; cyan, p1-p6; magenta, reverse-transcriptase-ribonucleaseH; and 
yellow, ribonucleaseH-integrase. B. The substrate envelope as it fits within the active site 
of HIV-1 protease. The α-carbon trace is of the CA-p2 substrate peptide complex (Prabu-
Jeyabalan, Nalivaika, and Schiffer, 2000b).  
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(TPV), that are being used successfully to treat HIV infections as a part of HAART 
(Figure I-5) (De Meyer et al., 2005; Dorsey et al., 1994; Kaldor et al., 1997; Kempf et al., 
1995; Kim et al., 1995; Roberts et al., 1990; Robinson et al., 2000; Sham et al., 1998; 
Turner et al., 1998). Except for TPV, all the PIs are peptidomimetics. These inhibitors are 
competitive inhibitors that bind within the active site of the protease and effectively 
prevent substrates from binding. The PIs act by mimicking a transition state of the 
substrates and thus, are able to maintain high affinity to the protease (De Clercq, 2009). 
Furthermore, the scissile bond of these peptidomimetics has been engineered in a way 
that it can no longer be cleaved by simple hydrolysis. 
 Drug resistance 
 Drug resistance is a major drawback in using all currently available anti-HIV 
drugs. Due to the error prone nature of HIV-1 reverse transcriptase, mutations can be 
introduced into the reverse transcribed viral genome.  These mutations can manifest as 
drug resistant amino acid substitutions in all HIV drug targets. Thus, amino acid 
substitutions that result from mutations in the protease gene can weaken the protease- 
inhibitor interactions. Drug resistance mutations function by causing a change in 
molecular recognition (Figure I-6A). Wild type HIV-1 protease can bind both substrates 
and inhibitors. However, drug resistance mutations that accumulate within the protease 
prevent the effective binding of inhibitors but still allow substrates to bind the protease 
and be cleaved. Drug resistance substitutions develop against all currently available PIs 
(Table I-2). 
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FIGURE I-5 
FDA approved HIV-1 protease inhibitors that are used in HAART. 
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FIGURE I-6  
 
Panels 6B-5D are reprinted from Chemistry & Biology, Vol. 11, “Combating 
Susceptibility to Drug Resistance: Lessons from HIV-1 Protease”, Pages 1333-8, © 2004, 
with permission from Elsevier.  
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FIGURE I-6 A. Drug resistance is a change in molecular recognition. Drug resistance 
mutations effectively prevent inhibitors from binding but allow substrates to bind. B. The 
inhibitor envelope calculated from overlapping van der Waals volume of five or more of 
eight inhibitor complexes. The colors of the inhibitors are yellow, nelfinavir (NFV); gray, 
saquinavir (SQV); cyan, indinavir (IDV); light blue, ritonavir (RTV); green, amprenavir 
(APV); magenta, lopinavir (LPV); blue, atazanavir (ATV); and red, darunavir (DRV). C. 
The inhibitor envelope as it fits within the active site of HIV-1 protease. D. Superposition 
of the substrate envelope (blue) with the inhibitor envelope (red). Residues that contact 
the inhibitors where the inhibitors protrude beyond the substrate envelope and confer 
drug resistance when they mutate are labeled. 
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TABLE I-2. Common drug resistance substitutions (primary drug resistance 
substitutions) that are observed in patients failing currently available FDA approved 
inhibitors. Active site amino acid substitutions are indicated in bold font. 
Inhibitor Common drug resistance mutations 
Amprenavir V32I, I47V, I50V, I54M/L, I84V, L76V  
Atazanavir I50L, N88S 
Darunavir V32I, I47V/A, I50V, I54M/L, L76V, I84V/A/C 
Indinavir V82A/T/F/S/M, M46I/L, I54V/T/A, I84V, L90M  
Lopinavir V82A/T/F/S, I54V/L/M/A/T/S, M46I/L, I50V, I47A/V, V32I, L76V  
Nelfinavir D30N/A± N88D, M46I/L, L90M, N88S  
Saquinavir G48V/M, L90M, I84V/A/C 
Tipranavir V82L/T, V32I, I47V, I54V/A/M, I84V  
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 The obvious drug resistance mutations occur within the active site and directly 
disrupt interactions between the protease and the inhibitor. Similar to the substrate 
envelope, an inhibitor envelope can be defined using the consensus volume taken up by 
PIs when bound within the active site (Figure I-5B and C). The majority of drug 
resistance mutations occur at positions within the protease where the inhibitor envelope 
protrudes outside the substrate envelope (Figure I-5D) (King et al., 2004a). However, a 
number of drug resistance substitutions occur outside the active site. The mechanism by 
which these substitutions modulate inhibitor binding is poorly understood. Furthermore, 
drug resistance substitutions are usually accompanied by secondary resistance 
substitutions and are mostly outside the active site. While several of these secondary 
substitutions enhance protease stability and activity, others enhance the effect of primary 
resistance substitutions. The extent to which these secondary mutations contribute to drug 
resistance is not clearly understood. 
Drug resistance in HIV-1 protease has been extensively studied in clade B viral 
strains. The amino acid sequences of non-B clade proteases differ by about 10% when 
compared to the clade B sequence (Table I-3). The effect of these clade specific sequence 
variations on protease activity and drug resistance has not been looked at in detail. 
Several clade specific amino acid changes have been associated with protease inhibitor 
resistance in clade B protease (Table I-3). Given that there is clinical evidence to indicate 
that factors like virus transmission and disease progression are affected by the clade, it is 
important to fill the void in our understanding of how clade specific sequence variations 
contribute to inhibitor resistance.  
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TABLE I-3. Amino acid sequence variations between the major HIV-1 clades. The clade 
B amino acid residues at positions that are variable between clades are shown in the row 
shaded in blue. Amino acid substitutions that are associated with protease inhibitor 
resistance in clade B are indicated in the row shaded in pink.
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Summary 
Emergence of drug resistance continues to be a major problem in using PIs. 
Inhibitor resistance can be defined as a change in molecular recognition where the 
protease no longer binds PIs efficiently but maintains its ability to bind and cleave 
substrates. The work presented in the following chapters is an attempt to understand the 
molecular mechanisms by which amino acid substitutions within HIV-1 protease confer 
inhibitor resistance. A combination of biochemical and biophysical techniques were used 
to explore how amino acid substitutions within the active site as well as those outside the 
active site affect inhibitor binding. Furthermore, these studies attempted to investigate the 
role of clade specific amino acid variations on inhibitor resistance. With limited 
biochemical and biophysical data available on non-B clade proteases, the findings 
presented in the following chapters add to our understanding of how clade specific sequence variations affect protease structure, function and inhibitor resistance. Overall, 
being able to understand how drug resistance occurs at a molecular level can provide 
valuable insights that can help in the design of robust PIs that are not susceptible to 
resistance mutations and aid in the formulation of better treatment strategies to slow 
down the progression of HIV infections to AIDS. 
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CHAPTER II 
Structural Analysis of HIV-1 CRF01_AE Protease in Complex with the 
Substrate p1-p6 
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ABSTRACT 
The effect of amino acid variability between human immunodeficiency virus 
type-1 (HIV-1) clades on structure and the emergence of resistance mutations in HIV-1 
protease has become an area of significant interest in recent years. We determined the 
first crystal structure of HIV-1 CRF01_AE protease in complex with the p1-p6 substrate 
determined to a resolution of 2.8 Å. Hydrogen bonding between the flap hinge and 
protease core regions show significant structural rearrangements in CRF01_AE protease 
when compared to the clade B protease structure. 
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INTRODUCTION 
Based on its genomic diversity, the HIV-1 has been classified into three groups, 
M (major), N (non-major) and O (other/outlier) (Robertson et al., 2000). Group M has 
been further defined into nine clades (clades A-D, F-H, J and K) and a number of sub-
clades and circulating recombinant forms (CRFs). HIV-1 protease is one of the major 
proteins targeted for anti-HIV drug development. The pol gene which codes for protease 
differs by 10-15 % between clades (Gonzales, Machekano, and Shafer, 2001) and 
sequence diversity within HIV-1 clades has been an important area of study in recent 
years due to its possible role in altering resistance pathways within the protease (Ariyoshi 
et al., 2003a; Kantor et al., 2005).  In particular HIV-1 CRF01_AE acquires Nelfinavir 
resistance via an alternative mutational pathway (Ariyoshi et al., 2003a), making the 
detailed study of non-B proteases strongly warranted.  
Structural studies on clade B protease have lead to the successful development of 
a number of protease inhibitors (PIs). However, the majority of HIV-1 infections in the 
world result from non-clade B variants and there is limited evidence that non-clade B 
variants respond differently to currently available PIs (Clemente et al., 2006; Velazquez-
Campoy, Vega, and Freire, 2002). Although a large number of clade B protease 
structures have been solved over the years, to date, very little structural information is 
available on non-B HIV proteases. The first non-B clade protease structures for clade F 
were recently published by Sanches et al. (Sanches et al., 2007b) and the crystallization 
of clade C protease-inhibitor complexes has been reported by Corman et al. (Coman et 
al., 2007). We present here, the crystal structure of an inactive HIV-1 CRF01_AE  
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FIGURE II-1 
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FIGURE II-1. A. Amino acid sequence alignment of CRF01_AE protease with clade B 
protease. Positions where sequences differ are indicated in red. B. CRF01_AE protease in 
complex with the p1-p6 substrate (green). Amino acid changes in monomer A (cyan) are 
indicated in red and changes in monomer B (magenta) are indicated in blue. 
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protease variant (D25N) in complex with a decameric peptide corresponding to the p1-p6 
cleavage site within the Gag and Gag-Pro-Pol polyprotein. CRF01_AE was one of the 
first CRFs to be identified and is now the predominant HIV-1 variant in Southeast Asia 
(McCutchan, 2006). The protease was derived from a Japanese patient isolate and has ten 
amino acid substitutions (R14K, K20R, E35D, M36I, R41K, P63L, V64I, H69K, L89M 
and I93L) compared to clade B (Figure II-1A-B).  
 
MATERIALS AND METHODS  
Crystallization and structure determination.  
The CRF01_AE protease was expressed and purified as previously described 
(Prabu-Jeyabalan et al., 2004a).  The protein was concentrated to 1.8 mg ml-1 using a 10 
kDa molecular weight limit Amicon Ultra-15 centrifugal filter device. The decameric p1-
p6 peptide (Arg-Pro-Gly-Asn-Phe-Leu-Gln-Ser-Arg-Pro, Quality Controlled 
Biochemicals Inc. (QBC), Hopkinton, MA) was solubilized in Dimethyl sulfoxide 
(DMSO) and was equilibrated with the protein with a 5 fold molar excess for 1 hour on 
ice. Crystals were grown over a reservoir solution consisting of 126mM phosphate buffer 
at pH 6.2, 63mM sodium citrate and ammonium sulfate in the range of 18-33% (Silva et 
al., 1996). A 2:1 volume ratio of substrate-protein solution and reservoir solution were 
combined to set up hanging drops with a final volume of 6 µL. The crystals were grown 
at ambient temperature.  
Crystallographic data was collected under cryo conditions using a R-AXIS IV 
image plate mounted on a Rigaku rotating anode X-ray generator. The data were reduced 
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and scaled using the programs DENZO and SCALEPACK respectively (Otwinowski and 
Minor, 1997). The structure solution was obtained by using a HIV-1 protease inhibitor 
complex (PDB code: 1T3R) with the program AMoRe (Navaza, 1994). Structure 
determination and refinement was carried out using programs within the CCP4 suite as 
previously described (Prabu-Jeyabalan et al., 2006b). Model building was carried out 
followed by real space refinement with the molecular graphics program COOT (Emsley 
and Cowtan, 2004). Refinement of initial models was done without the p1-p6 substrate 
and the peptide was built into the Fo-Fc density within the active site as the refinement 
progressed. A truncated p1-p6 peptide lacking ArgP5 and ProP4 was modeled into the 
active site as the 2Fo-Fc and Fo-Fc maps indicated weak and discontinuous electron 
density at the N-terminus of the peptide. The ArgP4’ of the p1-p6 peptide was modeled in 
as alanine since the electron density was not well defined to model in the arginine side 
chain. The stereochemical parameters of the final model were checked using 
PROCHECK (Laskowski et al., 1993). The CRF01_AE protease in complex with p1-p6 
was determined to a resolution of 2.8 Å (Table II-1).  
Protease structure comparison.   
The inactive clade B protease in complex with p1-p6 (PDB code: 1KJF) was used 
for structural comparisons. The terminal regions (residues 1-9 and 86-99) from both 
monomers were used to superimpose the clade B structure onto the CRF01_AE complex. 
The superimposition was performed in a way that the orientation of the substrate peptide 
between the two structures was preserved. A double difference plot was generated to 
visualize structural differences between the two complexes. Distances between all the Cα 
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atoms within the dimer were calculated for each complex and then the difference of the 
difference between the two dimers was plotted as a contour plot as previously described 
(Prabu-Jeyabalan et al., 2006b).  The presence of significant contour peaks within the plot 
indicates regions that differ between the two structures.  
 
RESULTS 
Based on the Cα superimposition, the CRF01_AE and clade B structures display a 
high level of structural similarity to each other with a root mean square deviation 
(RMSD) of 0.37 Å (Figure II-2A).  However, peaks within the double difference plot  
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TABLE II-1. Crystallographic data and statistics for CRF01_AE in complex with the 
substrate p1-p6 
Parameter Value 
Resolution (Å) 2.8 
Temperature (K) 100 
Space group P61 
Cell dimensions   
     a=b (Å) 62.1 
     c (Å) 82.1 
Za 6 
Rmerge (%) 9.5 
Completeness (%) 99.4 
Total number of relections 45,495 
Number of unique reflections 4,523 
I/σI 8.4 
RMSDb in:  
     Bond lengths (Å) 0.008 
     Bond angles (Å) 1.2 
Rfactor (%) 19.9 
Rfree (%) 25.8 
 
a Number of dimeric molecules in the unit cell. 
b Root mean square deviation 
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FIGURE II-2 
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FIGURE II-2 A. Ribbon diagram superposition of CRF01_AE (blue) and clade B (gray) 
p1p6 structures. The flap hinge region is indicated by the red box. B. Double difference 
plot comparing the CRF01_AE and clade B p1p6 structures. Contours in the plot 
represent the degree of how close or far residues are between the structures being 
compared. Black indicates a distance of <-0.6 Å, red -0.59 Å and -0.3 Å, blue 0.3 Å and 
0.59 Å and green >0.6 Å. C. Stereo view of the rearrangement of the flap hinge region of 
CRF01_AE structure (blue) compared to the clade B structure (gray). The Asn37 side 
chain in the CRF01_AE structure is disordered and has been modeled in as alanine. D. 
p1-p6 substrate conformation (blue – CRF01_AE, gray – clade B) 
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showed that the  CRF01_AE complex had significant structural rearrangement at the flap 
hinge region (residues 33-39) and near the protease core region (residues 16-22) (Figure 
II-2B). These structural differences are present in both monomers of the complex. Closer 
examination of the Ile36 showed that its shorter side chain is stabilized through van der 
Waals interactions with the side chains of Asn18, Leu38 and Arg20 allowing the flap 
hinge region to pack closer to the core region when compared to longer M36 side chain in 
the clade B structure (Fig II-2C). The collapse of the flap hinge towards the core is 
further enhanced by the formation of a hydrogen bond between the carbonyl oxygen of 
Asp35 with NE or NH2 of the Arg20 side chain. This interaction causes the Asp35 side 
chain to flip inward towards the core region.  In comparison, the longer Glu35 side chain 
in clade B is flipped out into the solvent allowing its OE2 oxygen to form a hydrogen 
bond with the side chain NH1 of Arg57. The positioning of the Arg57 side chain also 
allows the NH2 hydrogen to form a hydrogen bond with the carbonyl oxygen of Met36. 
The Arg57 side chain of the CRF01_AE structure is not involved in making any 
interactions with the flap hinge and packs against Trp42. These observations suggest that 
the flap hinge region of the CRF01_AE protease is likely to have reduced flexibility as a 
result of its tighter packing against the protease core region when compared to that of 
clade B.  
Substrate conformation.  
The p1-p6 peptide is bound within the active site in an extended conformation with the 
Phe-Leu cleavage site at P1 and P1’ positions oriented between the “catalytic” Asn25 
residues. AsnP2 in the CRF01_AE structure adopts a conformation different to that of the 
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clade B structure (Figure 2II-D). OG of SerP3’ also adopts a different orientation to that 
seen in the clade B structure. ProP5’ is rotated by 180o which causes the C-terminus of 
the peptide to kink towards the P4’ position whereas in the clade B complex the p1-p6 
peptide adopts an extended conformation at the C-terminus. Despite changes in peptide 
conformation, the protease-substrate hydrogen bonding patterns show a high degree of 
similarity between the two structures with thirteen substrate-protease hydrogen bonds 
conserved between the CRF01_AE and clade B structures (Table II-2). However, the 
CRF01_AE structure makes four additional substrate-protease hydrogen bonds that are 
not seen in clade B structure. The AsnP2 side chain conformation allows OD1 to form a 
hydrogen bond with either Asp29 N or Asp30 N while ND2 forms a hydrogen bond with 
Asp30 OD2. Furthermore, the AsnP2 side chain confirmation allows it to make 
significant van der Waals interactions with Asp29 and Asp30. The hydrogen bond 
formed between SerP3’ OG and Arg8 NH1 is a result of SerP3’ OG adopting a different 
orientation to that seen in the clade B structure. Thus, when compared to the clade B 
structure the p1-p6 substrate appears to form better interactions with the CRF01_AE 
active site.   
 
CONCLUSIONS 
The structure described in this study is the first CRF01_AE protease structure as 
well as the first non-B HIV-1 protease-substrate complex structure to be reported to date. 
Arg20, Asp35, Ile36, Lys69, Met89 and Leu93 seen in the structure have been implicated 
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TABLE II-2 Substrate-protease hydrogen bonds 
 
Distance (Å)a 
Substrate Atom Protease Atom 
CRF01_AE Clade B 
GlyP3 N Gly48 O 3.5 3.0 
GlyP3 O Asp29 N 3.0 2.8 
AsnP2 OD1 Asp29 N 2.8 - 
AsnP2 OD1 Asp30 N 2.8 - 
AsnP2 ND2 Asp30 OD2 3.1 - 
PheP1 N Gly27 O 2.6 2.9 
PheP1 O Asn25 ND2 2.8 2.7 
GlnP2’ N Gly27’ O 2.9 3.0 
GlnP2’ OE1 Asp29’ N 3.1 2.9 
GlnP2’ OE1 Asp30’ N 2.7 2.7 
GlnP2’ NE2 Asp30’ OD2 2.6 3.0 
GlnP2’ O Asp29’ N 2.8 3.1 
Gln P2’ OE1 Asp30’ OD2 3.4 3.3 
SerP3’ OG Asp29’ OD2 2.8 3.4 
SerP3’ OG Arg8 NH1 3.1 - 
SerP3’ N Gly48’ O 3.1 3.0 
SerP3’ O Gly48’ N 3.2 2.8 
ArgP4’ NE Asp30’ OD1 NAb 3.2 
ArgP4’ NE Asp30’ OD2 NAb 3.0 
ArgP4’ NH2 Gln58’ OE1 NAb 3.4 
 
a Distances highlighted in bold are hydrogen bonds that are observed only in the 
CRF01_AE structure. 
b  Distances are not available as the ArgP4’ side chain is disordered.  
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as resistance associated mutations in clade B protease (Becker-Pergola et al., 2000; Julg 
and Goebel, 2005; Kantor and Katzenstein, 2003). While no significant structural  
changes were observed at Lys69, Met89 and Leu93, the substitutions Arg20, Asp35 and 
Ile36 in the CRF01_AE protease result in significant structural rearrangements of the flap 
hinge and core regions when compared to the clade B structure. We have observed a 
similar structural rearrangement in other CRF01_AE protease-inhibitor complexes 
(Chapter 3), which might be an indication that the interactions observed are unique to 
CRF01_AE protease.  
Movement of the flaps is essential for substrate binding and the flap hinge and 
core regions play a key role in flap dynamics (Rose, Craik, and Stroud, 1998a; Scott and 
Schiffer, 2000; Todd and Freire, 1999a). The close packing observed between these 
regions in the CRF01_AE protease structure is likely to restrict flexibility and thereby 
affect flap dynamics. The protease molecule itself undergoes large conformational 
changes in order to facilitate substrate binding and product release following substrate 
cleavage (Foulkes-Murzycki, Scott, and Schiffer, 2007). Thus, reduced flexibility 
resulting from the packing of the flap hinge and core regions may have an effect on 
protease activity as well. Previously reported enzyme kinetics data on a CRF01_AE 
variant indicate that the active site specificity and catalytic efficiency are slightly lower 
for the CRF01_AE protease when compared to the clade B protease (Clemente et al., 
2006). Furthermore, polymorphisms occurring within these regions are thought to affect 
binding affinities for PIs (Velazquez-Campoy et al., 2001).  Therefore, the structural 
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changes observed might influence how CRF01_AE protease interacts with PIs and may 
thereby alter levels of resistance to currently available inhibitors when compared to clade 
B protease. 
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CHAPTER III 
The Effect of Clade Specific Sequence Polymorphisms on HIV-1 Protease Activity 
and Inhibitor Resistance Pathways 
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ABSTRACT 
The majority of HIV-1 infections around the world result from non-B clade HIV-
1 strains. The CRF01_AE (AE) strain is seen principally in Southeast Asia. AE protease 
differs by ~10% in amino-acid sequence from clade B protease and carries several 
naturally occurring polymorphisms that are associated with drug resistance in clade B. 
AE protease has been observed to develop resistance through a non-active site N88S 
mutation in response to nelfinavir (NFV) therapy, whereas clade B protease develops 
both the active site mutation D30N and the non-active site mutation N88D. Structural and 
biochemical studies were carried out on wild type and NFV resistant clade B and AE 
protease variants. The relationship between clade specific sequence variations and 
pathways to inhibitor resistance was also assessed. AE protease has a lower catalytic 
turnover rate when compared to clade B, and also has weaker affinity for both NFV and 
darunavir (DRV).  This weaker affinity may lead to the non-active site N88S variant in 
AE, which exhibits significantly decreased affinity for both NFV and DRV. The 
D30N/N88D in clade B resulted in a significant loss of affinity for NFV and to a lesser 
extent for DRV. Comparison of crystal structures of AE protease shows significant 
structural rearrangement in the flap hinge region compared with clade B and suggests 
insights into the altered pathways to NFV resistance. In combination, our studies show 
that sequence polymorphisms within clades can alter protease activity and inhibitor 
binding, and are capable of altering the pathway to inhibitor resistance.  
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INTRODUCTION 
HIV-1 is classified into nine major clades (A, B, C, D, F, G, H, J, and K) and 43 
circulating recombinant forms (CRFs) based on viral genomic diversity (Plantier et al., 
2009; Robertson et al., 2000). The majority of HIV-1 infections across the globe result 
from non-B clade HIV-1 variants; clade B only accounts for ~12% of infections 
(Hemelaar et al., 2006). However, the development of currently available anti-HIV 
therapies has been based on the virology of clade B variants. In recent years, several 
studies have shown that there are clear differences between clades when it comes to viral 
transmission and the progression to AIDS, which raises questions about the effectiveness 
of the currently available anti-HIV therapies against the other clades and CRFs (Hu et al., 
1999; Kaleebu et al., 2002b; Kanki et al., 1999b; Spira et al., 2003a).  
HIV-1 protease has been an important drug target in the global effort to curb the 
progression to AIDS. However, the accumulation of drug-resistant mutations in the 
protease has been a major drawback in using HIV-1 protease inhibitors. The effects of 
mutations associated with drug resistance in HIV-1 clade B protease have been studied 
extensively over the years. For the most part, resistance-mutation patterns are very 
similar in HIV-1 clade B and non-B clade proteases (Kantor et al., 2005). However, 
several altered resistance pathways have been observed in non-B clade proteases 
compared with those of clade B protease (Ariyoshi et al., 2003a; Gomes et al., 2002; 
Grossman et al., 2004a; Nunez et al., 2002). Limited data are available on how sequence 
polymorphisms, some of which are associated with drug resistance in clade B protease, 
might influence the pathway to drug resistance in non-B clade proteases. Furthermore, 
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very little is understood about how sequence polymorphisms in non-B clade proteases 
affect protease function and inhibitor binding. 
HIV-1 CRF01_AE (AE) was the first CRF to be observed in patient populations 
and is seen principally in Southeast Asia (Carr et al., 1996; Gao et al., 1996; Murphy et 
al., 1993). AE protease differs by ~10% in amino-acid sequence from that of clade B 
protease (Figure III-1A). Interestingly, AE protease develops a different resistance 
pathway from that of clade B protease to confer resistance to the protease inhibitor 
nelfinavir (NFV) (Ariyoshi et al., 2003a). In patients infected with AE the protease 
predominantly acquires N88S in response to NFV therapy, whereas in patients with clade 
B the protease acquires D30N/ N88D.  
In the present study, biochemical and biophysical methods were used to determine 
the effect of sequence polymorphisms in AE protease on enzyme activity and inhibitor 
binding. Through determination of crystal structures and analysis of changes in hydrogen 
bonding patterns, a structural rationalization is described for the two different pathways 
observed in clade B and AE proteases to attain resistance to NFV.  
 
MATERIALS AND METHODS 
Protease-gene construction 
The clade B wild-type (B-WT) protease gene was generated as previously 
described (Prabu-Jeyabalan et al., 2004a) with the Q7K substitution introduced to prevent 
autoproteolysis (Rose, Salto, and Craik, 1993a). The AE wild type (AE-WT) protease 
gene was synthesized in fragments (Integrated DNA Technologies, Coralville, IA), with  
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FIGURE III-1 
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FIGURE III-1. (A) Amino acid sequence alignments of B-WT and AE-WT and NFV 
resistant mutants. Residue positions that differ between clade B and AE are indicated in 
red. NFV resistance mutations are indicated in blue. (B) Ribbon diagram superposition of 
DRVAE-WT (blue) and DRVAE-N88S (gray). (C) Double-difference plot comparing DRVAE-
WT and DRVAE-N88S. The color contours indicate distance differences of < -1.0 Å (black), 
-1.0 to -0.5 Å (green), 0.5 to 1.0 Å (blue) and > 1.0 Å (red). (D) Ribbon diagram 
superposition of clade DRVAE-WT (magenta) and clade DRVB-WT (gray). (E) Double-
difference plot comparing DRVAE-WT and DRV B-WT. 
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codons optimized for expression in Escherichia coli. The fragments were ligated to form 
the complete gene, which was then inserted into the pET11a expression vector 
(Novagen/EMD Chemicals, Gibbstown, NJ). The protease sequence was confirmed by 
DNA sequencing. The NFV-resistance mutations, N88S in AE (AE-N88S) and 
D30N/N88D in clade B (B-D30N/N88D) were generated by site-directed mutagenesis 
using the Stratagene QuikChange site-directed mutagenesis kit (Agilent Technologies, La 
Jolla, CA). Mutagenesis was confirmed by sequencing.  
Protease-gene construction 
The clade B wild-type (B-WT) protease gene was generated as previously 
described (Prabu-Jeyabalan et al., 2004a) with the Q7K substitution introduced to prevent 
autoproteolysis (Rose, Salto, and Craik, 1993a). The AE wild type (AE-WT) protease 
gene was synthesized in fragments (Integrated DNA Technologies, Coralville, IA), with 
codons optimized for expression in Escherichia coli. The fragments were ligated to form 
the complete gene, which was then inserted into the pET11a expression vector 
(Novagen/EMD Chemicals, Gibbstown, NJ). The protease sequence was confirmed by 
DNA sequencing. The NFV-resistance mutations, N88S in AE (AE-N88S) and 
D30N/N88D in clade B (B-D30N/N88D) were generated by site-directed mutagenesis 
using the Stratagene QuikChange site-directed mutagenesis kit (Agilent Technologies, La 
Jolla, CA). Mutagenesis was confirmed by sequencing.  
Protein expression and purification 
The clade B and AE variants were subcloned into the heat-inducible pXC35 
expression vector (American Type Culture Collection (ATCC), Manassas, VA) and 
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transformed into E. coli TAP-106 cells. Protein overexpression, purification and 
refolding was carried out, as previously described (King et al., 2002). Protein used for 
crystallographic studies was further purified with a Pharmacia Superdex 75 fast-
performance liquid-chromatography column (GE Healthcare, Chalfont St. Giles, U.K.) 
equilibrated with refolding buffer (50mM sodium acetate pH 5.5, 10% glycerol, 5% 
ethylene glycol, and 5mM dithiothreitol). 
Crystallization and structure determination 
Protease solutions between 1.0 and 2.0 mg mL-1 were equilibrated with fivefold 
molar excess of NFV, darunavir (DRV) and amprenavir (APV) for 1 hour on ice. Crystals 
were grown over a reservoir solution consisting of 126-mM phosphate buffer (pH 6.2), 
63-mM sodium citrate and 18% to 23% ammonium sulfate by the hanging-drop vapor-
diffusion method. X-ray diffraction data for AE-WT were collected on BioCARS 
beamline 14-BMC at the Advanced Photon Source (Argonne National Laboratory, 
Argonne, IL) at a wavelength tuned to 0.9 Å with a Quantum 315 CCD X-ray detector 
(Area Detector Systems Corporation, Poway, CA). Diffraction data for AE-N88S were 
collected on beamline X29A at the National Synchrotron Light Source (Brookhaven 
National Laboratory, Upton, NY) at a wavelength tuned to 1.08 Å with a Quantum 315 
CCD X-ray detector (Area Detector Systems Corporation). Data for the B-D30N/N88D 
variant was collected in-house on an R-Axis IV imaging-plate system (Rigaku 
Corporation, Tokyo, Japan) mounted on a rotating-anode X-ray source (Rigaku 
Corporation). All data were collected under cryo-cooled conditions. 
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The data were indexed, integrated and scaled using HKL/HKL-2000 software 
(HKL Research, Charlottesville, VA) (Otwinowski and Minor, 1997). Structure 
determination was done through molecular replacement with the program AMoRe 
(Navaza, 1994) and refinement were carried out using the CCP4 program suite 
(Collaborative Computational Project Number 4, 1994), as previously described (Prabu-
Jeyabalan et al., 2006b). The tensor (T), libration (L), and screw (S) parameter files used 
in TLS refinement were generated using the TLS Motion Determination server (Painter 
and Merritt, 2006). Model building was carried out, followed by real-space refinement, 
with COOT molecular-graphics software (Emsley and Cowtan, 2004). Structure 
comparisons were made by superposing the structures using the Cα atoms of the terminal 
regions (residues 1 to 9 and 86 to 99) from both monomers. In the case of the AE 
complexes, which have multiple orientations for the inhibitor, each orientation was 
refined with an occupancy of 0.5. Only the orientation common with the clade B 
structures was used for analysis. Structures were visualized using PyMol molecular-
graphics software (DeLano, 2002). 
Double-difference plots were generated for AE and clade B protease structures to 
graphically visualize structural differences between the clades, as previously described 
(Prabu-Jeyabalan et al., 2006b). Briefly, distances between all Cα atoms within the dimer 
were calculated for each complex. A distance-difference matrix was then computed for 
each atom for a given pair of complexes. The distance-difference matrix was then plotted 
as a contour plot using gnuplot plotting software (Williams and Kelley, 1998b).  
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Nomenclature 
 The following nomenclature will be followed to refer to each crystal structure: 
Inhibitorprotease variant.  Thus, DRV in complex with AE-WT, clade B-WT, AE-N88S and 
AE-D30N/N88D protein will be described as DRVAE-WT, DRVB-WT , DRVAE-N88S, and 
DRVB-D30N/N88D. Prime notation is used to distinguish the two monomers in the protease 
dimer. For example, residue 30 from the first monomer would be referred to as Asp30 
and the same residue from the second monomer would be referred to as Asp30’. 
Isothermal titration calorimetry (ITC) 
Binding affinities and thermodynamic parameters of inhibitor binding to clade B 
and AE variants were determined by ITC on a VP isothermal titration calorimeter 
(MicroCal, LLC, Northampton, MA). The buffer used for all protease and inhibitor 
solutions consisted of 10 mM sodium acetate (pH 5.0), 2% dimethyl sulfoxide, and 2 mM 
tris[2-carboxyethyl]phosphine. Binding affinities for all protease variants were obtained 
by competitive-displacement titration using acetyl-pepstatin as the weaker binder. A 
solution of 30–45 µM protease was titrated with 10-µL injections of 200 µM acetyl-
pepstatin to saturation. The pepstatin was then displaced by titrating 36 8-µL injections of 
200 µM amprenavir (APV) or NFV or 41 7-µL injections of 40 µM DRV. Heats of 
dilution were subtracted from the corresponding heats of reaction to obtain the heat 
resulting solely from the binding of the ligand to the enzyme. Data were processed and 
analyzed with the ITC data analysis module (Microcal) for Origin 7 data analysis and 
graphing software (OriginLab, Northampton, MA). Final results represent the average of 
at least two measurements.  
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Measurement of protease activity 
Protease activity was assayed by following each variant’s ability to hydrolyze the 
fluorogenic substrate HiLyte Fluor 488-Lys-Ala-Arg-Val-Leu-Ala-Glu-Ala-Met-Ser-Lys 
(QXL-520) (AnaSpec Inc., Fremont, CA) which corresponds to the HIV-1 Ca-p2 
substrate. The assay was carried out in a 96-well plate, and the enzymatic reaction was 
initiated by adding 20 µL of a solution of 100–250 nM protease to 80 µL of substrate 
solution.  The buffer used in all reactions consisted of 10 mM sodium acetate (pH 5.0), 
2% dimethyl sulfoxide, and 2 mM tris[2-carboxyethyl]phosphine. Final concentrations in 
each experiment were 0–40 µM substrate and 20–50 nM protease. Accurate 
concentrations of properly folded active protease were determined by carrying out ITC 
experiments for each variant with acetyl-pepstatin as described in the previous section. 
Fluorogenic response to protease cleavage was monitored at 23°C using a Victor3 
microplate reader (PerkinElmer, Waltham, MA) by exciting the donor molecule at 485 
nM and recording emitted light at 535 nM. Data points were acquired every 30 seconds. 
The data points in relative fluorescence units (RFU) were converted into concentrations 
using standard calibration curves generated for HiLyte Fluor 488 at each substrate 
concentration. In addition to converting RFUs to concentrations, generating calibration 
curves at each substrate concentration allowed us to correct for the inner filter effect 
(Copeland, 1996). Rates of each enzymatic reaction were determined from the linear 
portion of the data and were fitted against substrate concentrations to determine KM and 
kcat (catalytic-turnover rate) values using VisualEnyzmics enzyme-kinetics software 
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(SoftZymics, Princeton, NJ). Final results for each variant represent the average of at 
least two experiments. 
In order to determine the biochemical fitness of a particular variant in the 
presence of a given inhibitor, vitality values were calculated using Equation 1, based on 
the vitality function previously described (Gulnik et al., 1995; Velazquez-Campoy et al., 
2003). 
 
Vitality =
Kd × kcat /KM( )[ ]mutant
Kd × (kcat /KM )[ ]clade B WT
   (Equation 1) 
The calculated vitality value for B-WT for a particular inhibitor would be 1.0 and vitality 
values greater than 1.0 would indicate that a given variant had a selective advantage over 
the same inhibitor while values lower than 1.0 would indicate that the variant did not 
have selective advantage. 
 
RESULTS 
Crystal structures 
The AE WT and NFV-resistant clade B and AE variants were co-crystallized with 
NFV, DRV, and APV to reveal the structural basis for the altered NFV-resistance 
pathways. In addition the effects of background polymorphisms in AE-WT on inhibitor 
binding compared with clade B-WT were discerned. Crystals of AE protease in complex 
with NFV and APV did not diffract to high resolution, and therefore structural 
comparisons were carried out on AE and clade B protease in complex with DRV. The 
structure of DRVB-WT was solved previously in the lab and was used for structural 
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comparisons (PDB code: 1T3R). Both DRVAE-WT and DRVAE-N88S crystallized with DRV 
bound in two orientations in the active site and therefore, the inhibitor was refined with 
an occupancy factor of 0.5. Crystallographic data and refinement statistics for DRVAE-WT, 
DRVB-WT , DRVAE-N88S, and DRVB-D30N/N88D are given in Table III-1.   
Structural comparisons were carried out for AE and clade B DRV complexes by 
pairwise structural superposition and double-difference plots (Figure III-1B-E). The 
DRVAE-WT and DRVAE-N88S complexes were structurally similar (Figure III-1B-C). 
Although the DRVAE-WT and DRVB-WT superimposed on each other very well (RMSD of 
0.21 Å), there were clear and significant differences between the variants in the main 
chain at the flap-hinge region (residues 33–39) and 21the protease-core region (residues 
16–22) (Figure III-1D and Figure III-2A-D). These differences were 22further evident by 
the presence of significant peaks in the double-difference plot (Figure III-1E). The Ile36 
side chain in DRVAE-WT packs well against the core region through favorable van der 
Waals interactions and is shorter than the Met36 in DRVB-WT (Figure III-2C). In addition 
the shorter Asp35 in DRVAE-WT further enhances the packing by being flipped inward 
against the core, while in DRVB-WT, the longer Glu35 is flipped outward into the solvent 
and forms a salt bridge with Arg57 (Figure III-2D). The packing of the flap-hinge and 
core regions in DRVAE-WT is further stabilized by a hydrogen bond between the carbonyl 
oxygen of Asp35 and Lys20 NZ that is not present in DRVB-WT.   
The Asp30’ side chain of DRVAE-WT forms a direct hydrogen bond with the N1 
atom of DRV (Figure III-3C). In contrast, the Asp30’ side chain of DRVB-WT does not 
directly hydrogen bond with DRV but indirectly interacts with the N1 atom of DRV  
56
TABLE III-1 Crystallographic statistics for CRF01_AE and clade B variants in complex 
with DRV. 
 DRVB-WTa DRVB-D30N/N88D DRVAE-WT DRVAE-N88S 
Inhibitor DRV DRV DRV DRV 
Resolution (Å) 1.2 2.15 1.96 1.76 
Space group P 21 21 21 P 21 21 21 P 61 P 61 
Zb 4 4 6 6 
Cell dimensions:   a (Å) 54.9 50.9 62.2 61.9 
b (Å) 57.8 57.7   
c (Å) 62.0 61.6 82.7 82.1 
Total no. of reflections 302,022 108,838 89,284 79,445 
No. of unique reflections 55,056 10,326 12,493 17,277 
Rsymm (%) 3.8 6.7 5.5 4.6 
Completeness (%) 95.5 99.6 93.9 97.4 
I/σI 25.0 9.6 11.2 19.6 
Rwork (%) 14.1 18.1 20.0 19.6 
Rfree (%) 17.9 23.6 25.9 23.9 
RMSDc:  Bond length (Å) 0.004 0.009 0.009 0.007 
Bond angle 1.5 1.9 1.5 1.7 
PDB code 1T3R 3LZV 3LZS 3LZU 
 
a King et al.(King et al., 2004d) Surleraux et al.(Surleraux et al., 2005b) 
b Number of dimeric molecules in the unit cell 
c Root mean square deviation 
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FIGURE III-2 
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FIGURE III-2. (A) Ribbon diagram superposition of DRVAE-WT (blue) and DRVB-WT 
(gray). The red box indicates the region of the protease molecule highlighted in panels B-
D. (B) Structural rearrangement of the flap hinge and core regions between DRVAE-WT 
(blue) and DRVB-WT (gray). (C) Flap hinge and core regions of DRVAE-WT. (D) Flap hinge 
and core regions of DRVB-WT protease. Hydrogen bond interactions are indicated in red 
dashed lines. 
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FIGURE III-3
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FIGURE III-3. Protease-inhibitor hydrogen bonding interactions. DRV is shown in 
orange and hydrogen bond interactions are indicated in red dashed lines. (A) DRVB-WT 
(gray). (B) DRVB-D30N/N88D (salmon). (C) DRVAE-WT (blue). (D) DRVAE-N88S (green).  
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through a water molecule mediated hydrogen bond network (Figure III-3A). Residue 30 
of both NFV resistant variants also interacts with the N1 atom of DRV through water 
molecule mediated hydrogen bonding (Figure III-3B and 3D). However, in addition to  
this interaction, Asn30 of DRVB-D30N/N88D and Asp30 of DRVAE-N88S are oriented away 
from the active site enabling them to form hydrogen bonds with Asp88 and Ser88 
respectively. In both cases, the NFV resistance mutations stabilize residue 30 away from 
the active site via hydrogen bonding. 
Binding thermodynamics 
To determine the effects of background sequence polymorphisms and NFV-
resistance mutations on inhibitor binding, the binding thermodynamic parameters of 
NFV, DRV, and APV binding to WT and resistant AE and clade B variants were 
determined by isothermal titration calorimetry. The AE-WT protease had a 6.9-fold 
weaker affinity for NFV and 2.7-fold weaker affinity for DRV compared with the 
affinities of B-WT protease (Table III-2). This indicates that the AE-WT protease has an 
inherent weaker affinity for NFV and DRV.  
No significant differences in the enthalpy of NFV binding were observed among 
any of the variants. Although the binding of DRV to all protease variants was 
enthalpically favorable, the enthalpic contribution was reduced with the AE variants (–
10.1 kcal mol–1 for AE-WT and –5.1 kcal mol–1 AE-N88S) compared with the clade B 
variants (–12.1 kcal mol–1 for B-WT and –12.5 kcal mol–1 for B-D30N/N88D) (Table III-
2). As expected the NFV resistant variants showed a significant reduction in binding 
affinity for NFV when compared to the wild type variants. With the AE-N88S variant the  
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TABLE III-2 Binding thermodynamic parameters for NFV, DRV, and APV binding to CRF01_AE and clade B variants. 
Protease Variant Ka (M–1) Kd (nM) Kd ratio 
ΔH  
(kcal mol–1) ΔΔH 
–TΔS  
(kcal mol–1) 
Δ(–
TΔS) 
ΔG  
(kcal mol–1) ΔΔG 
NFV 
Clade B WT (2.6 ± 0.5) × 109 0.39 ± 0.07 1.0 4.4 ± 0.1 - –17.0 - –12.6 ± 0.1 - 
Clade B D30N, N88D (1.2 ± 0.4) × 108 8.1 ± 2.8 20.7 ± 8.1 6.7 ± 0.3 2.3 –17.5 0.5 –10.8 ± 0.2 1.8 
CRF01_AE WT (3.7 ± 1.0) × 108 2.7 ± 0.7 6.9 ± 2.1 5.0 ± 0.3 0.6 –16.6 0.9 –11.5 ± 0.2 1.1 
CRF01_AE N88S (5.8 ± 1.2) × 107 17.2 ± 3.5 44.1 ± 12.0 6.2 ± 0.7 1.8 –16.6 0.9 –10.4 ± 0.1 2.2 
DRV 
Clade B WT (2.2 ± 1.1) × 1011 0.004 ± 0.002 1.0 –12.1 ± 0.9 - –3.1 - –15.2 ± 0.3 - 
Clade B D30N, N88D (3.7 ± 0.7) × 1010 0.026 ± 0.005 6.5 ± 3.5 –12.5 ± 0.4 –0.4 –1.6 1.5 –14.2 ± 0.1 1.0 
CRF01_AE WT (9.1 ± 0.3) × 1010 0.0109 ± 0.0003 2.7 ± 1.4 –10.1 ± 0.5 2.0 –4.6 –1.5 –14.7 ± 0.02 0.5 
CRF01_AE N88S (1.1 ± 0.8) × 1010 0.087 ± 0.062 21.8 ± 18.9 –5.1 ± 3.6 7.0 –8.4 –5.3 –13.5 ± 0.4 1.7 
APV 
Clade B WT (2.6 ± 1.3) × 109 0.39 ± 0.20 1.0 –7.3 ± 0.9 - –5.3 - –12.6 ± 0.3 - 
Clade B D30N, N88D (1.2 ± 0.2) × 1010 0.08 ± 0.01 0.2 ± 0.1 –10.2 ± 1.5 –2.9 –3.3 2.0 –13.5 ± 0.09 –0.9 
CRF01_AE WT (3.1 ± 0.2) × 109 0.32 ± 0.02 0.8 ± 0.4 –5.5 ± 0.3 –1.8 –7.3 –2.0 –12.70 ± 0.03 –0.1 
CRF01_AE N88S (1.3 ± 0.9) × 1010 0.08 ± 0.06 0.2 ± 0.2 –5.0 ± 3.6 2.3 –8.6 –3.3 –13.6 ± 0.4 –1.0 
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affinity for NFV was reduced by 44.1-fold (Kd = 17.2 nM) and was far more significant 
than the D30N, N88D mutations in clade B protease, which reduced the affinity for NFV 
by 20.7-fold (Kd = 8.1 nM).  Similarly the AE-N88S variant had a 21.8-fold weaker 
affinity (Kd = 0.087 nM) for DRV compared to a 6.5-fold weaker affinity (Kd = 0.026 
nM) in B-D30N/N88D variant. Thus, the single N88S substitution in the AE protease has 
a profound effect on the binding of NFV and DRV.  
In contrast to NFV and DRV, clade-specific sequence differences and NFV-resistance 
mutations had only minimal effect on the affinities for APV of both AE and clade B 
protease. Despite this, there were some differences in energy parameters. The binding of 
APV to the clade B variants appeared to be more enthalpically favorablecompared with 
that of the AE variants. This was compensated for by an increase in the entropic 
component to the binding energy for the AE proteases. 
Protease activity and vitality 
The enzyme-kinetic parameters determined for each clade B and AE variant with 
the Ca-p2 fluorogenic substrate analog are summarized in Table III-3. The KM value for 
B-D30N/N88D protease (35.9 µM) was 2.1-fold greater than that of B-WT protease (16.7 
µM). However, the KM values for the AE protease variants (17.5 µM for AE-WT and 
19.0 µM for AE-N88S) were similar to that of B-WT protease. The turnover rate for B-
D30N/N88D protease (kcat = 0.13 sec–1) was significantly lower than that of B-WT (kcat = 
1.79 sec–1) protease. Turnover rates for AE-WT (kcat = 0.7 sec–1) and AE-N88S (kcat = 0.2 
sec–1) were 2.5 and 8.5-fold lower, respectively, than that of clade B-WT. The kcat/KM 
values, or catalytic efficiency, for B-D30N/N88D and AE variants were lower than that  
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TABLE III-3. Enzyme-kinetics parameters for clade B and CRF01_AE WT and NFV-
resistant variants.  
 
 B WT B D30N, N88D AE WT AE N88S 
KM (µM) 16.7 ± 6.0 35.9 ± 0.1 17.5 ± 4.0 19.0 ± 0.8 
kcat (sec–1) 1.79 ± 0.28 0.13 ± 0.09 0.70 ± 0.08 0.20 ± 0.02 
kcat/KM (sec–1µM–1) 0.11 ± 0.04 0.004 ± 0.002 0.04 ± 0.01 0.010 ± 0.001 
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of B-WT protease. Therefore, the reduction in catalytic efficiency of the B-D30N/N88D 
protease compared with that of B-WT protease resulted from the combined effects of the 
KM and kcat values. However, for the AE variants the smaller turnover rates alone were 
responsible for the reduced catalytic efficiencies. Overall, these results indicate that the 
polymorphic sequence differences in AE protease can alter the activity profile of the 
enzyme when compared to the clade B protease.  
Vitality values were calculated to determine if the protease variants had a selectie 
advantage over NFV, DRV and APV, AE-WT and AE-N88S protease had calculated 
vitality values of 2.5 and 4.0 respectively when compared with B-WT for NFV (Table 
III-4). However, vitality values for DRV were not significantly different from that of 
B-WT protease. Vitality values for APV were significantly lower in all variants when 
compared to that of B-WT protease. These results indicate that AE-WT may have a 
selective advantage over NFV when compared to B-WT but the AE variants may not 
have a significant selective advantage against DRV or APV 
  
DISCUSSION 
Although the majority HIV-1 patients are infected with non-B forms of the virus, 
molecular studies have been predominantly carried out on clade B variants. The AE 
protease has several polymorphisms that are associated with inhibitor resistance in clade 
B.  AE also shows altered patterns of drug resistance to NFV.  We have performed 
detailed studies to determine the effects of sequence polymorphisms on enzyme structure,  
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TABLE III-4 Vitality values for clade B-D30N, N88D, AE-WT and AE-N88S variants. 
 
Inhibitor B D30N, N88D AE WT AE N88S 
NFV 0.8 ± 0.6 2.5 ± 1.4 4.0 ± 1.9 
DRV 0.2 ± 0.2 0.9 ± 0.7 2.0 ± 2.0 
APV 0.007 ± 0.005 0.3 ± 0.2 0.02 ± 0.02 
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activity and inhibitor binding. These analyses lead to a structural rationalization for the 
altered pathways for drug resistance. AE-WT protease has an inherently weaker affinity 
for NFV and DRV than B-WT as is evident from the thermodynamic data (Table III-2). 
The weaker affinity observed for NFV is consistent with previously published data for 
another AE protease variant (Clemente et al., 2006) as well as for clade A protease 
(Valzaquez-Campoy et al., 2001), which is closely related. The inherent weaker affinity 
for NFV likely allows the AE protease to gain resistance to NFV through a single non-
active site substitution, N88S. The clade B protease, by contrast, which has a relatively 
stronger affinity for NFV, requires a combination of an active site (D30N) and non-active 
site mutation (N88D) to gain NFV resistance. The ability of the AE-N88S protease to 
maintain affinity for substrates is evident from our enzyme-kinetics data (Table III-4), in 
which the KM value for AE-N88S was comparable to that of AE-WT and B-WT protease. 
The KM value for clade B-D30N/N88D, on the other hand, was significantly worse than 
that of the B-WT, likely reflecting the effect of the altered active site.  
As an active site residue, Asp30 plays a key role in substrate recognition by 
interacting with substrates through side-chain–mediated hydrogen bonds with the MA-
CA, CA-p2, p1-p6 and p2-NC cleavage sites (Prabu-Jeyabalan, Nalivaika, and Schiffer, 
2002). Therefore, as is evident from our enzyme kinetics data, the D30N/N88D mutations 
in clade B will likely affect substrate binding and processing. Several studies have 
observed substrate co-evolution in instances where the protease mutates active site 
residues in order to confer inhibitor resistance (Kolli, Lastere, and Schiffer, 2006; Kolli et 
al., 2009). However, since the AE-N88S protease variant has no active site mutations, the 
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enzyme retains the ability to effectively recognize substrates while conferring NFV 
resistance.  Therefore, the presence of the N88S substitution in AE protease is unlikely to 
induce co-evolution of the viral substrates in order maintain effective enzymatic activity. 
Despite having KM values that were comparable to that of B-WT protease, both 
AE-WT and AE-N88S had significantly lower catalytic-turnover rates (kcat) than that of 
the B-WT protease (Table III-3). As a result, the catalytic efficiency of the AE variants is 
lower than that of the B-WT protease. The lower turnover rates of the AE variants could 
be a direct result of the reduced flexibility of the flap-hinge (residues 33–39) and core 
regions (residues 16–22) of the protein. Molecular-dynamics studies have revealed that 
hydrophobic sliding of the core region facilitates substrate binding through the opening of 
the active site (Foulkes-Murzycki, Scott, and Schiffer, 2007). The unique hydrogen bonds 
observed between the flap hinge and the core in the AE variants alter movement of the 
core, thus impacting the ability of the active site to open up for substrate binding and 
product release. Based on our enzyme kinetics data, this altered flexibility of the flap 
hinges in the AE variants has little effect on substrate binding but rather affects the 
catalytic step of the reaction by slowing down product release. 
The higher vitality value observed for AE-WT with NFV provides supporting 
evidence for the reduction in the efficacy of NFV against the AE protease compared with 
that of clade B (Table III-4). This result is consistent with previous vitality calculations 
for the clade A protease (Valzaquez-Campoy et al., 2001). In addition, these results 
further highlight the idea that background polymorphic sequence variations in the AE 
protease can affect the potency of NFV.  The sub-optimal efficacy of NFV against the 
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AE-WT protease likely permits a non-active site variant, AE-N88S, to emerge over 
variants with active site mutations to effectively confer resistance to NFV.  
 The impact on other inhibitors, however, is complex. APV and DRV are 
chemically very closely related compounds, and similar susceptibility and resistance 
patterns have been observed for these two inhibitors (Parkin et al., 2007).  However, this 
pattern is not evident for this series of resistant variants.  Both the N88S in the AE and 
D30N, N88D in the clade B proteases result in hypersusceptibility to APV. Similar 
results have been observed also for a B-N88S protease variant (Masquelier et al., 2008; 
Ziermann et al., 2000).  In contrast, these same substitutions in the protease give rise to 
even greater resistance to DRV. However, since DRV presents a greater genetic barrier to 
resistance than APV (Poveda et al., 2007), the in vivo implications of weaker affinity for 
DRV in the AE variants are likely negligible. Indeed our calculated vitality values 
indicate that DRV maintains its potency against the AE variants despite having a weaker 
affinity for AE-WT and AE-N88S relative to clade B protease. 
A close look at the NFVB-WT protease complex reveals an important interaction 
between the Asp30 residue side chain and the inhibitor bound in the active site. (PDB 
code: 3EKX, Figure III-4B). One of the side chain oxygen atoms of Asp30 forms a direct 
hydrogen bond with the O38 atom of NFV. Our crystal structures of the NFV resistant 
variants show that N88S in AE and N88D in clade B have the ability to interact with 
residue 30 and orient it away from the active site (Figure III-3B and III-3D) and thereby 
disrupt the interaction between residue 30 and the inhibitor. These structural observations 
are similar to interpretations made in previous molecular-dynamics studies involving   
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FIGURE III-4 
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FIGURE III-4 Hydrogen bond network involving residue 88 (A) Asn88 bridges the 
terminal helix with Asp30 from the active site and Thr74 from one of the outer beta-
strands. The red box indicates the region of the protease molecule highlighted in panels 
B-D. (B) Asn88 in NFVB-WT (PDB code: 3EKX). (C) Asp88 in DRVB-D30N/N88D. (D) 
Ser88 in DRVN88S-WT. Hydrogen bond interactions are indicated in red dashed lines. 
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NFV-protease complexes (Ode et al., 2007; Ode et al., 2005).  Thus, NFV resistance is 
likely caused in large part due to the loss of this interaction in the NFV resistant variants.  
Overall, mutations that emerge in response to inhibitor therapy need to have a 
minimal impact on protease structure and activity to maintain the enzyme’s function. The 
D30N substitution, which is associated with NFV resistance, is one of the few drug 
resistant mutations that involve a change in charge. The additional substitution of N88D 
likely helps preserve the net charge on the protein.  In AE, resistance to NFV occurs 
indirectly with the N88S mutation. Likewise, the sole NFV resistant alteration N88S in 
the AE protease, does not change the overall electrostatics. Thus, in both clade B and AE, 
NFV resistance is attained with no change to the net charge of the enzyme. In the wild 
type variants Asn88 is one of the few internal hydrogen bonding side chains in the core of 
the protease monomer.  The side chain of Asn88 has a key role in the protease structure 
bridging the terminal helix with residues 30 and 31 coming from the active site to the 
backbone of Thr 74 in the center of one of the outer beta-strands (Figure III-4A-B). With 
the substitutions of Asp in clade B and Ser in AE for Asn at position 88 in the NFV 
resistant protease variants, the hydrogen bonding network is preserved through the 
coordination of some key water molecules in the core of the protease monomer (Figure 
III-4B-D). Thus mutations confer resistance to NFV through a series of interdependent 
changes that preserve the structural and electrostatic properties of HIV-1 protease.  
 In conclusion protease activity and the response to protease inhibitors can be 
affected by clade-specific sequence differences.  Our findings likely extend beyond HIV-
1 protease and to other drug targets within HIV and underscore the need to consider 
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clade-specific polymorphisms when developing new drugs and formulating treatment 
plans. Furthermore, drug-resistance pathways observed in the context of clade B viruses 
cannot be assumed to hold true for other HIV-1 clades. 
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CHAPTER IV 
Differential Resistance in HIV-1 Protease: The Role of Residue 50 in Pathways for 
Amprenavir/Darunavir and Atazanavir Resistance. 
75
ABSTRACT 
The emergence of inhibitor resistance mutations is a major drawback in the use 
protease inhibitors in the treatment of HIV-1 infections. Residue 50 in HIV-1 protease is 
an active site residue that is often substituted in order to confer resistance to amprenavir 
(APV), darunavir (DRV) and atazanavir (ATV). The I50V substitution is often associated 
with APV and DRV resistance while the I50L substitution is observed in patients failing 
ATV therapy. Structural and binding thermodynamics studies were carried out to explain 
how APV, DRV and ATV susceptibility are influenced by mutations at residue 50 in 
HIV-1 protease.  Binding affinity data indicates that the I50V substitution can reduce 
affinity for APV and DRV. Interestingly, the I50V substitution made the protease more 
susceptible to ATV. The I50L variant had reduced affinity for ATV and DRV but was 
more susceptible to APV binding. Structural data indicate that perturbations resulting 
from substitutions at residue 50 affect how APV, DRV and ATV interact with protease. 
Thus, the varied inhibitor susceptibilities observed between the protease variants are 
likely a direct consequence of the structural differences resulting from the substitutions at 
residue 50. 
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INTRODUCTION 
With no cure available for the treatment of HIV infections at present, slowing 
down the progression of the infection to AIDS has been a major focus in anti-HIV 
therapy development. The aspartyl protease of HIV-1 has been an important drug target 
and presently there are nine FDA approved protease inhibitors (PIs) that are an important 
part of highly active anti retroviral therapy (HAART) (Debouck, 1992).  However, the 
selection of HIV-1 variants with inhibitor resistant mutations in the protease gene impairs 
the ability of PIs to effectively block protease activity (Condra et al., 1995; Emini et al., 
1996; Roberts, 1995). 
The HIV-1 protease is a homodimeric protein with 99 amino acid residues in each 
monomer with the dimeric interface forming the active site.  At least ten non-homologous 
and asymmetric substrate sites within the Gag and Gag-Pro-Pol polyproteins are cleaved 
by the HIV-1 protease to release viral enzymes and structural proteins essential for the 
formation of mature virions (Chou, 1996b; Henderson et al., 1988; Pettit et al., 1998; 
Sadler and Stein, 2002). PIs have been designed to effectively inhibit the binding and 
subsequent cleavage of the HIV-1 substrates and thereby prevent mature virion 
formation. Amino acid substitutions that accumulate within the protease can reduce the 
ability of a PI to effectively bind within the active site. This leads to PI resistance where 
the protease retains the ability to bind and cleave viral substrates regardless of the 
presence of the inhibitor. 
Amprenavir (APV), darunavir (DRV) and atazanavir (ATV) are three potent FDA 
approved PIs that bind to HIV-1 protease with high affinity (Figure IV-1A) (King et al.,  
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FIGURE IV-1 
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FIGURE IV-1 (A) Chemical structures of amprenavir, darunavir and atazanavir. 
Chemical groups that correspond to substrate residues when bound within the active site 
are indicated as P1, P2, P1’ and P2’. (B) Homodimeric HIV-1 protease with positions 50 
and 71 indicated by red spheres in each monomer.  
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2004d; Robinson et al., 2000; Sadler and Stein, 2002). However, substitutions at a 
number of amino acid positions within the protease have been observed to reduce the 
efficacy of APV, DRV or ATV. From these observations, substitutions accumulating at 
the active site residue position 50  (Figure IV-1B) are commonly associated with 
resistance for APV, DRV and ATV.  
Ile to Val substitution at residue 50 has been identified as the signature APV and 
DRV resistance mutation in patients failing APV and DRV therapy (Partaledis et al., 
1995b; Tisdale et al., 1999; Van Marck et al., 2007; Vermeiren et al., 2007). In patients 
undergoing ATV therapy, Ile to Leu at residue 50 was observed to accumulate in patients 
failing therapy (Colonno et al., 2004a; Colonno et al., 2004b). However, patients with the 
I50L substitution in protease have been observed to respond significantly better to other 
PIs and suggest that I50L makes the protease hypersusceptible to other PIs (Colonno et 
al., 2004b). The substitutions at residue 50 are often observed together with a secondary 
A71V substitution (Figure IV-1B) that is outside the active site (Colonno et al., 2004b). 
The A71V substitution has been shown compensate the loss of activity resulting from 
primary drug resistance substitutions (Nijhuis et al., 1999).  Overall, changes at residue 
50 appear to have the ability modulate differential resistance for APV, DRV and ATV.  
In the present study, structural and biophysical methods were used to determine 
the impact of substitutions at residue 50 on APV, DRV and ATV susceptibility. Binding 
thermodynamics data show that the I50V and I50L substitutions indeed affect protease 
susceptibility to APV, DRV and ATV. Through the determination of crystal structures 
and analysis of interactions between inhibitors and protease, structural rationalizations  
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are described for the molecular basis for the varied susceptibility observed in the residue 
50 variants. 
 
MATERIALS AND METHODS 
Protease-gene construction 
The wild-type protease (WT) gene was generated as previously described (Prabu-
Jeyabalan et al., 2004a) with the Q7K substitution introduced to prevent autoproteolysis 
(Rose, Salto, and Craik, 1993b).  The APV and DRV resistant variant (I50V) and the 
ATV resistant variant (I50L) protease genes were generated by introducing either I50V 
and A71V or I50L and A71V to the wild-type gene by site-directed mutagenesis using 
the Stratagene QuikChange site-directed mutagenesis kit (Agilent Technologies, La Jolla, 
CA). Mutagenesis was confirmed by sequencing.  
Protein expression and purification 
Each variant was subcloned into the heat-inducible pXC35 expression vector 
(American Type Culture Collection (ATCC), Manassas, VA) and transformed into E. coli 
TAP-106 cells. Protein overexpression, purification and refolding was carried out, as 
previously described (King et al., 2002). Protein used for crystallographic studies was 
further purified with a Pharmacia Superdex 75 fast-performance liquid-chromatography 
column (GE Healthcare, Chalfont St. Giles, U.K.) equilibrated with refolding buffer 
(50mM sodium acetate pH 5.5, 10% glycerol, 5% ethylene glycol, and 5mM 
dithiothreitol). 
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Isothermal titration calorimetry (ITC) 
Binding affinities and thermodynamic parameters of APV, DRV and ATV 
binding to the WT, I50V and I50L protease variants were determined by ITC on a VP 
isothermal titration calorimeter (MicroCal, LLC, Northampton, MA). The buffer used for 
all protease and inhibitor solutions consisted of 10 mM sodium acetate (pH 5.0), 2% 
dimethyl sulfoxide, and 2 mM tris[2-carboxyethyl]phosphine. Binding affinities for all 
protease variants were obtained by competitive-displacement titration using acetyl-
pepstatin as the weaker binder. A solution of 6–40 µM protease was titrated with 200-400 
µM acetyl-pepstatin to saturation. The pepstatin was then displaced by titrating 200-330 
µM of APV, DRV or ATV. Heats of dilution were subtracted from the corresponding 
heats of reaction to obtain the heat resulting solely from the binding of the ligand to the 
enzyme. Data were processed and analyzed with the ITC data analysis module (Microcal) 
for Origin 7 data analysis and graphing software (OriginLab, Northampton, MA). Final 
results represent the average of at least two measurements.  
Crystallization and structure determination 
Protease solutions of I50V and I50L at concentrations between 1.0 and 2.0 mg 
mL-1 were equilibrated with three- to five-fold molar excess of APV, DRV and ATV for 
1 hour on ice. Crystals were grown over a reservoir solution consisting of 126-mM 
phosphate buffer (pH 6.2), 63-mM sodium citrate and 18% to 40% ammonium sulfate by 
the hanging-drop vapor-diffusion method. X-ray diffraction data for I50V in complex 
with DRV were collected on BioCARS beamline 14-BMC at the Advanced Photon 
Source (Argonne National Laboratory, Argonne, IL) at a wavelength tuned to 0.9 Å with 
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a Quantum 315 CCD X-ray detector (Area Detector Systems Corporation, Poway, CA). 
Diffraction data for I50V in complex with APV and ATV were collected on BioCARS 
beamline 14-IDB at the Advanced Photon Source (Argonne National Laboratory) at a 
wavelength tuned to 1.03 Å with a MarCCD 165 X-ray detector (Rayonix, LLC, 
Evanston, IL). Data for all other complexes were collected in-house on an R-Axis IV 
imaging-plate system (Rigaku Corporation, Tokyo, Japan) mounted on a rotating-anode 
X-ray source (Rigaku Corporation) at a wavelength of 1.54 Å. All data were collected 
under cryo-cooled conditions. 
The data were indexed, integrated and scaled using HKL/HKL-2000 software 
(HKL Research, Charlottesville, VA) (Otwinowski and Minor, 1997). Structure 
determination was done by molecular replacement with the program AMoRe (Navaza, 
1994) and refinement were carried out using the CCP4 program suite (Collaborative 
Computational Project Number 4, 1994), as previously described (Prabu-Jeyabalan et al., 
2006b). The tensor (T), libration (L), and screw (S) parameter files used in TLS 
refinement of the I50V complexes were generated using the TLS Motion Determination 
server (Painter and Merritt, 2006). Model building was carried out, followed by real-
space refinement, with either the O molecular graphics software (Jones, Bergdoll, and 
Kjeldgaard, 1990) or the COOT molecular-graphics software (Emsley and Cowtan, 
2004). Structure comparisons were made by superposing structures using the Cα atoms 
of the terminal regions (residues 1 to 9 and 86 to 99) from both monomers. Structures 
were visualized using PyMol molecular-graphics software (DeLano, 2002). 
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TABLE IV-1. Crystallographic statistics for WT, I50V and I50L variants in complex with APV, DRV and ATV. 
 WT I50V I50L 
Inhibitor APV DRVa ATV APV DRV ATV APV DRV ATV 
Resolution (Å) 1.8 1.2 1.8 1.6 1.9 1.6 2.2 2.1 2.1 
Space group P 212121 P 212121 P 212121 P21 P21 P21 P 212121 P 212121 P21 
Cell dimensions:  a (Å) 50.7 54.9 50.9 50.6 50.62 51.2 50.9 51.4 51.2 
b (Å) 57.9 57.8 58.1 63.3 63.34 58.4 58.1 57.9 59.5 
c (Å) 61.7 62.0 62.0 58.6 58.64 62.1 61.2 61.4 59.9 
β (°) - - - 96.6 97.3 95.8 - - 82.2 
Zc 4 4 4 4 4 4 4 4 4 
Total no. of reflections 49,469 302,022 114,163 148,290 118,410 146,999 32,037 33,870 56,701 
Unique no. of reflections 14,987 50,056 16,905 36283 26,674 42,520 9,311 10,762 20,006 
Rmerge (%) 2.9 3.8 7.1 7.0 7.0 4.9 8.6 6.2 4.7 
Completeness (%) 79.7 95.5 95.7 98.0 99.6 96.2 95.7 96.6 95.8 
I/σI 19.0 25.0 11.3 8.7 8.4 11.6 6.4 7.9 9.8 
Rwork (%) 19.6 14.1 17.7 16.9 16.3 17.3 19.6 18.0 19.0 
Rfree (%) 22.6 17.9 20.9 20.5 21.2 21.5 25.8 24.0 24.8 
RMSDb:Bond length (Å) 0.007 0.004 0.008 0.008 0.010 0.009 0.008 0.004 0.008 
 Bond angle (°) 1.4 1.5 1.2 1.4 1.4 1.4 1.4 1.2 1.4 
PDB code 3EKV 1T3R 3EKY    3EM3 3EM6 3EM4 
 
a Adapted from (King et al., 2004) 
b Root mean square deviation. 
c Number of dimeric molecules in a unit cell. 
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Crystallographic and refinement statistics are given in Table IV-1. The structures of WT 
protease in complex with APV, DRV and ATV were previously solved in the lab. 
Double-difference plots were generated for each wild-type-inhibitor and mutant-
inhibitor protease structures to graphically visualize structural differences between the 
wild type and mutant inhibitor complexes, as previously described (Prabu-Jeyabalan et 
al., 2006b). Briefly, distances between all Cα atoms within the dimer were calculated for 
each complex. A distance-difference matrix was then computed for each atom for a given 
pair of complexes. The distance-difference matrix was then plotted as a contour plot 
using gnuplot plotting software (Williams and Kelly, 1998). 
The inhibitor-protease van der Waals contacts were estimated for each structure 
using a simplified Lennard-Jones potential as previously described (King et al., 
submitted). 
Nomenclature 
 The following nomenclature will be followed to refer to each crystal structure: 
Inhibitorprotease variant.  For example, APVWT, APVI50V and APVI50V refer to the WT, I50V 
and I50L variants in complex with APV. Prime notation is used to distinguish the two 
monomers in the protease dimer. For example, residue 30 from the first monomer would 
be referred to as Asp30 and the same residue from the second monomer would be 
referred to as Asp30’. 
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TABLE IV-2. Binding thermodynamic parameters for APV, DRV and ATV binding to WT, I50V and I50L protease. 
Protease 
Variant Ka (M
−
1) Kd (nM) Kd ratio 
ΔH  
(kcal mol–1) ΔΔH 
−TΔS  
(kcal mol–1) Δ(−TΔS) 
ΔG  
(kcal mol–1) ΔΔG 
APV 
WT (2.6 ± 1.3) × 109 0.39 ± 0.20 1.0 −7.3 ± 0.9 - −5.3 - −12.6 - 
I50V (1.1 ± 0.03) × 109 0.88 ± 0.02 2.3 ± 1.8 −11.8 ± 0.3 −4.5 −0.3 5.0 −12.1 0.5 
I50L (7.3 ± 1.2) × 109 0.14 ± 0.02 0.4 ± 0.2 −9.5 ± 0.2 −2.2 −3.8 1.5 −13.2 −0.6 
DRV 
WT (2.2 ± 1.1) × 1011 0.004 ± 0.002 1.0 −12.1 ± 0.8 - −3.1 - −15.2 - 
I50V (1.5 ± 0.5) × 1010 0.067 ± 0.021 16.8 ± 9.9 −12.0 ± 0.6 0.1 −1.6 1.5 −13.6 1.6 
I50L (6.1 ± 0.5) × 1010 0.016 ± 0.001 4.0 ± 2.0 −13.4 ± 0.9 −1.3 −1.1 2.0 −14.5 0.7 
ATV 
WT (4.5 ± 2.4) × 109 0.23 ± 0.12 1.0 −1.1 ± 0.2 - −11.8 - −12.9 - 
I50V (0.4 ± 0.2) × 109 0.03 ± 0.01 0.13 ± 0.08  −7.3 ± 1.1 −6.2 −6.6 5.2 −13.9 −1.0 
I50L (1.5 ± 0.1) × 109 0.65 ± 0.05 2.8 ± 1.5 −3.6 ± 0.4 −2.5 −8.7 3.1 −12.3 0.6 
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RESULTS 
Binding thermodynamics 
To determine the effects of resistance mutations at position 50 in HIV-1 protease 
on inhibitor binding, the binding thermodynamic parameters of APV, DRV and ATV 
binding to WT, I50V and I50L variants were determined by ITC (Table IV-2). The I50V 
variant showed 2.2-fold and 16.7-fold weaker affinity for APV and DRV respectively 
when compared to the binding affinities of the WT protease. In contrast, the I50V variant 
had a 7.7-fold improved binding affinity for ATV  (Kd = 0.03 nM) when compared with 
the WT protease (0.23 nM). Thus, the binding data indicated that while the I50V variant 
had reducing affinity for APV and DRV, the protease was more susceptible to ATV. 
 The I50L variant had a 2.8-fold and 2.0-fold weaker affinity for ATV and DRV 
respectively when compared with the WT protease.  Despite the weaker affinity for DRV, 
the I50L variant nonetheless exhibits a Kd for DRV (Kd = 0.016 nM) that is 40.6-fold 
better than for ATV (Kd  = 0.65 nM). In contrast, APV bound with higher affinity to the 
I50L variant when compared with WT protease and indicated that the I50L variant was 
more susceptible to APV. 
No significant changes were observed in the free energies of binding for APV, 
DRV or ATV with I50V or I50L when compared to the WT protease. The binding of 
DRV to all protease variants was enthalpically favorable and the drug resistance 
mutations had negligible effects on the binding thermodynamic parameters. The binding 
of APV and ATV was enthalpically favorable with all protease variants. However, with 
the drug resistant variants, the enthalpic contribution was reduced and was compensated 
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by an increase of the entropic contribution when compared to the binding to WT 
protease.  
Crystal Structures 
To evaluate effect of substitutions at residue 50 in protease I50V and I50L 
protease variants were co-crystallized with APV, DRV and ATV and compared to the 
WT inhibitor of each complex. The APVWT, DRVWT and ATVWT complexes were 
previously solved in the lab. The DRVI50V, ATVI50V and ATVI50L protease complexes 
crystallized with two protease dimers in the asymmetric unit. The APVI50V protease had a 
second inhibitor molecule bound outside the active site of one of the dimers and is likely 
a crystallographic artifact since ITC data for APV binding to the I50V variant does not 
support the presence of a second binding site. Structural comparisons were carried out for 
each inhibitor-protease resistant variant and corresponding WT protease complex by 
pairwise structural superpositions and double difference plots as described in the 
Materials and Methods section (Figure IV-2).  
  The superposed structures and double difference plots for APVI50V, DRVI50V and 
ATVI50V revealed several regions of the protease backbone that differed between the 
mutant and WT structures (Figure IV-2 A-I). These differences predominantly were 
concentrated around Gly40-Arg57 (flap region), which included the I50V substitution, 
and Gly68-Gly71, which included the A71V substitution. The differences seen in the flap 
region were more prominent in one monomer of the DRVI50V structure. Similar structural 
changes were observed in the APVI50L, DRVI50L and ATVI50L structures (Figure IV-2 J- 
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FIGURE IV-2. Ribbon representations of structural superpositions and double difference 
plots. WT structures are colored in grey, I50V in blue and I50L in magenta in the ribbon 
diagrams. The color contours in the double difference plots indicate distance differences 
of < -1.0 Å (black), -1.0 to -0.5 Å (green), 0.5 to 1.0 Å (blue) and > 1.0 Å (red). (A) 
APVWT and APVI50V. (B) Double difference plot for APVWT and APVI50V dimer 1. (C) 
Double difference plot for APVWT and APVI50V dimer 2. (D) DRVWT and DRVI50V. (E) 
Double difference plot for DRVWT and DRVI50V dimer 1.  (F) Double difference plot for 
DRVWT and DRVI50V dimer 2.  (G) ATVWT and ATBI50V (H) Double difference plot for 
ATVWT and ATBI50V dimer 1. (I) Double difference plot for ATVWT and ATVI50V dimer 
2. (J) APVWT and APVI50L. (K) APVWT and APVI50L. (L) Double difference plot for 
DRVWT and DRVI50L. (M) DRVWT and DRVI50L. (N) Double difference plot for ATVWT 
and ATVI50L. (O) Double difference plot for ATVWT and ATVI50L dimer 1. (P) Double 
difference plot for ATVWT and ATVI50L dimer 2.  
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P). However the, APVI50L and DRVI50L structures had contours in the double difference 
plots that map to backbone shifts greater than 1.0 Å when compared to the WT 
complexes (Figure IV-2 J and L). Furthermore, difference peaks observed for the 
APVI50L and DRVI50L complexes were significantly less than for that of ATVI50L (Figure 
IV-2 K, M, O and P) and indicated that backbone shifts resulting from the I50L 
substitution were smaller than those observed for ATVI50L.  
 To investigate if residues 50 and 71 play a role in modifying inhibitor binding, 
hydrogen bond interactions between the inhibitors and protease variants were analyzed. 
The APVI50V structure showed no significant difference in the hydrogen bonding pattern 
when compared to the APVWT structure. The APVI50L structure exhibited a loss in one 
hydrogen bond between Asp29 N of the protease and O6 of APV while two new 
hydrogen bond interactions were observed between N3 of APV and Asp30 OD2, and 
with O1 of APV and a water molecule. Hydrogen bond interactions between DRVwt, 
DRVI50V and DRVI50L were almost identical with the notable difference being that the N1 
atom of DRV in the DRVI50V and DRVI50L complexes directly interacted with the Asp30’ 
side chain whereas in the DRVWT structure, the N1-Asp30’ interaction was bridged via a 
water molecule. Analyses of the ATV complexes revealed no significant changes in the 
hydrogen bonding interactions between the inhibitor and protease. Thus, the varied 
inhibitor susceptibilities observed with the binding data are not a direct result of changes 
in protease-inhibitor hydrogen bonding. 
 Van der Waals interactions between the protease and inhibitors were analyzed for 
each complex (Figure IV-3A-I). Ile50 interacts with the sulfonyl moiety in the APV and  
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FIGURE IV-3
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FIGURE IV-3. Van der Waals interactions of residue 50 with APV, DRV and ATV with 
the protease variants. Protease variants are colored: WT (gray), I50V (blue) and I50L 
(green). The inhibitors are colored in salmon. (A) APVWT. (B) APVI50V. (C) APVI50L. (D) 
DRVWT. (E) DRVI50V. (F) DRVI50L. (G) ATVWT. (H) ATVI50V. (I) ATVI50L. 
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DRV complexes and packs against the t-butyl group at the P2’ position in the ATV 
complex (Figure IV-3). A significant loss of van der Waals interactions was observed at 
Val50 in the APVI50V, DRVI50V and ATVI50V complexes when compared to the WT 
complexes (Figure IV-3A, B, D, E, G and H). Similarly, Leu50 in the ATVI50L variant 
had reduced van der Waals interactions with the inhibitor when compared to the WT 
complex (Figure IV-3I). However, in comparison, the change in van der Waals 
interactions between the I50L variant and APV and DRV was negligible (Figure IV-3A, 
C, D and F).  Overall, amino acid changes at residue 50 resulted in changes in van der 
Waals contacts with the inhibitor predominantly around the P2 position of the inhibitors. 
 
DISCUSSION 
 APV, DRV and ATV are potent inhibitors that are used as a part of HAART to 
slow down the progression of HIV-1 to AIDS (King et al., 2004d; Robinson et al., 2000; 
Sadler and Stein, 2002). However, amino acid substitutions accumulating at residue 50 in 
protease have been observed to affect susceptibility to these inhibitors. The I50V/A71V 
substitutions have been observed predominantly in patients failing APV and DRV 
therapy while the substitutions I50L/A71V occur in patients failing ATV therapy 
(Colonno et al., 2004a; Colonno et al., 2004b; Partaledis et al., 1995b; Tisdale et al., 
1999; Van Marck et al., 2007; Vermeiren et al., 2007). To examine how substitutions at 
residue 50 affect inhibitor susceptibility we have performed detailed analyses on binding 
thermodynamics and structural data of APV, DRV and ATV interactions with I50V and 
I50L protease variants.   The results presented in this study provide insights into the 
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molecular basis for differential susceptibility profiles observed in HIV-1 protease 
resulting from the I50V and I50L resistance mutations.  
 The I50V/A71V substitutions reduced affinity of both APV and DRV, which have 
closely related chemical structures (Table IV-1 and Figure IV-1A). Thus, the weaker 
affinity observed for the I50V variant provides a likely explanation for therapy failure in 
patients receiving APV and DRV therapy. Conversely, the I50V variant was more 
susceptible to ATV. The idea of hypersusceptibility of the I50V variant to ATV has not 
been widely established. However, there have been clinical reports of increased or no 
change in susceptibility to ATV in patients who carry the I50V mutation in the protease 
gene (Colonno et al., 2004a; Elston et al., 2006; Wainberg, Martinez-Cajas, and Brenner, 
2007). In one instance the hypersusceptibility was observed in the presence of Gag 
cleavage site mutations (Wainberg et al., 2007). Our binding thermodynamics data, in 
combination with the clinical observations, suggest that the I50V substitution has the 
potential to make the protease more susceptible to ATV. However, secondary mutations 
or cleavage site mutations might be required in order to enhance the binding of ATV to 
I50V protease in-vivo.  
 Binding thermodynamics data indicate the the I50L variant has reduced affinity 
for ATV (Table IV-2). This result is consistent with previously published reports and 
supports clincal observations where patients who accumulate the I50L mutation in the 
protease gene respond poorly to ATV therapy (Colonno et al., 2004b). The increased 
affinity of the I50L variant to APV is also consistent with previously published data and 
corroborates the idea that the I50L substitution makes the protease hypersusceptible to 
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APV (Colonno et al., 2004b; Yanchunas et al., 2005). While a similar result was expected 
for DRV given its high degree of similarity to APV, a two-fold loss of affinity was 
observed with DRV binding to the I50L variant. Despite the loss of affinity DRV 
maintained a high affinity (Kd = 16.0 pM) to the I50L variant which is 14-fold higher 
than ATV binding WT protease (Kd = 230.0 pM) . Thus, despite the loss of affinity for 
the I50L variant, DRV could still effectively inhibit the protease. 
 Based on our structural analysis the I50V subsitution loses a signficant amount of 
van der Waals interactions with the sulfonyl group of APV and DRV (Figure IV-3). With 
the I50V substitution, residue 50 loses the ability to form better interactions with thus 
sulfonyl moeity due to the loss of the branched methyl group in valine. This loss of 
interactions could contribute to the reduced  binding affinities observed for APV and 
DRV with the I50V variant. However, reasons for the increased suceptibility of the I50V 
variant to ATV are not evident from the crystal structures. The shorter side chain of 
Val50 is unlikely to have steric clashes with the bulky t-butyl group of ATV at P2’ 
position. Thus, Val50 can pack well against the t-butyl group of ATV and allow the 
inhibitor to bind with minimal structural perturbations which is likely reflected in the 
gain of free energy of binding (ΔΔG = −1.0 kcal mol-1). 
 The longer side chain of Leu50 likely results in steric clashes with the bulky t-
butyl groups of ATV at the P2’ positions in the ATVI50L complex.  Therefore, in order to 
accommodate the inhibitor residue 50 is slightly shifted outward relative to Ile50 in the 
WT complex. This shift in the flap backbone is relected in the structural superpositions 
and double difference plots (Figure IV-2 N-P). Furthermore, the backbone shift results in 
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the loss of favorable van der Waals contacts with the inhibitor particularly at Ile50 and 
P2’ position. These observations are similar to results obtained by modeling studies on 
ATV with I50L protease (Yanchunas et al., 2005). Conversely, with the I50L 
substitution, the additional methyl group in Leu allows residue 50 to maintain its 
interactions with the sulfonyl group at P2 and likely contributes to the increased affinity 
observed for APV. 
 In conclusion, our findings show that amino acid substitutions at residue 50 in 
HIV-1 protease can alter APV, DRV and ATV susceptibility and are consistent with 
observations seen in clinical studies. Results presented in this study suggest that the 
varied susceptibility to APV, DRV and ATV are likely a consequence from structural 
perturbations resulting from substitutions at residue 50 that alter interactions between 
inhibitors and protease. Furthermore, the accumulation of I50V or I50L as inhibitor 
resistance substitutions is likely influenced by the chemical moeities that interact with 
residue 50. While the results presented in this study provide insights into the molecular 
basis for APV, DRV and ATV resistance through changes at residue 50, further studies 
are needed to evaluate secondary resistance mutations that occur together with I50V and 
I50L as well as cleavage site mutations order to better understand observations seen in 
clinical settings.  
 
ACKNOWLEDGEMENTS 
This work was supported by the National Institutes of Health grant (P01-
GM66524) and Tibotec Inc.  Use of the Advanced Photon Source for x-ray data 
98 
collection was supported by the U.S. Department of Energy, Basic Energy Sciences, 
Office of Science, under Contract No. DE-AC02-06CH11357. Use of the BioCARS 
Sector 14 was supported by the National Institutes of Health, National Center for 
Research Resources, under grant number RR007707. The protease inhibitors used in this 
study were obtained through the NIH AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH. I would also like to thank Drs. William Royer and 
Madhavi Nalam for helpful discussion when solving the crystal structures. 
99 
CHAPTER V 
Discussion 
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The HIV-1 and AIDS pandemic continues to be a serious global health issue 
despite efforts for almost thirty years to suppress the virus. With no cure available to treat 
HIV-1 infections and AIDS, inhibiting the spread of the virus has been a key focus in 
efforts to slow down the progression of the infection to AIDS. HIV-1 protease is an 
important component of the viral replication cycle and thus, has been a key anti-HIV 
drug target. Currently there are nine FDA approved protease inhibitors that are used 
successfully as a part of HAART. However, as is with all anti-HIV drugs, the emergence 
of drug resistance substitutions within the protease has been a major obstacle with the use 
of PIs. These substitutions can significantly reduce the efficacy of the PI being used and 
resistance substitutions emerge against all currently available PIs. The emergence of 
resistance substitutions gives rise to a constant need to design new inhibitors to help 
patients combat drug resistant viral strains. Thus, it is important to understand how 
resistance substitutions modulate inhibitor binding in order to design robust inhibitors 
that are not influenced by resistance substitutions. 
The primary focus of my dissertation research was to try and understand the 
molecular basis for drug resistance due to amino acid substitutions in protease. A 
combination of biochemical and biophysical studies were performed to gain mechanistic 
insights into how amino acid substitutions within protease affect enzyme function as well 
as to understand how they contribute to PI resistance. Furthermore, as a part of these 
studies, I have analyzed the role of clade specific protease sequence variations in 
modulating enzyme activity and PI susceptibility. 
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Drug resistance in non-B clade HIV-1 proteases 
Until recently, the genetic diversity of the HIV-1 genome was not considered to 
be important in formulating anti-HIV treatment strategies. However, as the incidence of 
HIV-1 continues, the genetic variability of HIV-1 has been identified to be an important 
factor that influences viral transmission and disease progression (Hu et al., 1999; Kaleebu 
et al., 2002a; Kanki et al., 1999a; Spira et al., 2003b). Clinical observations show that 
clade specific sequence variations within HIV-1 protease can affect inhibitor 
susceptibility as well as the development of inhibitor resistance (Kantor and Katzenstein, 
2003; Kantor and Katzenstein, 2004). Furthermore, different HIV-1 clades have been 
observed to develop altered pathways to inhibitor resistance (Ariyoshi et al., 2003a; 
Grossman et al., 2004b). Clade B is the most widely studied HIV-1 clade and at present, a 
vast body of biochemical and structural knowledge exists on clade B protease. At the 
time this dissertation research was undertaken, limited biochemical data and no structural 
data were available on non-B clade proteases.  
Work carried out by Valzaquez-Campoy and colleagues on a number of HIV-1 
clades from the sub-Saharan Africa region initially showed that clade specific sequence 
variation had varied enzymatic activity and inhibitor susceptibility when compared to 
clade B protease (Velazquez-Campoy et al., 2003; Velazquez-Campoy, Vega, and Freire, 
2002). In work presented in chapters II and III, I have focused on the HIV-1 CRF01_AE 
(AE) protease, which is one of the prototypic recombinant HIV-1 variants, and have 
examined how sequence variations specific to AE protease affected protease structure 
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and function as well as their role in influencing the pathway to nelfinavir (NFV) 
resistance.  
 AE protease has seven amino acid positions that can differ from the clade B 
protease sequence. A number of these amino acid differences seen in the wild type AE 
protease sequence, are associated with inhibitor resistance in clade B protease. Therefore, 
one working hypothesis in this study was that AE protease has a baseline level of 
resistance when compared to clade B protease. Moreover, this baseline level of resistance 
should enable AE protease to confer resistance much faster than clade B protease. From 
results presented in Chapter III, I was able to show that AE protease had an inherent 
weaker affinity for the PIs NFV and darunavir (DRV) and thus confirmed the hypothesis.  
The weaker affinity observed for NFV is also consistent with previously published data 
for another AE protease variant as well as for clade A protease, which closely related to 
AE (Velazquez-Campoy et al., 2003). Furthermore, preliminary binding studies on wild 
type clade C protease (Appendix I) strengthen the idea that non-B clade proteases can 
have varied resistance profiles when compared to clade B protease. 
 Structural data presented in chapters II and III show that sequence polymorphisms 
in AE protease result in structural changes within the protease. These changes are 
primarily centered around the flap hinge region and core region of the protease. The 
crystal structures of AE protease show that the flap hinge is packed against the core 
region and this packing is stabilized by hydrogen bonds. The relatively short side chain of 
Ile36 likely facilitates the packing of the flap hinge against the core region of the 
protease. Conversely, Met36 in clade B protease has a longer side chain and prevents the 
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flap hinge from collapsing against the core region. Thus, the AE protease flap hinge is 
more restrained when compared to the clade B protease flap hinge. Recently published 
crystal structures of clades A and F protease show flap hinge restrictions similar to AE 
protease (Robbins et al., 2010; Sanches et al., 2007a). The protease from clades A and F 
also have Ile36, which appears to facilitate the packing of the flap hinge against the core 
region of the protease.  
 The movement of the protease flaps is essential for allowing substrates to bind 
and for cleaved products to be released (Foulkes-Murzycki, Scott, and Schiffer, 2007). 
Thus, the flap hinge region of HIV-1 protease plays an important role in modulating flap 
dynamics (Rose, Craik, and Stroud, 1998b; Scott and Schiffer, 2000; Todd and Freire, 
1999b). The structural data presented in chapters II and III suggest that the AE protease 
flap hinge is more restricted when compared to the clade B protease. With enzyme 
kinetics data described in Chapter III, I was able to show that the catalytic efficiency of 
AE protease was significantly less than clade B protease. The decreased catalytic 
efficiency could be a result of the restricted flap hinge of the AE protease.  
 The protease needs to undergo significant conformational changes in order to 
facilitate substrate binding. Molecular dynamics studies have suggested that hydrophobic 
sliding of residues within the core region of the protease may be important to facilitate 
the conformational changes the protease needs to undergo to allow substrate binding and 
product release (Foulkes-Murzycki, Scott, and Schiffer, 2007). The hydrogen bond 
interactions between the flap hinge and core region of the AE protease have the ability to 
disrupt the hydrophobic sliding or the core. Thus, the constrained movement of the core 
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region may well be reflected in the decreased catalytic efficiency values observed for AE 
protease.     
 NFV resistance in clade B protease occurs through a combination of an active site 
mutation D30N and a non-active site mutation N88D. However, NFV resistance in AE 
occurs mainly through the non-active site N88S substitution. In data presented in Chapter 
III, I provide structural explanations for the molecular basis for NFV resistance resulting 
from the two different pathways. Clinical observations report that AE infected patients 
who accumulate the N88S substitution in response to NFV, quickly develop an additional 
L10F substitution in protease (Ariyoshi et al., 2003a). In vitro viral replication capacity 
studies have indicated that accumulation of the N88S substitution in protease 
significantly reduces the replicative capacity of the virus (Dr. Wataru Sugiura, personal 
communication). L10F is a non-active site substitution and therefore, it is not clear how 
this substitution enhances replicative capacity of the N88S variant. Kinetics studies have 
shown that the L10F substitution by itself did not have any significant effect on protease 
activity (Pazhanisamy et al., 1996). Thus, future enzyme kinetics and inhibitor binding 
studies need to evaluate the role of L10F in AE protease combination with the N88S 
substitution. Additional crystallographic studies on AE protease with N88S and L10F 
substitutions may provide structural insights into the role of L10F in enhancing the 
effects of the N88S substitution. 
 At present, very little is known about the variability of substrate sequences 
between HIV-1 clades. A study analyzing a set of 89 HIV-1 sequences from a number of 
clades revealed that while the majority of substrate cleavage sites were conserved 
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between clades, the p2/NC, TFP/p6pol, and p6pol/PR sites were variable between clade B 
and C HIV-1 variants (de Oliveira et al., 2003). Recent years have seen an increase in the 
number of full-length non-B clade HIV-1 sequences available through sequence 
repositories. Therefore, as a future direction, I propose to examine how substrate 
cleavage sites differ between clades. Substrate cleavage sites often co-evolve in response 
to drug resistance substitutions in protease (Kolli, Lastere, and Schiffer, 2006; Kolli et al., 
2009). Thus, analysis of non-B substrate sites might reveal substrates that have co-
evolved in response to clade specific sequence variations in protease. The sequence in 
which the Gag and Gag-Pro-Pol polyproteins are processed is essential for the proper 
maturation of HIV virions. The decreased catalytic efficiency of AE protease may well 
alter how Gag and Gag-Pro-Pol polyproteins are processd. If substrates co-evolve in 
response to clade specific variations in protease, they likely restore proper Gag and Gag-
Pro-Pol processing and this can be tested experimentally.  
 
The role of residue 50 in altering inhibitor susceptibility 
 Residue 50 in protease is one of the few active site residues that change to confer 
differential PI resistance. Ile50 is often seen substituted to valine in patients failing 
amprenavir (APV) and DRV therapy (Partaledis et al., 1995a; Tisdale et al., 1999; Van 
Marck et al., 2007). Patients failing atazanavir (ATV) therapy predominantly accumulate 
the I50L substitution in protease (Colonno et al., 2004a; Colonno et al., 2004b). Using 
binding thermodynamics data described in Chapter IV, I have shown that changes at 
residue 50 change the susceptibility profiles of APV, DRV and ATV. By analyzing 
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crystal structures I have shown that changes at residue 50 can cause subtle structural 
changes that alter protease-inhibitor interactions. These altered protease-inhibitor 
interactions are the likely cause for the varied susceptibility profiles observed with the 
binding data. 
 Clinical observations show that the I50L substitution makes the protease 
hypersusceptible to other inhibitors (Colonno et al., 2004b). Binding data obtained for the 
I50L variant appear to support this observation. Interestingly, the binding data show that 
the I50V substitution makes the protease more susceptible to ATV. Hypersusceptibility 
of the I50V variant to ATV has not been well described in the literature. However, a 
recent report describes a case where ATV hypersusceptibility was observed in 
combination with cleavage site mutations (Wainberg, Martinez-Cajas, and Brenner, 
2007).  
Since residue 50 is within the active site, substitutions at this position can 
significantly affect protease activity. A number of studies have indeed shown that 
enzymatic activity and replicative capacity are affected by substitutions to Ile50. The 
A71V substitution partially restores defects resulting from substitutions at residue 50 
(Colonno et al., 2004b; Pazhanisamy et al., 1996). Furthermore, analysis of Gag cleavage 
sites has shown that the I50V substitution is often associated with co-evolution of the p1-
p6 substrate (Kolli et al., 2009). Moreover, substitutions at residue 50 often occur in 
combination with a number of secondary mutations (Colonno et al., 2004b; Pazhanisamy 
et al., 1996). Therefore, future directions need to examine substitutions at residue 50 in 
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combination with common secondary mutations as well as in combination with cleavage 
site substitutions.  
 
Conclusions 
Collectively, my dissertation research provides mechanistic insights into how 
amino acid substitutions within protease modulate protease activity and contribute to 
inhibitor resistance. Furthermore, these studies have examined how clade specific 
sequence variations contribute to inhibitor resistance. The genetic diversity of HIV-1 
continues to grow as HIV-1 prevails across the world. There is evidence to suggest that 
genetic variation is a factor in viral transmission and disease progression as well as in the 
emergence of inhibitor resistance. Thus, it is essential that we understand how genetic 
variations modulate HIV drug targets and contributes to inhibitor resistance. Being able 
to understand how drug resistance occurs at a molecular level can provide valuable 
insights that can help in the design of robust PIs that are not susceptible to resistance 
substitutions. Furthermore, until a definitive cure is developed to treat HIV-1 infection 
and AIDS, mechanistic insights into drug resistance can aid in the formulation of better 
treatment strategies to slow down the progression of HIV infections to AIDS. 
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APPENDIX I 
Structural and Biochemical Studies on HIV-1 Clade C Protease 
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INTRODUCTION 
 Based on genomic diversity the HIV-1 is classified into nine major clades (A, B, 
C, D, F, G, H, J and K) and 43 circulating recombinant forms (Los Alamos Laboratory, 
2010; Robertson et al., 2000). While the majority of knowledge available on HIV-1 is 
based on studies carried out on clade B viral strains, non-B clade infections account for 
over 80% of HIV-1 infections in the world.  In recent years, several studies have 
observed that disease progression and modes of transmission can differ between clades 
(Hu et al., 1999; Kanki et al., 1999a; Kiwanuka et al., 2008). Thus, given that currently 
available anti-HIV therapeutics were developed using studies on clade B strains, these 
observations raise legitimate questions regarding the efficacy of currently available anti-
HIV therapies against different clades.  
Clade C is the most predominant form and accounts for over 50% of the 
infections in the world and is primarily seen is sub-Saharan regions and in south and 
central Asia (Buonaguro, Tornesello, and Buonaguro, 2007; Wainberg, 2004). Several 
clinical studies have observed that clade C has differences in the mode of viral 
transmission as well as progression to AIDS when compared to other clades (Essex, 
1996; Kanki et al., 1999a; Renjifo et al., 2004). Furthermore, the clade C protease has 
also been observed to have a different resistance pathway from that of clade B to confer 
resistance to the protease inhibitor nelfinavir (NFV). In patients infected with clade C, the 
protease predominantly accumulates the L90M substitution while D30N/ N88D is the 
most common NFV resistance profile in patients with clade B. Thus, additional studies 
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on non-B clades are warranted in order to better understand the reasons for these 
observed differences so that better treatment strategies can be formulated. 
The amino acid sequence of clade C protease differs by ~10% when compared to 
the clade B protease with all the amino acid differences mapping to positions outside the 
active site (Figure AI-1). Several of these amino acid differences are associated with 
protease inhibitor resistance in clade C. The biochemical and biophysical data presented 
in this appendix are an effort to better understand how sequence variations in clade C 
when compared to clade B affect enzyme activity and inhibitor binding as well as to 
determine how they might influence pathway to NFV resistance. 
 
MATERIALS AND METHODS 
Protease-gene construction 
The clade C wild type (AE-WT) protease gene was synthesized (Integrated DNA 
Technologies, Coralville, IA), with codons optimized for expression in Escherichia coli. 
Q7K, L33I and L63I mutations were introduced into the protease gene to prevent 
autoproteolysis. The gene was subcloned into the pET11a expression vector 
(Novagen/EMD Chemicals, Gibbstown, NJ). The protease sequence was confirmed by 
DNA sequencing.  
Protein expression and purification 
The clade C gene was subcloned into the heat-inducible pXC35 expression vector 
(American Type Culture Collection (ATCC), Manassas, VA) and transformed into E. coli 
TAP-106 cells. Protein overexpression, purification and refolding was carried out, as 
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FIGURE AI-1
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FIGURE AI-1. A. Amino acid sequence alignment of clade B and C protease. Sequence 
differences between the two clades are indicated in red. B. Amino acid sequence 
differences in clade C map to positions outside the active site. Sequence differences are 
indicated in red spheres. 
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previously described (King et al., 2002). Protein used for crystallographic studies was 
further purified with a Pharmacia Superdex 75 fast-performance liquid-chromatography  
column (GE Healthcare, Chalfont St. Giles, U.K.) equilibrated with refolding buffer 
(50mM sodium acetate pH 5.5, 10% glycerol, 5% ethylene glycol, and 5mM 
dithiothreitol). 
Isothermal titration calorimetry (ITC) 
Binding affinities and thermodynamic parameters of inhibitor binding to clade C 
protease were determined by ITC on a VP isothermal titration calorimeter (MicroCal, 
LLC, Northampton, MA). The buffer used for all protease and inhibitor solutions 
consisted of 10 mM sodium acetate (pH 5.0), 2% dimethyl sulfoxide, and 2 mM tris[2-
carboxyethyl]phosphine. Binding affinities for all protease variants were obtained by 
competitive-displacement titration using acetyl-pepstatin as the weaker binder. A solution 
of 30–45 µM protease was titrated with 10-µL injections of 200 µM acetyl-pepstatin to 
saturation. The pepstatin was then displaced by titrating 36 8-µL injections of 200 µM 
amprenavir (APV) or NFV or 41 7-µL injections of 40 µM DRV. Heats of dilution were 
subtracted from the corresponding heats of reaction to obtain the heat resulting solely 
from the binding of the ligand to the enzyme. Data were processed and analyzed with the 
ITC data analysis module (Microcal) for Origin 7 data analysis and graphing software 
(OriginLab, Northampton, MA). Final results represent the average of at least two 
measurements. ITC data were compared with previously described clade B data (Chapter 
3). 
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Crystallization trials 
Protease solutions between 1.0 and 2.0 mg mL-1 were equilibrated with a fivefold 
molar excess of NFV, darunavir (DRV) for 1 hour on ice. Crystal trials were set up with a 
reservoir solution consisting of 126-mM phosphate buffer (pH 6.2), 63-mM sodium 
citrate and 18% to 23% ammonium sulfate by the hanging-drop vapor-diffusion method. 
Additional crystal screens were set up with the Hampton Crystal Screen and Crystal 
Screen 2 (Hampton Research, Aliso Viejo, CA) by the sitting-drop vapor diffusion 
method using a PHENIX crystallization robot (Art Robbins Instruments, Sunnyvale, CA). 
Measurement of protease activity 
Clade B and C protease activity was assayed by following each variant’s ability to 
hydrolyze the fluorogenic substrate HiLyte Fluor 488-Lys-Ala-Arg-Val-Leu-Ala-Glu-
Ala-Met-Ser-Lys (QXL-520) (AnaSpec Inc., Fremont, CA) that corresponds to the HIV-1 
Ca-p2 substrate. The assay was carried out in a 96-well plate, and the enzymatic reaction 
was initiated by adding 20 µL of a solution of 100–250 nM protease to 80 µL of substrate 
solution.  The buffer used in all reactions consisted of 10 mM sodium acetate (pH 5.0), 
2% dimethyl sulfoxide, and 2 mM tris[2-carboxyethyl]phosphine. Final concentrations in 
each experiment were 0–40 µM substrate and 20–50 nM protease. Accurate 
concentrations of properly folded active protease were determined by carrying out ITC 
experiments for each variant with acetyl-pepstatin as described in the previous section. 
Fluorogenic response to protease cleavage was monitored at 23°C using a Victor3 
microplate reader (PerkinElmer, Waltham, MA) by exciting the donor molecule at 485 
nM and recording emitted light at 535 nM. Data points were acquired every 30 seconds. 
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The data points in relative fluorescence units (RFU) were converted into concentrations 
using standard calibration curves generated for HiLyte Fluor 488 at each substrate 
concentration. In addition to converting RFUs to concentrations, generating calibration 
curves at each substrate concentration allowed us to correct for the inner filter effect 
(Copeland, 1996). Rates of each enzymatic reaction were determined from the linear 
portion of the data and were fitted against substrate concentrations to determine KM and 
kcat (catalytic-turnover rate) values using VisualEnyzmics enzyme-kinetics software 
(SoftZymics, Princeton, NJ). Final results for each variant represent the average of at 
least three experiments. 
 
RESULTS  
Binding thermodynamics 
 Binding thermodynamics parameters of NFV, DRV and APV binding to clade C 
and clade B protease were determined in order to evaluate the effects of background 
sequence polymorphisms on inhibitor binding in clade C. The binding thermodymics 
parameters are compared to values from clade B in Table AI-1. Clade C protease had a 
14.6-fold weaker affinity (Kd = 5.7 nM) for NFV when compared to clade B protease (Kd 
= 0.39 nM). Similarly, DRV had a 28.5-fold reduced affinity (Kd = 0.114 nM) compared 
to clade B (Kd = 0.004 nM). However, the affinity of APV binding to clade C protease 
was comparable to clade B. Overall, the binding of NFV, DRV and APV to clade C 
protease was enthalpically unfavorable (Table AI-1). However, the loss in binding  
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TABLE AI-1. Binding thermodynamic parameters for NFV, DRV and APV binding to Clade C and clade B protease variants. 
Protease Variant Ka (M–1) Kd (nM) 
Kd 
ratio 
ΔH  
(kcal mol–1) ΔΔH 
–TΔS  
(kcal mol–1) Δ(–TΔS) 
ΔG  
(kcal mol-1) ΔΔG 
NFV 
Clade B WT (2.6 ± 0.5) × 109 0.39 ± 0.07 1.0 4.4 ± 0.1 - –17.0 - –12.6 ± 0.1 - 
Clade C WT (1.7 ± 1.8) × 108 5.7 ± 5.9 14.6 8.3 ± 0.3 3.9 –19.3 –2.3 –11.1 ± 0.05 1.5 
DRV 
Clade B WT (2.2 ± 1.1) × 1011 0.004 ± 0.002 1.0 –12.1 ± 0.9 - –3.1 - –15.2 ± 0.3 - 
Clade C WT (8.8 ± 6.1) × 109 0.114 ± 0.080 28.5 –9.1 ± 1.2 3.0 –4.6 –1.5 –13.3 ± 0.04 1.9 
APV 
Clade B WT (2.6 ± 1.3) × 109 0.39 ± 0.20 1.0 –7.3 ± 0.9 - –5.3 - –12.6 ± 0.3 - 
Clade C WT (1.8 ± 0.1) × 109 0.56 ± 0.03 1.4 –4.73 ± 0.02 2.6 –7.7 –2.4 –12.4 ± 0.03 0.2 
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enthalpy was not compensated through a gain in binding entropy with NFV and DRV 
binding to clade C protease. This resulted in a net gain in the free energy of binding of 
NFV (ΔΔG = 1.5 kcal mol-1) and DRV (ΔΔG = 1.9 kcal mol-1) and thus, indicated that 
these binding reactions were unfavorable when compared to clade B. 
Crystal trials 
 Clade B protease readily crystallizes in the phosphate buffer with ammonium 
sulfate as the precipitant. However, crystal trials with clade C protease with the same  
buffers yielded no crystal hits. Four crystal hits were obtained with the Hampton Crystal 
Screen and Crystal Screen 2. However, no x-ray diffraction was visible when the larger 
crystals were mounted on the in-house x-ray source.  
Protease activity 
 The enzyme-kinetics experiments performed with the Ca-p2 fluorogenic substrate 
analog revealed that the clade B protease had a KM of 16.7 ± 6.0 µM and a catalytic 
turnover rate (kcat) of 1.79 ± 0.28 sec-1. The catalytic efficiency was calculated to be 0.11 
± 0.04 sec-1 µM-1. Using a substrate concentration range of 0 – 40 µM it was not possible 
to fit the initial velocities for clade C protease to the Michaelis–Menten equation. 
 
DISCUSSION 
HIV-1 clade C accounts for over 50% of HIV-1 infections in the world. Clade C 
protease carries a number of amino acid polymorphisms that are associated with inhibitor 
resistance in clade B.  The primary pathway to NFV resistance in clade C protease is 
different from clade B. The results described in this section attempt to elucidate the effect 
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of clade specific sequence polymorphisms in protease on enzyme activity and how they 
might influence inhibitor resistance pathways. 
Based on the binding affinity data it is clear that clade C specific amino acid 
variations have a significant effect on NFV and DRV binding when compared to clade B 
protease. The weaker affinity for NFV likely permits the protease to confer resistance by 
accumulating the non-active site substitution, L90M. In comparison, the clade B protease 
that has a higher affinity for NFV requires a combination of an active site (D30N) and 
non-active site (N88S) substitutions in order to effectively gain NFV resistance. 
Therefore, by not altering the active site, the clade C protease maintains its ability to 
effectively recognize and cleave substrates while conferring inhibitor resistance.  
Residue 90 is a non-active site residue and therefore, is not in a position to 
interact with ligands that bind within the protease active site (Figure AI-A). However, 
Leu90 is part of the termial helix and packs against the floor of the active site region that 
includes the catalytic aspartic acid residue (Figure AI-2B). Thus the L90M substitution 
most likely perturbs the packing interactions in this region. Mutating Leu90 in the wild 
type protease in complex with NFV (PDB code: 3EKX) to methionine in silico shows 
that Met90 side chain can pack against the floor region of the active site as well (Figure 
AI-C). However, based on this model the non-bonded electron pair in the sulfur atom in 
Met90 can serve as a hydrogen bond acceptor and interact the amide nitrogen of Asp25 
(Gregoret et al., 1991; Zhou et al., 2009). Asp25 is important for inhibitor binding. 
Therefore, it is possible that Met90 can interact with the floor region of the active site and 
disrupt these interactions that are crucial for NFV binding. 
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FIGURE AI-2 
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FIGURE AI-2. A. L90M is a non-active site substitution. The red box indicates the 
region highlighted in panels B and C. B. The Leu90 side chain packs against the floor 
region of the active site in the clade B protease in complex NFV (PDB code: 3EKX).  
C. In silico modeling of methionine at residue 90 shows that the methionine side chain 
can interact with the active site backbone. 
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Based on the current data on clade C protease, background polymorphisms in 
clade C have an effect on inhibitor susceptibility. However, additional biochemical and 
structural studies that include the L90M protease variant are required to obtain a detailed 
understanding of the molecular basis for the altered resistance pathways in clade C 
protease. 
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APPENDIX II 
Entropy-Enthalpy compensation in a Drug Resistant Variant of  
HIV-1 protease 
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ABSTRACT 
The development of HIV-1 protease inhibitors has been the historic paradigm of 
rational structure based drug design, where structural and thermodynamic analyses have 
assisted in the development of novel inhibitors.  Often the thermodynamics are analyzed 
in terms of particular properties of the inhibitors.  In the current study profound changes 
in the thermodynamics of binding of a series of six FDA approved inhibitors are observed 
as a function of a drug resistant variant of HIV-1 protease.  This protease variant has a 
combination of flap and active site mutations and exhibits extremely large entropy 
enthalpy compensation compared with wild-type, 5-15 kcal/mol, while only losing 1-3 
kcal/mol in total binding energy for any given inhibitor.  The co-crystal structures of this 
variant with four of the FDA approved inhibitors were determined and compared with 
both the wildtype complexes and complexes of another drug resistant variant that does 
not exhibit this energetic compensation.  Conserved structural changes were observed, 
that likely contribute to the thermodynamic compensation.  Although enthalpy-entropy 
compensation has been previously observed for a variety of systems, changes of this 
magnitude have not been reported.  The fact that drug resistant mutations can profoundly 
modulate the relative thermodynamic properties of a therapeutic target independent of the 
inhibitor presents a new challenge for rational drug design.   
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INTRODUCTION 
HIV-1 protease inhibitors (PI) were originally based on the substrate sequences as 
well as on the topology of the enzyme’s active site (Wlodawer and Erickson, 1993).  The 
original structure-based drug design strategy was to optimize the entropy of binding by 
introducing conformational restraints into compounds so that they were pre-shaped to fit 
into the active site.  In addition, these compounds are highly hydrophobic, resulting in an 
increase in solvation entropy upon binding.  Thus, the first generation drugs bind with 
favorable entropy but with a corresponding loss in enthalpy (Todd et al., 2000). Some 
newer HIV-1 PIs (King et al., 2004c; Muzammil et al., 2007; Ohtaka et al., 2002; 
Surleraux et al., 2005a; Valzaquez-Campoy et al., 2000; Valzaquez-Campoy, Todd, and 
Freire, 2000)bound enthalpically favorably and often, as with Darunavir (DRV), with 
higher affinity, leading to the hypothesis that favorable enthalpy may aid in attaining 
better inhibitors that are less susceptible to drug resistance, however, Tipranavir (TPV) 
appears to be highly entropically driven (Muzammil et al., 2007).  
The interplay between entropy and enthalpy in attaining high affinity is complex.  
Entropy-enthalpy compensation has been observed in many biological systems after 
relatively minor perturbations in the system including protein-metal interactions (Blasie 
and Berg, 2004; Kuroki, Nitta, and Yutani, 1992), cAMP receptor protein variants and 
RNA polymerase binding (Krueger et al., 2003), peptides binding to the Src Homology 2 
domain of the Src kinase (Davidson et al., 2002), as well as ligands binding to 
cyclodextrin variants (Houk, 2003; Rekharsky and Inoue, 1998).  This compensation, 
nearly equal and opposite, between the changes in TΔS and ΔH usually of 1-2 kcal/mol 
125 
often results in only minimal differences in the overall ΔG when comparing the binding 
of the different complexes (Sharp, 2001).  The consequence of which makes it difficult to 
integrate the direct properties of enthalpy and entropy into rational drug design. 
Drug resistant mutations in HIV protease throughout the enzyme can decrease the 
binding affinity with inhibitor molecules in a complex interdependent and cooperative 
manner (Ohtaka, Schon, and Freire, 2003; Olsen et al., 1999).  Combinations of 
thermodynamic and structural studies to evaluate the consequences associated with drug-
resistant mutations by many groups including our own (Bottcher et al., 2008; King et al., 
2002; King et al., 2004b; King et al., 2004c; Lafont et al., 2007; Ohtaka et al., 2004; 
Steuber, Heine, and Klebe, 2007).   Our earlier thermodynamic study on DRV and the 
chemically similar inhibitor amprenavir (APV), hypothesized a structural rationale for its 
unprecedented highly favorable enthalpy (King et al., 2004c).  The single-ringed 
tetrahydrofuran (THF) group of APV was replaced with a double-ringed bis-THF in 
DRV, which formed additional protease-inhibitor interactions (King et al., 2004c) 
correlating with high affinity and highly favorable enthalpy. Although thermodynamics 
of binding is an equilibrium property between the liganded and unliganded forms of the 
enzymes, aspects of conformational changes in the bound structure may correlate with 
conserved thermodynamic changes. 
In the present study, the crystal structures and thermodynamics are compared for 
the binding of the inhibitors APV, atazanavir (ATV), DRV, indinavir (IDV), nelfinavir 
(NFV) and saquinavir (SQV) of the wild-type (WT) HIV-1 protease with two multi-drug-
resistant variants of the protease (Figure 1):  (i) a variant (ACT) with the active site  
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FIGURE AI1-1 (a) Chemical structures of inhibitors. (b) Overview of the mutation sites 
of FLAP+ and ACT mutants mapped on an HIV-1 protease dimer. The monomers are 
distinguished in cyan and magenta, while the inhibitor is shown in yellow stick model. 
The mutation sites of FLAP+ (L10I/G48V/I54V/L63P/V82A) and ACT 
(L63P/V82T/I84V) are highlighted in red and green stick models.  
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mutations V82T and I84V; and (ii) a multi-drug-resistant variant (FLAP+) with L10I, 
G48V, I54V, and V82A derived as a combination of mutations that simultaneously occur 
in patients’ sequences with a combination of flap mutations and active site mutations 
(Shafer, Stevenson, and Chan, 1999). Both drug resistant protease variants lose similar 
amounts of binding affinity relative to the WT protease.  However the variant with flap 
mutations, FLAP+, exhibits extremely large and opposite changes in the entropy and 
enthalpy of interaction for all the inhibitors studied, indicating that the drug resistant 
mutations are directly modulating the relative thermodynamics of interactions.  
 
METHODS 
Protease gene construction 
The WT protease gene was constructed using synthetic oligonucleotides 
optimized for Escherichia coli codon usage, and included a substitution of Q7K to 
prevent autoproteolysis (Rose, Salto, and Craik, 1993a).  Mutations were introduced 
using the Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, CA). 
Protein expression and purification 
HIV-1 protease was over-expressed in E. coli Tap106 cells using heat induction 
as previously described (King et al., 2002).  The protease was extracted from inclusion 
bodies using 50% acetic acid (Hui et al., 1993). High molecular weight proteins were 
separated from the desired protease by size exclusion chromatography on a 2.1-L 
Sephadex G-75 superfine (Sigma Chemical) column equilibrated with 50% acetic acid.  
The protein was then refolded by rapid dilution in a 10-fold volume of 50 mM sodium 
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acetate buffer at pH 5.5, also containing 10% glycerol, 5% ethylene glycol and 5 mM 
dithiothreitol (refolding buffer).  The refolded protein was concentrated using an Amicon 
ultrafiltration cell, followed by dialysis to remove any residual acetic acid (King et al., 
2002; King et al., 2004c; Prabu-Jeyabalan et al., 2004b).  The protein was further 
concentrated to approximately 1 to 2 mg/ml and stored at -80°C.  Protease used for 
crystallization was further purified with a Pharmacia Superdex 75 fast-performance liquid 
chromatography column equilibrated with refolding buffer. 
Isothermal titration calorimetry 
Isothermal titration calorimetry experiments were carried out at 20°C using a VP-
ITC microcalorimeter (MicroCal, Inc., Northampton, MA).  The protease first underwent 
buffer exchange using PD10 gel filtration columns from Amersham Biosciences.  All 
solutions were prepared in a buffer consisting of 10 mM sodium acetate (pH 5.0), 2% 
dimethyl sulfoxide, and 2 mM Tris (2-carboxyethyl) phosphine as final concentrations.  
Due to the high affinity of the WT protease for each of the inhibitors as well as the sharp 
transition to saturation, the thermodynamic parameters for these complexes were 
obtained by the displacement titration method (King et al., 2004c; Ohtaka et al., 2002; 
Sigurskjold, 2000; Valzaquez-Campoy et al., 2000).  Likewise, affinities for the mutant 
enzymes with the tight binding inhibitors APV and DRV were performed using the 
competition experiments.  The small magnitude of the signal for the ATV-ACT complex 
also necessitated the use of the displacement titration method in order to accurately 
determine its binding parameters. With one exception, acetyl-pepstatin (Bachem 
Bioscience, Inc., King of Prussia, PA) was used as the competing ligand at concentrations 
130 
ranging from 250 to 400 µM.  IDV was used as the weaker binder in displacement 
experiments with the ACT enzyme and DRV as described (King et al., 2004c) WT and 
mutant proteases at concentrations of approximately 6 to 20 µM pure enzyme were used 
in displacement experiments.  Concentrations of reactive, folded protease reported here 
were determined during curve fitting using the MicroCal software Origin 7.  This 
procedure involves adjusting the protease concentration to the value which results in a 
stoichiometric ratio of inhibitor to enzyme at half saturation.  The protease in the 
calorimetric cell was initially titrated with the weaker binding inhibitor, followed by 
titration with the higher affinity ligand for displacement of acetyl-pepstatin (or IDV).  
APV, ATV, DRV, IDV, NFV and SQV were used at concentrations of 150 to 250 µM.   
The thermodynamic parameters for APV and DRV with the WT protease were obtained 
as previously described (King et al., 2004c).   
Due to the decrease in the binding affinity of ATV, IDV, NFV and SQV with 
FLAP+, the thermodynamic parameters for these complexes were obtained by direct 
titrations.  The same was true for experiments done on ACT with IDV, NFV, and SQV.  
In each case 200 µM inhibitor was titrated directly into the calorimetric cell containing 
protease at concentrations ranging from 16 to 26 µM.  The affinities of the mutants for 
APV and DRV were of sufficient magnitude to require displacement titrations.  
(Experimental conditions used for the ACT enzyme with APV and DRV are described 
elsewhere (King et al., 2004c).  For the FLAP+ displacement experiments, acetyl-
pepstatin was used as the competing ligand as above at a concentration of 300 µM in 
experiments with 250 µM APV, while 900 µM acetyl-pepstatin was required for 
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titrations with 66 µM DRV.  (For experiments carried out using the displacement method, 
direct titrations were also performed in order to confirm the enthalpy changes acquired 
through competition experiments.)  All experiments were carried out at least twice and 
their mean values are reported.  Heats of dilution obtained after saturation were 
subtracted from the heats of reaction in order to obtain the heat due solely to the inhibitor 
binding to the enzyme.  Data were analyzed using the Origin 7 software package 
provided by MicroCal. 
In order to calculate the heat capacity change (ΔCp) associated with binding of 
APV and DRV to WT and FLAP+ variants, the enthalpy change in binding was 
determined by titrating 200 µM APV or 84 µM DRV into 13 to 50 µM protein in the 
calorimetric cell between a temperature range of 10 to 42°C. 
Crystal structures: 
The following nomenclature will be followed to refer to each crystal structure: 
Inhibitorprotease variant.  For example, APVWT, APVACT and APVFLAP+ represent the WT, 
ACT and FLAP+ complexes of APV, respectively.  Inhibitors APV, ATV, DRV, IDV, 
NFV and SQV were cocrystallized with ACT and FLAP+.  To preserve consistency with 
our analysis, WT protease complexes were also determined.  However, crystals for the 
SQVWT complex could not be grown and hence the structure available in PDB was used 
for the entire analysis (Krohn et al., 1991) (PDB code:1HXB).  The NFVFLAP+ complex 
exhibited a different flap conformation while crystals for IDVFLAP+ complex could not be 
grown.  Hence, structural analyses for NFV and IDV were omitted.   
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Crystallization and data collection 
Crystal screens were set up with a three- to five-fold molar excess of inhibitor to 
protease to ensure ubiquitous binding. The final protein concentration ranged from 0.5-
2.5 mg/ml in refolding buffer. The hanging drop vapor diffusion method was used for 
crystallization as previously described (King et al., 2004c).  With two exceptions, crystal 
screens were set up at ambient temperature using reservoir solutions consisting of 126 
mM phosphate buffer at pH 6.2, 63 mM sodium citrate and ammonium sulfate at a range 
of 25 to 33 %.  Crystals for the APVFLAP+ and DRVFLAP+ complexes however, were 
grown at 4˚C using 10:1 molar ratios of inhibitor to protein.  The buffer used in each case 
consisted of 50 mM citrate phosphate at pH 5.0 with 7% DMSO, and ammonium sulfate 
at concentrations of 38% and 28% for APV and DRV respectively.   
Crystallographic data for all of the complexes discussed in this analysis was 
collected on an RAXIS IV.  The raw frames were indexed and integrated using DENZO 
and subsequently scaled using ScalePack (Minor, 1993; Otwinowski, 1993).  All of the 
complexes, except two, crystallized in the usual orthorhombic crystal form with 
isomorphous cell dimensions.  APVFLAP+ and DRVFLAP+ crystallized in an unusual 
hexagonal space group with 12 HIV-1 protease dimers per unit cell. The data collection 
statistics are listed in Table AII-1. 
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TABLE AII-1. Crystallographic statistics. 
Parameters FLAP+ (L10I/G48V/I54V/L63P/V82A) WT 
ACT 
(L63P/V82T/I84V) 
 APV ATV DRV SQV APV ATV DRVa,b SQVc APVRT,a ATV DRVa,b SQVRT 
Resolution (Å) 2.15 1.6 1.97 2.2 1.8 1.7 1.2 2.3 2.2 1.6 1.35 2.0 
Space group P61 P212121 P61 P212121 P212121 P212121 P212121 P61 P212121 P212121 P212121 P212121 
Unit Cell  a (Å) 92.0 51.2 92.0 51.2 50.7 51.0 54.9 63.3 51.1 50.7 50.9 51.3 
                 b (Å) - 58.5 - 59.3 57.4 58.8 57.8  59.3 58.1 58.0 59.3 
                 c (Å) 106.2 61.3 106.2 61.4 61.7 61.3 62.0 83.5 61.8 61.4 61.7 62.1 
Zd 6 4 6 4 4 4 4 6 4 4 4 4 
Total reflections 161411 175086 202358 37340 49469 68018 302022  49950 87982 256671 81540 
Unique reflections 27531 24185 34578 9789 14987 19646 55056  9705 23103 39998 12975 
Completeness (%) 99.5 96.6 95.8 98.3 79.7 93.5 95.5  96.8 93.6 98.0 97.2 
Rmerge (%) 5.4 3.3 5.0 4.6 2.9 5.0 3.8  8.7 4.8 4.4 7.0 
I/sI 11.1 17.1 15.4 11.4 19.0 11.3 25.0  5.9 11.7 13.5 6.0 
REFINEMENT Refmac5 Refmac5 Refmac5 Refmac5 Refmac5 Refmac5 Refmac5 X-PLOR CNS Refmac5 Refmac5 CNS 
R factor (%) 19.6 18.7 20.9 19.5 19.0 17.3 14.1 16.1 20.3 19.2 16.3 19.0 
Rfree (%) 25.5 22.2 25.6 24.6 22.6 20.5 17.9 NA 24.4 21.7 20.0 22.3 
RMSD in             
   bond length (Å) 0.009 0.006 0.007 0.008 0.007 0.007 0.004 0.013 0.007 0.006 0.005 0.007 
   bond angle (˚) 1.4 1.4 1.1 1.3 1.4 1.2 1.5 2.9 1.4 1.3 1.4 1.3 
 
a PDB codes: DRVWT – 1T3R; DRVACT – 1T7I; APVACT – 1T7J   
b Data collection carried out at Advanced Light Source (ALS) 
c PDB code 1HXB  
d Number of dimeric molecules in the unit cell. 
RT Room temperature
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Structure solution and crystallographic refinement 
The suite of programs from CCP4i (Collaborative-Computational-Project, 1994) was 
used for most of the crystallographic operations.  Structure solution for all complexes was 
carried out using the molecular replacement package AMoRe (Navaza, 1994). The 
substrate complex of capsid-p2 bound with D25N inactive HIV-1 protease (Prabu-
Jeyabalan, Nalivaika, and Schiffer, 2000a) (PDB.code: 1F7A) was used as the starting 
model. This substrate structure was used to solve inhibitor complexes to reduce model 
bias.   For the orthorhombic crystals, the structure solution was straightforward.  
However, for the APVFLAP+ and DRVFLAP+ complexes, which crystallized in a hexagonal 
form, a combination of self-rotation maps were computed, revealing that the space group 
is P61 with two dimers per asymmetric unit.  The subsequent refinement strategy 
involving ARP/wARP, TLS parameters and Refmac5 was similar to our earlier structural 
analyses (Prabu-Jeyabalan et al., 2006a).  Interactive model building was conducted using 
the package O (Jones, Bergdoll, and Kjeldgaard, 1990) and the quality of the structures 
was assessed using PROCHECK (Laskowski et al., 1993).  The dimers of the APVFLAP+ 
and DRVFLAP+ complexes within the asymmetric unit were restrained by non-
crystallographic symmetry (NCS) restraints.  However, no NCS restraints were imposed 
between the monomers of the dimer for any of the complexes.  The refinement statistics 
are provided in Table AII-2. 
Structural analysis 
(i) Structural superimpositions: The twelve inhibitor complexes chosen for 
structural comparisons were superimposed on a complex containing the peptide fragment 
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representing the Gag substrate capsid-p2 (PDB code 1F7A (Prabu-Jeyabalan, Nalivaika, 
and Schiffer, 2000a)) using the protease terminal domain (Pro1-Pro9 & Arg87-Phe99).  
This capsid-p2 complex was chosen to preserve consistency with our previous analyses 
(King et al., 2004b; King et al., 2004c). 
(ii) Double difference plots:  Double-difference plots, computed using Ca-Ca 
distances, reveal structural differences between similar structures without the bias due to 
structural superimpositions or space group differences (Prabu-Jeyabalan et al., 2006a; 
Williams and Kelley, 1998a).  Distances between all the Cα atoms within each dimer 
were computed (nDij, where D is the double difference and i and j are residue numbers). 
This was repeated for each of the “n” structures. Double differences (D) were generated 
as a (i x  j) matrix by computing the difference of the differences between the two dimers 
(D = nDij – n’Dij). The (i x j) matrix was then displayed as a contour diagram using 
GnuPlot (Williams and Kelley, 1998a).   
(iii) Estimation of van der Waals potential: Inhibitor-protease van der Waals 
contacts were estimated by a simplified Lennard-Jones potential V(r)  using the relation 
4ε[(σ/r)12 – (σ/r)6]; where r is the protease-inhibitor inter-atomic distances, and ε and σ 
are the well depth and hard sphere diameter, respectively, for each protease-inhibitor 
atom pair. V(r) is computed for all possible protease-inhibitor atom pairs within 5 Å and 
when potentials for non-bonded pairs separated less than a distance corresponding to ε, 
V(r) were equated to ε.  Using this simplified potential for each non-bonded protease-
inhibitor pair, ∑V(r) was then computed for each protease residue.   
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RESULTS 
Thermodynamics of inhibitor binding 
Isothermal titration calorimetry was used to determine the thermodynamics of inhibitor 
binding to the WT and multi-drug resistant (MDR) proteases.   Table AII-2 lists the 
thermodynamic parameters for each protease-inhibitor pair along with their 
corresponding Kd ratios (KdMDR/KdWT).  In each case, there is a decrease in binding 
affinity to the mutant proteases relative to that of the WT. APV binding to each of the 
MDR proteases is the least affected in terms of affinity, followed by DRV.  In addition, 
the FLAP+ mutations appear to have less of an effect on the binding of these two 
inhibitors when compared to that of the ACT mutant.  The Kd ratios for ACT-APV and 
ACT-DRV binding are 5.9 and 14.7 respectively, while the same ratios for FLAP+ 
binding are only 3.3 and 5.8.  ATV binding of ACT and FLAP+ exhibit a decrease in 
affinity by 17.8 and 48.4 fold, respectively.  The binding of IDV is further compromised 
with Kd ratios of 49.0 and 76.9 for the ACT and FLAP+ proteases, respectively.  Also, 
NFV binding to ACT and FLAP+ shows similar reductions in affinity with values of 48.2 
and 87.0, respectively.  In contrast, SQV binding is the most compromised of all the 
inhibitors studied, with Kd ratios of 135 for ACT and 353 for FLAP+.   Thus APV and 
DRV, which fit well within the substrate envelope (King et al., 2004b; King et al., 
2004c), are the most robust against the drug-resistant variants. 
A closer examination of the specific enthalpic and entropic contributions to the 
changes in free energy (Table AII-2) reveals that the binding of the first generation 
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TABLE AII-2 Thermodynamics of the binding of inhibitors to WT, ACT and FLAP+ variants of HIV-1 protease.  
(Experiments were performed at 20˚C.) 
Protease 
variant 
ΔG 
(kcal mol-1) 
ΔH 
(kcal mol-1) 
-TΔS 
(kcal mol-1) 
Ka 
(M-1) 
Kd 
(nM) 
Kd 
 ratio 
ΔCp 
(cal K-1 mol-1) 
   APV     
WT -12.6 -7.3 ± 0.9 -5.3 (2.6 ± 1.3) x 109 0.39 ± 0.20 1 -429 
ACT -11.6 -6.0 ± 2.0 -5.6 (4.4 ± 1.5) x 108 2.3 ± 0.79 5.9  
FLAP+ -11.9 3.3 ± 0.5 -15.2 (7.6 ± 0.06) x 108 1.3 ± 0.01 3.3 -534 
   ATV     
WT -12.9 -1.1 ± 0.1 -11.8 (4.5 ± 2.4) x 109 0.23 ± 0.12 1  
ACT -11.3 -0.33 ± 0.1 -10.9 (2.5 ± 0.13) x 108 4.0 ± 0.21 17.8  
FLAP+ -10.7 4.5 ± 0.1 -15.2 (9.1 ± 1.3) x 107 10.9 ± 1.6 48.4  
   DRV     
WT -15.2 -12.1 ± 0.9 -3.1 (2.2 ± 1.1) x 1011 0.0045 ± 0.0023 1 -373 
ACT -13.6 -10.0 ± 0.05 -3.7 (1.5 ± 0.42) x 1010 0.066 ± 0.02 14.7  
FLAP+ -14.2 2.0 ± 0.6 -16.2 (3.9 ± 0.75) x 1010 0.026 ± 0.005 5.8 -507 
   IDV     
WT -12.2 1.7 ± 0.2 -14.0 (1.4 ± 0.3) x 109 0.74 ± 0.14 1  
ACT -10.0 7.4 ± 0.03 -17.4 (2.8 ± 1.1) x 107 36.0 ± 13.5 49.0  
FLAP+ -9.7 10.9 ± 0.08 -20.6 (1.8 ± 0.07) x 107 56.5 ± 22.9 76.9  
   NFV     
WT -12.6 4.4 ± 0.1 -17.0 (2.6 ± 0.5) x 109 0.39 ± 0.07 1  
ACT -10.4 7.1 ± 0.1 -17.4 (5.3 ± 0.07) x 107 18.9 ± 0.25 48.2  
FLAP+ -10.0 10.8 ± 0.03 -20.8 (2.9 ± 0.11) x 107 34.1 ± 1.3 87.0  
   SQV     
WT -12.5 3.6 ± 0.1 -16.1 (2.0 ± 0.1) x 109  0.50 ± 0.03 1  
ACT -9.6 9.5 ± 0.03 -19.1 (1.5 ± 0.006) x 107  67.4 ± 0.28 135.1  
FLAP+ -9.1 12.9 ± 0.09 -21.9 (5.7 ± 0.14) x 106  176 ± 4.2 352.7  
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inhibitors IDV, NFV, and SQV to each of the protease variants is entropically driven 
(negative TΔS) at the experimental temperature of 20˚C.  In contrast, APV, ATV, and 
DRV are both enthalpically (negative ΔH) and entropically driven when binding to the 
WT and ACT proteases (Table1).  However, the binding of these same compounds (APV, 
ATV, and DRV) becomes endothermic (positive ΔH) with the FLAP+ enzyme.  In fact, 
the magnitude of the differences in both the enthalpic and entropic contributions to APV 
and DRV in particular are much greater for the FLAP+ variant (Figure 2a) when 
compared to those of the other inhibitors.  The corresponding differences for APV and 
DRV when bound to the ACT variant are however less dramatic (Figure 2b) .  The ΔΔH 
values for FLAP+ are 10.7 and 14.1 with APV and DRV respectively.  The highly 
unfavorable enthalpy change is compensated for by a relatively large favorable change in 
the entropic component as demonstrated in the Δ-TΔS values of -10.0 and -13.1 for APV 
and DRV respectively.  This enthalpy-entropy compensation gives rise to the very 
minimal overall change in the free energy for the binding of APV and DRV to the 
FLAP+ enzyme when compared to the same compounds binding to the WT protease 
(Figure 2a).  Although inhibitors binding to the ACT protease also result in minimal 
overall ΔΔG values, the magnitude of the entropy-enthalpy compensation is much less 
than that of binding to the FLAP+ enzyme (Figure 2), thus suggesting the FLAP+ 
protease variant is energetically unique. 
Heat capacities were measured to further elucidate these dramatic thermodynamic 
changes by measuring the enthalpy of the interactions at a variety of temperatures with 
APV and DRV.  The temperature dependence of the enthalpy changes gives rise to heat  
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FIGURE AII-2  
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FIGURE AII-2 Differences in binding energetics between (a) WT and FLAP+ and (b) 
WT and ACT variants. The histograms representing the differences in ΔG, TΔS and ΔH 
are shown in green, red and blue, respectively.  
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capacity changes.  The heat capacities obtained for the WT enzyme in association with 
APV and DRV were -429 and -373 cal.mol.K-1 respectively (Table AII-2).  The 
substitutions in the FLAP+ protease gave rise to even larger (more negative) heat 
capacity changes for the corresponding inhibitor complexes with values of -534 and -507 
cal.mol.K-1 for APVand DRV respectively.  Thus, the five mutations in the FLAP+ 
variant have substantially changed the overall heat capacity for the binding of these two 
inhibitors by more than 100 cal.mol.K-1.   This change in overall heat capacity for binding 
further indicates that the mutations within FLAP+ fundamentally change the 
thermodynamic properties of this enzyme.   
Overall features of the crystal structures: 
The crystal structures of inhibitor-protease complexes involving WT, ACT and 
FLAP+ protease variants were determined.  The IDV complex did not form diffraction 
quality crystals and the flaps in NFVFLAP+ exhibit an unusual conformation (Prabu-
Jeyabalan et al., 2006a) and therefore, structural comparisons with those two inhibitor 
complexes are not included. Also, crystals for the SQVWT complex could not be grown 
and therefore, the complex from the PDB was used (PDB code 1HXB (Krohn et al., 
1991)).  The three-dimensional structures for the twelve crystal complexes discussed here 
are consistent with other structures found in the database (Vondrasek and Wlodawer, 
2002). Most of  the structures have been determined at resolutions better than 2.0 Å The 
entire crystallographic statistics are listed in Table AII-2.  The inhibitor in all of the 
complexes, except ATVWT and SQVWT, binds in a unique conformation.  In the ATVWT 
and SQVWT complexes, the inhibitor binds in two orientations with nearly 50% 
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occupancy for each orientation.  Also, in the ATVWT structure, the second phenyl group 
at P1’ does not have electron density, and therefore, it was not used during any of the 
subsequent structural analyses.  Altogether, this analysis includes eight new HIV-1 
protease-inhibitor complexes, three previously reported from our laboratory and one from 
the database, allowing for a detailed structural comparison of these drug resistant HIV-1 
protease variants with the WT enzyme.   
Structural comparisons between the protease complexes: 
The twelve inhibitor complexes chosen for this structural analysis were 
superimposed as described in the Methods section.  The root mean squared deviation 
(RMSD) in the coordinate positions for Ca atoms in each variant were calculated and 
plotted against residue numbers (Figure 3a).   Although the distributions of RMSD values 
for the WT and ACT complexes follow the same pattern, the distribution observed in the 
FLAP+ complexes is significantly different. Not unsurprisingly, the FLAP+ structures 
exhibit the largest difference near the flap region.  The RMSD in coordinates near Lys41 
and Lys57 for both monomers of FLAP+ is the highest (> 0.8Å), while for the tip of the 
flap (Ile50) the RMSD value drops to <0.25Å.  For the WT and ACT complexes, the 
RMSD values for the entire flap region remain uniform 0.5-0.65 Å.  Thus the RMSD in 
coordinates suggest that the flap region of the FLAP+ complexes is invariant.      
The RMSDs were mapped on an HIV-1 protease dimer model to illustrate which 
regions of the protease exhibit the most deviation (Figure 3b-d).  This comparison further 
reveals that the FLAP+ (Figure 3b) complexes are different from the WT and ACT 
complexes (Figures c and d), especially at the flaps.  Figure 3b demonstrates the high- 
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FIGURE AII-3 (a) Distribution of root mean squared deviations (RMSD) in Cα 
coordinates between the four inhibitor complexes of FLAP+ (black), WT (blue) and ACT 
(green) variants. The RMSD in Cα coordinates in (b) FLAP+, (c) WT and (d) ACT 
mapped on an HIV-1 protease dimer model. The color code for distinguishing the RMSD 
values are: blue – 0-0.25 Å; purple – 0.25-0.5 Å; red – 0.5-0.65 Å; yellow – 0.65-0.8 Å; 
white – 0.8 Å and above.  
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degree of structural conservation at the b-hairpin forming the tip of the flaps (Ile50-
Gly51) in the FLAP+ complexes along with the significant variability in the b-strands 
flanking the tip.  In contrast, the entire flap region in the WT and ACT complexes 
exhibits uniform structural variation (Figures 3c & d).  Detailed comparison of the flaps 
in the FLAP+, WT and ACT complexes shows the conformational alterations in the 
FLAP+ structures (Figure 4a-c).  While the structure of the flap tips for the WT and ACT 
complexes are conformationally variable, the FLAP+ complexes appear to converge to a 
single conformation regardless of which inhibitor is bound.  Thus, the comparison of 
structures grouped by protease variant suggests that the flap tips of FLAP+ may have 
become rigid. The FLAP+ variant contains two flap mutations, G48V and I54V, flanking 
the flap tip, perhaps restricting the conformation of this region resulting in the apparent 
rigidity.  
A pair-wise structural comparison was carried out for the three complexes of each 
inhibitor comparing WT vs FLAP+ and WT vs ACT using double-difference plots 
(Figure 5) (Prabu-Jeyabalan et al., 2006a; Williams and Kelley, 1998a).  The double-
difference plots displaying the deviations between the WT and FLAP+ complexes reveal 
several structural differences over 1 Å (Figures 5a-d).  As illustrated in Figures 5a-d, the 
structural differences are chiefly concentrated around the flaps (Pro44-Lys57) and the P1-
loop regions (Pro79-Ile84).  In contrast with the changes observed between the WT-
FLAP+ pairs, the plots computed for the WT-ACT pairs exhibit fewer peaks for all four 
inhibitors (Figures 5e-h), indicating that the structures of WT and ACT, when complexed 
to the same inhibitor, are similar to each other.    
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FIGURE AII-4 The active site region (Asp25-Asp30), flaps (Lys45-Lys55) and the 
inhibitors of (a) FLAP+, (b) WT and (c) ACT are superposed and illustrated as stereo 
pairs. The complexes involving APV, ATV, DRV and SQV are distinguished in red, 
green, cyan and magenta, respectively.  
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FIGURE AII-5 Double difference plots illustrating the WT vs FLAP+ structural changes 
in (a) APV, (b) ATV, (c) DRV and (d) SQV, and WT vs ACT structural changes in (e) 
APV, (f) ATV, (g) DRV, (h) SQV. The key for contours: (i) black -5.0 to -1.0 Å and 
green -1.0 to -0.5Å (Corresponding residue distances in the mutant structures have 
increased); (ii) blue 0.5 to 1.0 Å and magenta 1.0 to 5.0 Å (Corresponding distances in 
the mutant structures have decreased).  
150 
The majority of the structural differences between the WT and FLAP+ structures occur 
primarily in one monomer.   The flap of that monomer (Pro44-Lys57) of the FLAP+ 
variant, in relation to the WT complexes, has moved closer to the non-flap regions (1’-
43’ and 58’-99’) of the opposite monomer by over 1 Å (Figure 5a-d). The flap-specific 
changes are observed between the FLAP+ and WT complexes and not between ACT and 
WT, in both the double-difference plots and RMSD plots (Figure 4). This conserved 
asymmetric structural change observed in the FLAP+ variant could be a factor leading to 
its unique thermodynamic characteristic. 
Inhibitor-Protease Hydrogen bonds: 
Hydrogen bonds between the inhibitor and the protease atoms for each variant 
were also computed.  In each protease variant, the inhibitors APV, ATV, DRV and SQV 
form 9, 13, 11, and 12 hydrogen bonds, respectively.  The APVWT and APVACT 
complexes form two hydrogen bonds between Asp29 N and Asp30 N and the inhibitor 
atom O6 which are absent in the FLAP+ complex.  However, these two interactions are 
maintained in all the complexes of DRV.  One new hydrogen bond is observed in both 
the APV and DRV FLAP+ complexes between Asp30’ OD1 and APVFLAP+ (N3) or 
DRVFLAP+ (N1), respectively.  Another feature in all of the APV and DRV complexes is 
the absence hydrogen bonds with the flaps, while ATV and SQV inhibitors form 4 and 2 
hydrogen bonds, respectively, to the backbone of residue 48.  Also, the N to Gly48 O 
hydrogen bond found in the SQVWT and SQVACT does not exist in SQVFLAP+. Thus 
specific changes in the hydrogen bond patterns for each of the inhibitors are observed in 
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the FLAP+ complexes that are not observed in the corresponding inhibitor complexes of 
the other two protease variant complexes.   
Inhibitor-Protease van der Waals contacts: 
Estimates of total van der Waals contacts between the inhibitor and the protein 
were calculated with a simplified Lennard-Jones potential. Not unsurprisingly, the larger 
inhibitors ATV and SQV inhibitors had more favorable van der Waals interactions then 
the smaller ones like APV and DRV, especially in the FLAP+ complexes. Probably 
indicative of the locations of the mutations, the total van der Waals inhibitor-protease 
contacts for the ACT complexes of APV, ATV and SQV are slightly less favorable than 
in the corresponding WT and FLAP+ complexes (Figure 6a).  The difference in van der 
Waals interaction for each protease residue (ΔV(r)) for the FLAP+ and ACT complexes 
with respect to the WT were also examined (Figure 6b-e).  The figure panels also show 
the actual van der Waals for the WT (V(r)WT) for comparison.  This analysis reveals that 
increase in van der Waals contacts by one inhibitor-protease atom pair is usually 
compensated by a decrease in contacts between another pair and therefore, the net change 
in van der Waals contacts (ΣΔV(r)) is negligible. However, the absolute change in van 
der Waals contacts (Σ|(ΔV(r)|) will be significant.  Thus, the absolute values of the 
difference in van der Waals contacts relative to the APVWT and DRVWT were analyzed.  
The APVFLAP+ and DRVFLAP+  complexes exhibit the largest differences (APV:9.1 and 
DRV:13.1), while smaller differences were observed in APVACT and DRVACT (APV:5.7 
and DRV:4.4) (Figures 6b & d).Thus, the inhibitor-protease packing in the APV and  
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FIGURE AII-6 
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FIGURE 6a Histogram representation of the total inhibitor-protease van der Waals 
interaction energies for WT (gray), ACT (white) and FLAP+ (black). Residue-wise 
distribution of interaction energy is shown in (b) APV, (c) ATV, (d) DRV and (e) SQV. 
The distribution of energies in the WT complexes are shown in the upper panels while 
the lower panels illustrate the WT vs FLAP+ (black) and WT vs ACT (white) differences 
in energy distribution.
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DRV complexes of the FLAP+ variant are significantly different.  Similar comparisons 
for ATV and SQV reveal smaller changes in absolute differences in van der Waals 
contacts either between WT and FLAP+ (ATV:6.5 and SQV:6.9) or WT and ACT 
(ATV:3.6 and SQV:6.2) (Figures 6c and e). The van der Waals interactions for the active 
site protease residues were examined (Figures 6b-e) in detail.  In the APVFLAP+ and 
DRVFLAP+ complexes, an increase in van der Waals interactions occurs in residues 
Asp25-Asp30, while a decrease in interactions is seen for the same residues in the second 
monomer (Asp25’-Asp30’).  However, these changes in interactions are not observed in 
the ATV and SQV complexes.  Interestingly, although the flap regions were observed to 
have large structural changes (Figure 3 and 4) these actually resulted in almost no 
changes in the extent of van der Waals changes.  Overall, APVFLAP+ and DRVFLAP+ 
complexes undergo several structural changes to preserve their net van der Waals 
contacts.  
To assess the direct affect of the resistance mutations, inhibitor atoms that lie 
within van der Waals distance of the sites of mutations, L10I, G48V, I54V, L63P, and 
V82A, were examined in detail.   The sidechain of Val48 forms interactions with the 
inhibitor in SQVFLAP+, while the inhibitor in all of the other FLAP+ complexes interact 
only with the backbone of Val48.  The V82A mutation site is the only other substitution 
involving direct contact with inhibitors in FLAP+ while in ACT the substitution is V82T.  
In relation to Thr82 in the ACT complexes (0.3), the FLAP+ complexes exhibit a loss in 
contacts by Ala82 (0.7).  Despite this loss in interaction, due to the valine to alanine 
substitution, the three-dimensional arrangement of this region, among the FLAP+ 
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complexes, is highly conserved.  The loss/gain due to the I84V substitution in the ACT 
complexes was also assessed.  Like the V82A mutation in the FLAP+ complexes, the 
I84V mutation in the ACT complexes results in a reduction in van der Waals contact by 
~0.5 although the absolute values vary.  The V82T mutation in the ACT complexes 
results in minor changes in van der Waals contacts.  Overall, the impact of the mutations 
appears not to be a direct change in van der Waals contact but rather an indirect change 
subtly rearranging the active site and therefore the energetics of the inhibitor binding.  
Comparison of ΔCp and change in Accessible Surface Area on binding inhibitor : 
Heat capacity changes for the binding of APV and DRV were computed (Table 
AII-2).  The ΔCp for both inhibitors binding to FLAP+ was more negative relative to WT.  
FLAP+ exhibits a ΔΔCpAPV = -105 cal·K-1mol-1 and ΔΔCpDRV = -134 cal·K-1mol-1.  
Negative ΔCp values generally correlate with a loss in accessible surface area  (Ladbury 
and Chowdhry, 1998), as well as a more favorable entropy change as was observed here 
(Table AII-2).  Changes in accessible surface area for APV and DRV were computed 
using the crystal structures.  In relation to the WT structures, the FLAP+ complexes of 
APV and DRV have a change in accessible surface area of -36 Å2 and -27 Å2, 
respectively.   These values are not large enough to explain the considerable differences 
in ΔCp values found experimentally.  Therefore, the large compensatory entropic changes 
found for APV and DRV binding to the FLAP+ mutant are likely not limited to changes 
in accessible surface area but likely arise from other sources such as subtle structural 
rearrangement in the flaps or changes in the dynamics of the flaps in the free form of the 
enzyme.  
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Crystallographic waters and entropy-enthalpy compensation: 
One possible explanation for entropy-enthalpy compensation involves 
desolvation.  The loss of ordered water molecules upon binding an inhibitor gives rise to 
a favorable change in entropy, however this is compensated by a loss in enthalpy as 
specific hydrogen bonds with water molecules are broken.  The magnitudes of the 
differences in the entropy and enthalpy changes associated with the binding of APV and 
DRV to FLAP+ when compared to WT are greater than those observed for the binding of 
the other inhibitors, and thus are of particular interest.  The significant differences in the 
enthalpy changes observed for APV and DRV binding to FLAP+ relative to WT 
(ΔΔHAPV =10.7 kcal·mol-1and 14.1 kcal·mol-1) (Table AII-2 and Figure AII-2), may be 
associated with the loss of bound water molecules.  The approximate energy of a 
hydrogen bond (5 kcal·mol-1) (Dunitz, 1995), could potentially account for the release of 
two to four water molecules for APV and DRV binding to FLAP+ respectively.   In an 
attempt to search for a structural correlation for the observed changes in enthalpy, the 
crystallographic waters within a 4.2Å hydration shell around the protein were analyzed.  
Detailed comparisons were conducted to elucidate possible changes in water structure 
between the FLAP+ and the WT or ACT complexes, with particular focus on the APV 
and DRV complexes.  However, no systematic change in the water structure of the 
FLAP+ complexes was observed.  Nevertheless these large changes in entropy and 
enthalpy could still be due to differential solvation of the free state of the FLAP+ 
enzyme. 
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DISCUSSION 
A major challenge during the treatment of HIV infections is the emergence of 
drug-resistant viruses.  Substitutions in the protease that arise as a result of these 
mutations lead to a reduction in the affinity of the inhibitor, thereby maintaining the viral 
load.  The majority of thermodynamic studies involving drug-resistant variants of HIV-1 
protease have revealed a loss in the enthalpic contribution resulting in the loss of overall 
free energy of binding (King et al., 2004c; Lafont et al., 2007; Muzammil, Ross, and 
Freire, 2003; Ohtaka and Freire, 2005; Ohtaka, Schon, and Freire, 2003; Ohtaka et al., 
2002; Stoica, Sadiq, and Coveney, 2008).  In the current study, a variant of HIV-1 
protease, FLAP+ (L10I, G48V, I54V, L63P, and V82A) is characterized that exhibits an 
extremely large entropy-enthalpy compensation of a magnitude not previously reported 
for any system.  This compensation is observed to various extents with six different HIV-
1 protease inhibitors, and most dramatic for APV and DRV.  In these cases, the loss in 
the enthalpic interactions are 11 and 14 kcal·mol-1 for APV and DRV, respectively, and 
are compensated by large similar magnitude favorable entropy.  These compensating 
effects resulted in low overall losses in binding affinity.   
This extreme entropy-enthalpy compensation is a function of the physical 
characteristics of the FLAP+ variant of HIV-1 protease.  This variant has a combination 
of mutations in the flaps at G48V, I54V, an active site mutation V82A and a surface 
mutation just outside the active site L10I. Some conserved changes in the overall 
structure are observed between the FLAP+ versus either WT or ACT variants.  Changes 
in solvent accessibility (Ladbury and Chowdhry, 1998), hydrogen bonding, van der 
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Waals interactions and water structure (Dunitz, 1995), all which have been previously 
implicated as potential reasons for entropy-enthalpy compensation, were analyzed. 
However, particularly for the changes observed in the APV and DRV complexes, these 
properties of the inhibited forms of the enzyme do not fully explain the observed large 
changes in enthalpy, entropy and heat capacity.    
The changes in thermodynamics are likely caused by highly interdependent 
alterations in the enzyme, involving both the inhibited enzyme and changes in the 
dynamics and hydrophilicity of the free state of the FLAP+ HIV-1 protease.  This seems 
likely as two of the mutations are in the flexible flap regions, G48V and I54V.  Molecular 
dynamics simulations comparing the WT protease with a G48V mutant indicated a 
marked difference in the flexibility of the flap tips (Hamelberg and McCammon, 2005), 
reducing the frequency of trans-cis isomerization of the ω-bond for Val48 relative to 
Gly48.  To completely integrate thermodynamics in structure based drug design, a 
comprehensive approach is necessary involving structures and dynamic information of 
both the free and the bound states of the inhibitor and the therapeutic target.  The binding 
thermodynamic properties can be profoundly modulated not only by the inhibitor, but 
also by alteration of the target, such as in the evolution of drug resistance.  The challenge 
to rational drug design is to truly integrate interdependent sequence, structure, energetic 
and dynamic data in a productive manner. 
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APPENDIX III 
Binding Thermodynamics Profiles of Inhibitors that Bind Within the Substrate 
Envelope 
162 
INTRODUCTION 
 The homo-dimeric aspartyl protease of HIV-1 recognizes and cleaves at least ten 
non-homologous and asymmetric substrates in the Gag and Gag-Pro-Pol polyproteins and 
is essential for the formation of infectious viral particles (Chou, 1996a; Henderson et al., 
1988; Pettit et al., 1998). Given the vital role played by the protease in the viral life cycle, 
HIV-1 protease has been a key target in the development of anti HIV-1 therapies in an 
effort to slow down the progression of the infection to AIDS. At present, there are nine 
FDA approved inhibitors (PIs) that are successfully being used as a part of highly active 
anti-retroviral therapy (HAART). However, the accumulation of inhibitor resistance 
mutations within the protease gene can significantly reduce the efficacy of the inhibitors.  
Based on crystallographic data on HIV-1 protease in complex with substrate 
peptides, it has been established that HIV-1 protease recognizes a specific asymmetric 
shape the substrates conform to rather than a specific sequence (Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2002). The specific shape taken up by the substrates has been 
defined as the substrate envelope (Figure AIII-1A and B). Similarly, using crystal 
structures of HIV-1 protease in complex with PIs, an inhibitor envelope defining the 
shape taken up by the bound inhibitors has been generated (Figure AIII-1C and D). By 
superposing the inhibitor envelope on to the substrate envelope, it was observed that a 
significant number of inhibitor resistance substitutions within the protease active site 
occurred at positions where the inhibitor envelope protruded beyond the substrate  
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FIGURE AIII-1 
 
Reprinted from Chemistry & Biology, Vol. 11, “Combating Susceptibility to Drug 
Resistance: Lessons from HIV-1 Protease”, Pages 1333-8, © 2004, with permission from 
Elsevier.  
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FIGURE AIII-1. Substrate and Inhibitor Envelopes of HIV-1 Protease. A. The substrate 
envelope calculated with GRASP (Nicholls, Sharp, and Honig, 1991b)from the 
overlapping van der Waals volume of four or more substrate peptides. The colors of the 
substrate peptides are red, matrix-capsid; green, capsid-p2; blue, p2-nucleocapsid; cyan, 
p1-p6; magenta, reverse-transcriptase-ribonucleaseH; and yellow, ribonucleaseH-
integrase. B. The substrate envelope as it fits within the active site of HIV-1 protease. 
The α-carbon trace is of the CA-p2 substrate peptide complex (Prabu-Jeyabalan, 
Nalivaika, and Schiffer, 2000b). C. The inhibitor envelope calculated from overlapping 
van der Waals volume of five or more of eight inhibitor complexes. The colors of the 
inhibitors are yellow, Nelfinavir (NFV); gray, Saquinavir (SQV); cyan, Indinavir (IDV); 
light blue, Ritonavir (RTV); green, Amprenavir (APV); magenta, Lopinavir (LPV); blue, 
Atazanavir (ATV); and red, darunavir (DRV). D. The inhibitor envelope as it fits within 
the active site of HIV-1 protease. E. Superposition of the substrate envelope (blue) with 
the inhibitor envelope (red). Residues that contact the inhibitors where the inhibitors 
protrude beyond the substrate envelope and confer drug resistance when they mutate are 
labeled.  
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envelope to interact with the protein (Figure AIII-1E) (King et al., 2004a). Thus, if 
inhibitors can be designed to fit within the substrate, amino acid substitutions that 
accumulate within the active site will no longer be able to influence inhibitor binding.  
To test the hypothesis that the protease will not be able to develop resistant 
mutations in response to inhibitors that fit within substrate envelope, large libraries of 
protease inhibitors were designed using computational approaches. A major focus in the 
design effort has been with using the (R)- (hydroxyethylamino) sulfonamide isostere as a 
scaffold which is used in two potent FDA approved protease inhibitors, amprenavir 
(APV) and darunavir (DRV) (Figure AIII-2A). This has resulted in several APV and 
DRV analogs that have now been synthesized and characterized using structural and 
biochemical methods.  Crystal structures of protease variants in complex with many of 
these inhibitors indicate that they fit well within the substrate envelope (Nalam et. al., 
unpublished data). Data from enzyme and viral inhibition assays have revealed that 
several of these inhibitors were able to maintain exceptional potency against a number of 
inhibitor resistant enzyme variants and viral strains (unpublished data). Data presented in 
this section are a part of an ongoing effort to characterize the thermodynamic binding 
parameters of these newly synthesized APV and DRV analog inhibitors with a number of 
drug resistant protease variants.  
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FIGURE AIII-2 
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FIGURE AIII-2. A. Chemical structures of APV and DRV with the scaffold colored in 
red. Red circles indicate chemical moieties that were changed to generate the APV and 
DRV analogs. B. Chemical structures of APV analogs. C. Chemical structures of DRV 
analogs. 
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MATERIALS AND METHODS 
 Protease gene construction, protein expression and purification and displacement 
isothermal titration calorimetry (ITC) experiments for wild type, FLAP+ (L10I, G48V, 
I54V, V82A), I50V, D30N/N88D and M3 (L10I, A71V, G73S, I84V, L90M) protease 
variants were performed as described in previous chapters.  
 
RESULTS AND FUTURE DIRECTIONS 
 Thermodynamic binding parameters for APV and DRV analogs determined up to 
now with protease variants are summarized in Table AIII-1 and AIII-2. Both APV 
analogs had improved affinity for WT protease. The binding affinities of KC-47 to most 
variants were not significantly different from that of APV. Currently, ITC experiments 
are being performed to determine binding thermodynamic parameters for AF-57 with the 
inhibitor resistant protease variant panel.   
The affinities of DRV analogs binding to WT protease appeared to be 
significantly lower than the DRV affinity for WT protease. However, Ki data determined 
for all the DRV analogs indicated that they bound to WT protease with a greater affinity 
(sub-pico molar or better) than DRV (Nalam et al., unpublished data). Furthermore, IC50 
values determined for the DRV analogs against a panel of viruses indicated that the 
inhibitory concentrations were much lower than that for DRV. Together, the Ki and IC50 
data suggest that the DRV analogs are more effective that DRV. 
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TABLE AIII-1 Binding thermodynamic parameters for APV, KC47 and AF57. 
Protease 
Variant Ka (M
–1) Kd (nM) Kd ratio 
ΔH  
(kcal mol–1) ΔΔH 
–TΔS  
(kcal mol–1) 
Δ 
(–TΔS) 
ΔG  
(kcal mol-1) ΔΔG 
APV 
WT (2.6 ± 1.3) × 109 0.39 ± 0.20 1.0 –7.3 ± 0.9 - –5.3 - –12.6 ± 0.3 - 
FLAP+ (7.62 ± 0.06) × 108 1.3 ± 0.01 3.3 3.3 ± 0.5 10.6 –15.2 –9.9 –11.9 ± 0.3 0.7 
I50V, A71V (1.14 ± 0.03) × 108 0.88 ± 0.02 2.2 –11.8 ± 0.3 –4.5 –0.3 5.0 –12.1 ± 0.01 0.5 
D30N, N88D (1.19 ± 0.18) × 1010 0.08 ± 0.01 0.2 –10.2 ± 1.5 –2.9 –3.3 2.0 –13.5 ± 0.09 –0.9 
M3 (4.99 ± 0.05) × 108 2.0 ± 0.02 5.1 –7.2 ± 0.04 –0.1 –11.7 –6.4 –11.7 ± 0.006 0.9 
KC-47 
WT (5.4 ± 2.7) × 109 0.18 ± 0.09 1.0 –6.1 ± 0.5 - –7.0 - –13.1 ± 0.2 - 
FLAP+ (1.2 ± 0.4) × 109 0.84 ± 0.26 4.6 2.7 ± 0.3 8.8 −14.8 –7.8 –12.2 ± 0.2 0.9 
I50V, A71V (9.6 ± 1.3) × 108 1.04 ± 0.15 5.7 –8.4 ± 0.2 –2.3 –3.6 3.4 –12.0 ± 0.2 1.1 
D30N, N88D (5.8 ± 0.3) × 108 0.173 ± 0.009 1.0 –8.2 ± 0.6 –2.1 –3.6 3.4 –13.1 ± 3.0 0.0 
M3 (3.2 ± 0.5) × 108 3.1 ± 0.46 17.2 –9.3 ± 0.9 –3.2 –2.1 4.9 –11.4 ± 0.9 –1.7 
AF-57 
WT (3.9 ± 1.2) × 109 0.26 ± 0.07 1.0 –5.9 ± 1.3 - –7.02 - –12.9 ± 0.2 - 
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TABLE AIII-2 Binding thermodynamic parameters DRV analogs binding to wild type protease. 
Protease 
Variant Ka (M
–1) Kd (pM) 
ΔH  
(kcal mol–1) 
–TΔS  
(kcal mol–1) 
ΔG  
(kcal mol-1) 
WT (2.6 ± 1.3) × 109 4.0 ± 2.0 –12.1 ± 0.9 –3.1 –15.2 ± 0.3 
WT (1.18 ± 1.56) × 1012 85.0 ± 113.0 –7.3 ± 0.5 –6.2 –13.5 ± 0.3 
WT (9.6 ± 0.96) × 109 104.0 ± 11.0 –8.5 ± 0.8 –4.9 –13.4 ± 5.9 
WT (1.2 ± 0.3) × 1010 83.0 ± 20.0 –5.7 ± 0.5 –7.9 –13.5 ± 0.2 
WT (1.8 ± 0.2) × 1010 53.2 ± 4.6 –11.4 ± 1.3 –2.4 –13.8 ± 5.3 
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One explanation the weaker affinities observed in the ITC experiments could be 
the poor solubility of these analogs at the concentrations needed to carry out ITC 
experiments. While problems related to solubility are not obvious when carrying out the 
ITC experiments, it is possible that the inhibitors precipitate out of the inhibitor solutions 
to a certain level during the course of the experiment and thereby change the effective 
inhibitor concentration of the experiment. Another possible explanation could be the 
choice of the weak inhibitor used for the displacement experiments. Acetyl-pepstatin, 
which was used to initially saturate the protein, has a binding affinity for protease in the 
micro molar range. The protease inhibitory assay data show that the affinities of the DRV 
analogs are in the sub-pico molar range or better. Thus, given that the DRV analogs bind 
to protease about six orders of magnitude or better than acetyl-pepstatin, it might not be 
possible to accurately determine the affinity constants by using acetyl-pepstatin as the 
weak binding inhibitor for the displacement experiments. At present, experiments are 
being carried out using nelfinavir (NFV) as the weak binding inhibitor for the 
displacement experiments. The affinity of NFV to protease, which in the sub nano molar 
range, will be about three orders of magnitude tighter than acetyp-pepstatin and should 
not allow the DRV analogs to displace it too fast. This slow displacement should allow 
for the accurate determination of affinity constants for the DRV analogs. 
 Overall, determining the binding thermodynamic parameters for the APV and 
DRV analogs will provide insights into the how thermodynamics of binding are affected 
by modifying chemical groups within PIs that fit well within the substrate envelope. 
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Thus, data gathered from these studies will aid in the design of inhibitors that have 
improved binding thermodynamics while fitting well within the substrate envelope. 
173 
REFERENCES 
Adachi, M., Ohhara, T., Kurihara, K., Tamada, T., Honjo, E., Okazaki, N., Arai, S., 
Shoyama, Y., Kimura, K., Matsumura, H., Sugiyama, S., Adachi, H., Takano, K., 
Mori, Y., Hidaka, K., Kimura, T., Hayashi, Y., Kiso, Y., and Kuroki, R. (2009). 
Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined 
by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci U S A 
106(12), 4641-6. 
Alimonti, J. B., Ball, T. B., and Fowke, K. R. (2003). Mechanisms of CD4+ T 
lymphocyte cell death in human immunodeficiency virus infection and AIDS. 
Journal of General Virology 84(Pt 7), 1649-61. 
Ariyoshi, K., Matsuda, M., Miura, H., Tateishi, S., Yamada, K., and Sugiura, W. (2003a). 
Patterns of point mutations associated with antiretroviral drug treatment failure in 
CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir 
Immune Defic Syndr 33(3), 336-42. 
Ariyoshi, K., Matsuda, M., Miura, H., Tateishi, S., Yamada, K., and Sugiura, W. (2003b). 
Patterns of point mutations associated with antiretroviral drug treatment failure in 
CRF01_AE (subtype E) infection differ from subtype B infection. Journal of 
Acquired Immune Deficiency Syndromes 33(3), 336-42. 
Asamoah-Odei, E., Garcia Calleja, J. M., and Boerma, J. T. (2004). HIV prevalence and 
trends in sub-Saharan Africa: no decline and large subregional differences. Lancet 
364(9428), 35-40. 
Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., 
Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbaum, W., 
and Montagnier, L. (1983). Isolation of a T-lymphotropic retrovirus from a patient 
at risk for acquired immune deficiency syndrome (AIDS). Science 220(4599), 
868-71. 
Bebenek, K., Abbotts, J., Wilson, S. H., and Kunkel, T. A. (1993). Error-prone 
polymerization by HIV-1 reverse transcriptase. Contribution of template-primer 
misalignment, miscoding, and termination probability to mutational hot spots. 
Journal of Biological Chemistry 268(14), 10324-34. 
Becker-Pergola, G., Kataaha, P., Johnston-Dow, L., Fung, S., Jackson, J. B., and 
Eshleman, S. H. (2000). Analysis of HIV type 1 protease and reverse transcriptase 
in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 16(8), 
807-13. 
Berg, J. M., Tymoczko, J. L., and Stryer, L. (2007). Biochemistry. 6 ed. In 
"Biochemistry", pp. 252. Tenney, S. 
Blasie, C. A., and Berg, J. M. (2004). Entropy-enthalpy compensation in ionic 
interactions probed in a zinc finger peptide. Biochemistry 43(32), 10600-10604. 
Bonfanti, P., Capetti, A., and Rizzardini, G. (1999). HIV disease treatment in the era of 
HAART. Biomedicine and Pharmacotherapy 53(2), 93-105. 
Bottcher, J., Blum, A., Heine, A., Diederich, W. E., and Klebe, G. (2008). Structural and 
Kinetic Analysis of Pyrrolidine-Based Inhibitors of the Drug-Resistant Ile84Val 
Mutant of HIV-1 Protease. J Mol Biol, (in press) doi:10.1016/j.jmb.2008.07.062   
174 
Brik, A., and Wong, C. H. (2003). HIV-1 protease: mechanism and drug discovery. Org 
Biomol Chem 1(1), 5-14. 
Buonaguro, L., Tornesello, M. L., and Buonaguro, F. M. (2007). Human 
immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: 
pathogenetic and therapeutic implications. Journal of Virology 81(19), 10209-19. 
Carr, J. K., Salminen, M. O., Koch, C., Gotte, D., Artenstein, A. W., Hegerich, P. A., St 
Louis, D., Burke, D. S., and McCutchan, F. E. (1996). Full-length sequence and 
mosaic structure of a human immunodeficiency virus type 1 isolate from 
Thailand. J Virol 70(9), 5935-43. 
Chan, D. C., and Kim, P. S. (1998). HIV entry and its inhibition. Cell 93(5), 681-4. 
Chou, K. (1996a). Prediction of human immunodeficiency virus protease cleavage sites 
in proteins. Anal Biochem 233, 1-14. 
Chou, K. (1996b). Prediction of human immunodeficiency virus protease cleavage sites 
in proteins. Analytical Biochemistry 233, 1-14. 
Clemente, J. C., Coman, R. M., Thiaville, M. M., Janka, L. K., Jeung, J. A., Nukoolkarn, 
S., Govindasamy, L., Agbandje-McKenna, M., McKenna, R., Leelamanit, W., 
Goodenow, M. M., and Dunn, B. M. (2006). Analysis of HIV-1 CRF_01 A/E 
protease inhibitor resistance: structural determinants for maintaining sensitivity 
and developing resistance to atazanavir. Biochemistry 45(17), 5468-77. 
Collaborative Computational Project Number 4 (1994). The CCP4 suite: programs for 
protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-763. 
Collaborative-Computational-Project, N. (1994). The CCP4 suite: programs for protein 
crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-763. 
Colonno, R., Parkin, N., McLaren, C., Seekins, D., Hodder, S., Schnittman, S., and 
Kelleher, T. (2004a). Pathways to Atazanavir Resistance in Treatment-
experienced Patients and Impact of Residue 50 Substitutions. In "Conference on 
Retroviruses and Opportunistic Infections", San Francisco, California. 
Colonno, R., Rose, R., McLaren, C., Thiry, A., Parkin, N., and Friborg, J. (2004b). 
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in 
treatment-naive HIV-1-infected patients receiving ATV-containing regimens. 
Journal of Infectious Diseases 189(10), 1802-10. 
Coman, R. M., Robbins, A., Goodenow, M. M., McKenna, R., and Dunn, B. M. (2007). 
Expression, purification and preliminary X-ray crystallographic studies of the 
human immunodeficiency virus 1 subtype C protease. Acta Crystallograph Sect F 
Struct Biol Cryst Commun 63(Pt 4), 320-3. 
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J. 
C., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., 
Teppler, H., Squires, K. E., Deutsch, P. J., and Emini, E. (1995). In vivo 
emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 
569-571. 
Copeland, R. A. (1996). "Enzymes: A practical introduction to structure, mechanism, and 
data analysis." Wiley-VCH. 
Davidson, J. P., Lubman, O., Rose, T., Waksman, G., and Martin, S. F. (2002). 
Calorimetric and Structural Studies of 1,2,3-Trisubstituted Cyclopropanes as 
175 
Conformationally Constrained Peptide Inhibitors of Src SH2 Domain Binding. J. 
Am. Chem. Soc. 124(2), 205-215. 
De Clercq, E. (2009). The history of antiretrovirals: key discoveries over the past 25 
years. Rev Med Virol 19(5), 287-99. 
De Meyer, S., Azijn, H., Surleraux, D., Jochmans, D., Tahri, A., Pauwels, R., Wigerinck, 
P., and de Bethune, M. P. (2005). TMC114, a novel human immunodeficiency 
virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, 
including a broad range of clinical isolates. Antimicrobial Agents and 
Chemotherapy 49(6), 2314-21. 
de Oliveira, T., Engelbrecht, S., Janse van Rensburg, E., Gordon, M., Bishop, K., zur 
Megede, J., Barnett, S. W., and Cassol, S. (2003). Variability at human 
immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of 
viral fitness? Journal of Virology 77(17), 9422-30. 
Debouck, C. (1992). The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum 
Retroviruses 8(2), 153-164. 
Debouck, C., and Metcalf, B. W. (1990). Human Immunodeficiency Virus Protease: A 
target for AIDS therapy. Drug Develop Res 21, 1-17. 
The PyMol Molecular Graphics System. San Carlos, CA, USA.: DeLano Scientific. 
Dimitrov, D. S. (1997). How do viruses enter cells? The HIV coreceptors teach us a 
lesson of complexity. Cell 91(6), 721-30. 
Dorsey, B. D., Levin, R. B., McDaniel, S. L., Vacca, J. P., Guare, J. P., Darke, P. L., 
Zugay, J. A., Emini, E. A., Schleif, W. A., Quintero, J. C., and et al. (1994). L-
735,524: the design of a potent and orally bioavailable HIV protease inhibitor. 
Journal of Medicinal Chemistry 37(21), 3443-51. 
Dunitz, J. D. (1995). Win some, lose some: enthalpy-entropy compensation in weak 
intermolecular interactions. Chem Biol 2(11), 709-712. 
Elston, R., Scherer, J., Schapiro, J., Bethell, R., Kohlbrenner, V., and Mayers, D. (2006). 
De-Selection fo the I50V Mutation Occurs in Clinical Isolates During Aptivus/r 
(Tipranavir/Ritonavir) Based Therapy. In "15th International HIV Drug Resitance 
Workshop", Sitges, Spain. 
Emini, E. A., Schleif, W. A., Deutsch, P., and Condra, J. H. (1996). In vivo selection of 
HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and 
related compounds. Adv Exp Med Biol 394, 327-331. 
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. 
Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1), 2126-32. 
Essex, M. (1996). Retroviral vaccines: challenges for the developing world. AIDS 
Research and Human Retroviruses 12(5), 361-3. 
Fackler, O. T., and Peterlin, B. M. (2000). Endocytic entry of HIV-1. Current Biology 
10(16), 1005-8. 
Flexner, C. (2007). HIV drug development: the next 25 years. Nat Rev Drug Discov 
6(12), 959-66. 
Foulkes-Murzycki, J. E., Scott, W. R., and Schiffer, C. A. (2007). Hydrophobic sliding: a 
possible mechanism for drug resistance in human immunodeficiency virus type 1 
protease. Structure 15(2), 225-33. 
176 
Gao, F., Bailes, E., Robertson, D. L., Chen, Y., Rodenburg, C. M., Michael, S. F., 
Cummins, L. B., Arthur, L. O., Peeters, M., Shaw, G. M., Sharp, P. M., and Hahn, 
B. H. (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. 
Nature 397(6718), 436-41. 
Gao, F., Robertson, D. L., Morrison, S. G., Hui, H., Craig, S., Decker, J., Fultz, P. N., 
Girard, M., Shaw, G. M., Hahn, B. H., and Sharp, P. M. (1996). The heterosexual 
human immunodeficiency virus type 1 epidemic in Thailand is caused by an 
intersubtype (A/E) recombinant of African origin. J Virol 70(10), 7013-29. 
Gomes, P., Diogo, I., Goncalves, M. F., Carvalho, P., Cabanas, J., Lobo, M. C., and 
Camacho, R. (2002). Conference on Retroviruses and Opportunistic Infections 
(CROI), Seatle, WA. 
Gonzales, M. J., Machekano, R. N., and Shafer, R. W. (2001). Human immunodeficiency 
virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid 
mutation patterns, and prevalence in a northern California clinic-based 
population. J Infect Dis 184(8), 998-1006. 
Gregoret, L. M., Rader, S. D., Fletterick, R. J., and Cohen, F. E. (1991). Hydrogen bonds 
involving sulfur atoms in proteins. Proteins 9(2), 99-107. 
Grossman, Z., Paxinos, E. E., Averbuch, D., Maayan, S., Parkin, N. T., Engelhard, D., 
Lorber, M., Istomin, V., Shaked, Y., Mendelson, E., Ram, D., Petropoulos, C. J., 
and Schapiro, J. M. (2004a). Mutation D30N is not preferentially selected by 
human immunodeficiency virus type 1 subtype C in the development of resistance 
to nelfinavir. Antimicrob Agents Chemother 48(6), 2159-65. 
Grossman, Z., Paxinos, E. E., Averbuch, D., Maayan, S., Parkin, N. T., Engelhard, D., 
Lorber, M., Istomin, V., Shaked, Y., Mendelson, E., Ram, D., Petropoulos, C. J., 
and Schapiro, J. M. (2004b). Mutation D30N is not preferentially selected by 
human immunodeficiency virus type 1 subtype C in the development of resistance 
to nelfinavir. Antimicrobial Agents and Chemotherapy 48(6), 2159-65. 
Gulnik, S. V., Suvorov, L. I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., and Erickson, J. 
W. (1995). Kinetic characterization and cross-resistance patterns of HIV-1 
protease mutants selected under drug pressure. Biochemistry 34, 9282-9287. 
Hamelberg, D., and McCammon, J. A. (2005). Fast Peptidyl cis-trans Isomerization 
within the Flexible Gly-Rich Flaps of HIV-1 Protease. J. Am. Chem. Soc. 127(40), 
13778-13779. 
Hemelaar, J., Gouws, E., Ghys, P. D., and Osmanov, S. (2006). Global and regional 
distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20(16), 
W13-23. 
Henderson, L. E., Copeland, T. D., Sowder, R. C., Schultz, A. M., and Oraszlan, S. 
(1988). "Human retroviruses, cancer and AIDS: Approaches to prevention and 
therapy." Liss, New York. 
Hirsch, V. M., Olmsted, R. A., Murphey-Corb, M., Purcell, R. H., and Johnson, P. R. 
(1989). An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 
339(6223), 389-92. 
177 
Holguin, A., Ramirez de Arellano, E., Rivas, P., and Soriano, V. (2006). Efficacy of 
antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS 
Rev 8(2), 98-107. 
Houk, K. N., Leach, A.G, Kim, S. P, Zhang, X (2003). Binding Affinities of Host-Guest, 
Protein-Ligand, and Protein-Transition-State Complexes. Angewandte Chemie 
International Edition 42(40), 4872-4897. 
Hu, D. J., Buve, A., Baggs, J., van der Groen, G., and Dondero, T. J. (1999). What role 
does HIV-1 subtype play in transmission and pathogenesis? An epidemiological 
perspective. AIDS 13(8), 873-81. 
Huet, T., Cheynier, R., Meyerhans, A., Roelants, G., and Wain-Hobson, S. (1990). 
Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 
345(6273), 356-9. 
Hui, J. O., A.G., T., Reardon, I. M., Lull, J. M., Brunner, D. P., Tomich, C. C., and 
Heinrikson, R. L. (1993). Large scale purification and refolding of HIV-1 
protease from Escherichia coli inclusion bodies. J. Prot. Chem. 12, 323-327. 
Hyland, L. J., Tomaszek, T. A., Jr., and Meek, T. D. (1991). Human immunodeficiency 
virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to 
elucidate details of chemical mechanism. Biochemistry 30(34), 8454-63. 
Hyland, L. J., Tomaszek, T. A., Jr., Roberts, G. D., Carr, S. A., Magaard, V. W., Bryan, 
H. L., Fakhoury, S. A., Moore, M. L., Minnich, M. D., Culp, J. S., and et al. 
(1991). Human immunodeficiency virus-1 protease. 1. Initial velocity studies and 
kinetic characterization of reaction intermediates by 18O isotope exchange. 
Biochemistry 30(34), 8441-53. 
James, M. N., Sielecki, A. R., Hayakawa, K., and Gelb, M. H. (1992). Crystallographic 
analysis of transition state mimics bound to penicillopepsin: difluorostatine- and 
difluorostatone-containing peptides. Biochemistry 31(15), 3872-86. 
Jones, T. A., Bergdoll, M., and Kjeldgaard, M. (1990). O: A macromolecular modeling 
environment. In "Crystallographic and Modeling Methods in Molecular Design" 
(C. Bugg, and S. Ealick, Eds.), pp. 189-195. Springer-Verlag Press, Berlin. 
Julg, B., and Goebel, F. D. (2005). HIV genetic diversity: any implications for drug 
resistance? Infection 33(4), 299-301. 
Kaldor, S. W., Kalish, V. J., Davies, J. F., 2nd, Shetty, B. V., Fritz, J. E., Appelt, K., 
Burgess, J. A., Campanale, K. M., Chirgadze, N. Y., Clawson, D. K., Dressman, 
B. A., Hatch, S. D., Khalil, D. A., Kosa, M. B., Lubbehusen, P. P., Muesing, M. 
A., Patick, A. K., Reich, S. H., Su, K. S., and Tatlock, J. H. (1997). Viracept 
(nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 
protease. Journal of Medicinal Chemistry 40(24), 3979-85. 
Kaleebu, P., French, N., Mahe, C., Yirrell, D., Watera, C., Lyagoba, F., Nakiyingi, J., 
Rutebemberwa, A., Morgan, D., Weber, J., Gilks, C., and Whitworth, J. (2002a). 
Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and 
D on disease progression in a large cohort of HIV-1-positive persons in Uganda. 
Journal of Infectious Diseases 185(9), 1244-50. 
Kaleebu, P., French, N., Mahe, C., Yirrell, D., Watera, C., Lyagoba, F., Nakiyingi, J., 
Rutebemberwa, A., Morgan, D., Weber, J., Gilks, C., and Whitworth, J. (2002b). 
178 
Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and 
D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J 
Infect Dis 185(9), 1244-50. 
Kanki, P. J., Hamel, D. J., Sankale, J. L., Hsieh, C., Thior, I., Barin, F., Woodcock, S. A., 
Gueye-Ndiaye, A., Zhang, E., Montano, M., Siby, T., Marlink, R., I, N. D., Essex, 
M. E., and S, M. B. (1999a). Human immunodeficiency virus type 1 subtypes 
differ in disease progression. Journal of Infectious Diseases 179(1), 68-73. 
Kanki, P. J., Hamel, D. J., Sankale, J. L., Hsieh, C., Thior, I., Barin, F., Woodcock, S. A., 
Gueye-Ndiaye, A., Zhang, E., Montano, M., Siby, T., Marlink, R., I, N. D., Essex, 
M. E., and S, M. B. (1999b). Human immunodeficiency virus type 1 subtypes 
differ in disease progression. J Infect Dis 179(1), 68-73. 
Kantor, R., and Katzenstein, D. (2003). Polymorphism in HIV-1 non-subtype B protease 
and reverse transcriptase and its potential impact on drug susceptibility and drug 
resistance evolution. AIDS Rev 5(1), 25-35. 
Kantor, R., and Katzenstein, D. (2004). Drug resistance in non-subtype B HIV-1. Journal 
of Clinical Virology 29(3), 152-9. 
Kantor, R., Katzenstein, D. A., Efron, B., Carvalho, A. P., Wynhoven, B., Cane, P., 
Clarke, J., Sirivichayakul, S., Soares, M. A., Snoeck, J., Pillay, C., Rudich, H., 
Rodrigues, R., Holguin, A., Ariyoshi, K., Bouzas, M. B., Cahn, P., Sugiura, W., 
Soriano, V., Brigido, L. F., Grossman, Z., Morris, L., Vandamme, A. M., Tanuri, 
A., Phanuphak, P., Weber, J. N., Pillay, D., Harrigan, P. R., Camacho, R., 
Schapiro, J. M., and Shafer, R. W. (2005). Impact of HIV-1 subtype and 
antiretroviral therapy on protease and reverse transcriptase genotype: results of a 
global collaboration. PLoS Med 2(4), e112. 
Kempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. 
A., Green, B. E., Fino, L., Park, C. H., Kong, X. P., and et al. (1995). ABT-538 is 
a potent inhibitor of human immunodeficiency virus protease and has high oral 
bioavailability in humans. Proceedings of the National Academy of Sciences of 
the United States of America 92(7), 2484-8. 
Kim, E. E., Baker, C. T., Dwyer, M. D., Murcko, M. A., Rao, B. G., Tung, R. D., and 
Navia, M. A. (1995). Crystal structure of HIV-1 protease in complex with VX-
478, A potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 
117, 1181. 
King, N. M., Melnick, L., Prabu-Jeyabalan, M., Nalivaika, E. A., Yang, S.-S., Gao, Y., 
Nie, X., Zepp, C., Heefner, D. L., and Schiffer, C. A. (2002). Lack of synergy for 
inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci 11(2), 418-
429. 
King, N. M., Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C. A. (2004a). Combating 
susceptibility to drug resistance: lessons from HIV protease. Chemistry and 
Biology 11, 1333-1338. 
King, N. M., Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C. A. (2004b). Combating 
Susceptibility to Drug Resistance: Lessons from HIV-1 Protease. Chemistry and 
Biology 11, 1333-1338. 
179 
King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A., Wigerinck, P., de Bethune, M.-P., 
and Schiffer, C. A. (2004c). Structural and thermodynamic basis for the binding 
of TMC114, a next-generation human immunodeficiency virus type-1 protease 
inhibitor. J. Virol. 78(21), 12012-12021. 
King, N. M., Prabu-Jeyabalan, M., Wigerinck, P., De Bethune, M.-P., and Schiffer, C. A. 
(2004d). Structural and thermodynamic basis for the binding of TMC114, a next-
generation human immunodeficiency virus type 1 protease inhibitor. J Virol 
78(21), 12012-12021. 
Kiwanuka, N., Laeyendecker, O., Robb, M., Kigozi, G., Arroyo, M., McCutchan, F., 
Eller, L. A., Eller, M., Makumbi, F., Birx, D., Wabwire-Mangen, F., Serwadda, 
D., Sewankambo, N. K., Quinn, T. C., Wawer, M., and Gray, R. (2008). Effect of 
human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in 
persons from Rakai, Uganda, with incident HIV-1 infection. Journal of Infectious 
Diseases 197(5), 707-13. 
Knight, S. C., Macatonia, S. E., and Patterson, S. (1990). HIV I infection of dendritic 
cells. International Reviews of Immunology 6(2-3), 163-75. 
Koenig, S., Gendelman, H. E., Orenstein, J. M., Dal Canto, M. C., Pezeshkpour, G. H., 
Yungbluth, M., Janotta, F., Aksamit, A., Martin, M. A., and Fauci, A. S. (1986). 
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with 
encephalopathy. Science 233(4768), 1089-93. 
Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. A., 
Scolnick, E. M., and Sigal, I. S. (1988). Active human immunodeficiency virus 
protease is required for viral infectivity. Proc Natl Acad Sci U S A 85, 4686-4690. 
Kolli, M., Lastere, S., and Schiffer, C. A. (2006). Co-evolution of nelfinavir-resistant 
HIV-1 protease and the p1-p6 substrate. Virology 347(2), 405-9. 
Kolli, M., Stawiski, E., Chappey, C., and Schiffer, C. A. (2009). Human 
immunodeficiency virus type 1 protease-correlated cleavage site mutations 
enhance inhibitor resistance. Journal of Virology 83(21), 11027-42. 
Krohn, A., Redshaw, S., Ritchie, J. C., Graves, B. J., and Hatada, M. H. (1991). Novel 
binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-
hydroxyethylamine isostere. J Med Chem 34, 3340-3342. 
Krueger, S., Gregurick, S., Shi, Y., Wang, S., Wladkowski, B. D., and Schwarz, F. P. 
(2003). Entropic Nature of the Interaction between Promoter Bound CRP Mutants 
and RNA Polymerase. Biochemistry 42(7), 1958-1968. 
Los Alamos National Laboratory (2008). HIV Sequence Compendium 2008. Kuiken, C., 
Foley, B., Preston, M., Wolinksy, S., Leitner, T., Hahn, B. H., McCutchan, F., and 
Korber, B. 
Kuiken, C., Thakallapalli, R., Esklid, A., and de Ronde, A. (2000). Genetic analysis 
reveals epidemiologic patterns in the spread of human immunodeficiency virus. 
American Journal of Epidemiology 152(9), 814-22. 
Kuroki, R., Nitta, K., and Yutani, K. (1992). Thermodynamic changes in the binding of 
Ca2+ to a mutant human lysozyme (D86/92). Enthalpy-entropy compensation 
observed upon Ca2+ binding to proteins. J Biol Chem 267(34), 24297-301. 
180 
Ladbury, J. E., and Chowdhry, B. Z., Eds. (1998). Biocalorimetry. Applications of 
Calorimetry in the Biological Sciences. . Chichester: John Wiley & Sons Ltd. 
Lafont, V., Armstrong, A. A., Ohtaka, H., Kiso, Y., Mario Amzel L, and E., F. (2007). 
Compensating enthalpic and entropic changes hinder binding affinity 
optimization. Chem. Biol. Drug Des. 69, 413-422. 
Lama, J., and Planelles, V. (2007). Host factors influencing susceptibility to HIV 
infection and AIDS progression. Retrovirology 4, 52. 
Laskowski, R. A., Mac Arthur, M. W., Moss, D. S., and Thornton, J. M. (1993). 
PROCHECK. A program to check the stereochemical quality of protein 
structures. J Appl Cryst 26, 283-291. 
Liu, H., Muller-Plathe, F., and van Gunsteren, W. F. (1996). A combined 
quantum/classical molecular dynamics study of the catalytic mechanism of HIV 
protease. Journal of Molecular Biology 261(3), 454-69. 
Los Alamos Laboratory (2010). HIV Sequence Database. http://www.hiv.lanl.gov/. Los 
Alamos National Laboratory. 
Masquelier, B., Assoumou, K. L., Descamps, D., Bocket, L., Cottalorda, J., Ruffault, A., 
Marcelin, A. G., Morand-Joubert, L., Tamalet, C., Charpentier, C., Peytavin, G., 
Antoun, Z., Brun-Vezinet, F., and Costagliola, D. (2008). Clinically validated 
mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J Antimicrob 
Chemother 61(6), 1362-8. 
McCutchan, F. E. (2006). Global epidemiology of HIV. J Med Virol 78 Suppl 1, S7-S12. 
Purdue University. (1993).  
XDISPLAYF program. Minor, W. 
Miyauchi, K., Kim, Y., Latinovic, O., Morozov, V., and Melikyan, G. B. (2009). HIV 
enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 
137(3), 433-44. 
Murphy, E., Korber, B., Georges-Courbot, M. C., You, B., Pinter, A., Cook, D., Kieny, 
M. P., Georges, A., Mathiot, C., Barre-Sinoussi, F., and et al. (1993). Diversity of 
V3 region sequences of human immunodeficiency viruses type 1 from the central 
African Republic. AIDS Res Hum Retroviruses 9(10), 997-1006. 
Muzammil, S., Armstrong, A. A., Kang, L. W., Jakalian, A., Bonneau, P. R., Schmelmer, 
V., Amzel, L. M., and Freire, E. (2007). Unique thermodynamic response of 
tipranavir to human immunodeficiency virus type 1 protease drug resistance 
mutations. J Virol 81(10), 5144-54. 
Muzammil, S., Ross, P., and Freire, E. (2003). A Major Role for a Set of Non-Active Site 
Mutations in the Development of HIV-1 Protease Drug Resistance. Biochemistry 
42(3), 631-638. 
Navaza, J. (1994). AMoRe:  an automated package for molecular replacement. Acta 
Crystallogr D Biol Crystallogr A50, 157-163. 
Navia, M. A., and McKeever, B. M. (1990). A role for the aspartyl protease from the 
human immunodeficiency virus type 1 (HIV-1) in the orchestration of virus 
assembly. Annals of the New York Academy of Sciences 616, 73-85. 
181 
Nicholls, A., Sharp, K., and Honig, B. (1991a). Protein folding and association: insights 
from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11, 
281-296. 
Nicholls, A., Sharp, K. A., and Honig, B. (1991b). Protein folding and association: 
insights from the interfacial and thermodynamic properties of hydrocarbons. 
Proteins 11(4), 281-96. 
Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, 
P., Gulnik, S., and Boucher, C. A. (1999). Increased fitness of drug resistant HIV-
1 protease as a result of acquisition of compensatory mutations during suboptimal 
therapy. AIDS 13(17), 2349-59. 
Nunez, M., de Mendoza, C., Valer, L., Casas, E., Lopez-Calvo, S., Castro, A., Roson, B., 
Podzamczer, D., Rubio, A., Berenguer, J., and Soriano, V. (2002). Resistance 
mutations in HIV-infected patients experiencing early failure with nelfinavir-
containing triple combinations. Med Sci Monit 8(9), CR620-3. 
Ode, H., Matsuyama, S., Hata, M., Hoshino, T., Kakizawa, J., and Sugiura, W. (2007). 
Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, 
analyzed by molecular dynamics simulations. J Med Chem 50(8), 1768-77. 
Ode, H., Ota, M., Neya, S., Hata, M., Sugiura, W., and Hoshino, T. (2005). Resistant 
mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. 
J Phys Chem B 109(1), 565-74. 
Ohtaka, H., and Freire, E. (2005). Adaptive inhibitors of the HIV-1 protease. Prog 
Biophys Mol Biol. 88(2), 193-208. 
Ohtaka, H., Muzammil, S., Schön, A., Velazquez-Campoy, A., Vega, S., and Freire, E. 
(2004). Thermodynamic rules for the design of high affinity HIV-1 protease 
inhibitors with adaptability to mutations and high selectivity towards unwanted 
targets. Int. J Biochem. Cell Biol. 36, 1787-1799. 
Ohtaka, H., Schon, A., and Freire, E. (2003). Multidrug Resistance to HIV-1 Protease 
Inhibition Requires Cooperative Coupling between Distal Mutations. 
Biochemistry 42(46), 13659-13666. 
Ohtaka, H., Velazquez-Campoy, A., Xie, D., and Freire, E. (2002). Overcoming drug 
resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir 
and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. 
Protein Sci 11(8), 1908-1916. 
Olsen, D. B., Stahlhut, M. W., Rutkowski, C. A., Schock, H. B., vanOlden, A. L., and 
Kuo, L. C. (1999). Non-active site changes elicit broad-based cross-resistance of 
the HIV-1 protease to inhibitors. J Biol Chem 274, 23699-23701. 
Orenstein, J. M. (2001). The macrophage in HIV infection. Immunobiology 204(5), 598-
602. 
Osmanov, S., Pattou, C., Walker, N., Schwardlander, B., and Esparza, J. (2002). 
Estimated global distribution and regional spread of HIV-1 genetic subtypes in 
the year 2000. Journal of Acquired Immune Deficiency Syndromes 29(2), 184-90. 
Otwinowski, Z. (1993). CCP4 Study weekend: Data collection and processing, 29-30 Jan 
1993, SERC Daresbury Laboratory, England. 
182 
Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data collected in 
oscillation mode. Methods Enzymol 276, 307-326. 
Painter, J., and Merritt, E. A. (2006). Optimal description of a protein structure in terms 
of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 
62(Pt 4), 439-50. 
Parkin, N., Stawiski, E., Chappey, C., and Coakley, E. (2007). Darunavir/amprenavir 
cross-resistance in clinical samples submitted for phenotype/genotype 
combination resistance testing. In "Conference on Retroviruses and Opportunistic 
Infections (CROI)", Vol. Abstract #607, San Francisco, CA. 
Parris, K. D., Hoover, D. J., Damon, D. B., and Davies, D. R. (1992). Synthesis and 
crystallographic analysis of two rhizopuspepsin inhibitor complexes. 
Biochemistry 31(35), 8125-41. 
Partaledis, J. A., Yamaguchi, K., Tisdale, M., Blair, E. E., Falcione, C., Maschera, B., 
Myers, R. E., Pazhanisamy, S., Futer, O., Cullinan, A. B., and et al. (1995a). In 
vitro selection and characterization of human immunodeficiency virus type 1 
(HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide 
inhibitors of HIV-1 aspartyl protease. J Virol 69(9), 5228-5235. 
Partaledis, J. A., Yamaguchi, K., Tisdale, M., Blair, E. E., Falcione, C., Maschera, B., 
Myers, R. E., Pazhanisamy, S., Futer, O., Cullinan, A. B., and et al. (1995b). In 
vitro selection and characterization of human immunodeficiency virus type 1 
(HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide 
inhibitors of HIV-1 aspartyl protease. Journal of Virology 69(9), 5228-35. 
Pauza, C. D. (1991). The endocytic pathway for human immunodeficiency virus 
infection. Advances in Experimental Medicine and Biology 300, 111-38; 
discussion 139-44. 
Pazhanisamy, S., Stuver, C. M., Cullinan, A. B., Margolin, N., Rao, B. G., and 
Livingston, D. J. (1996). Kinetic characterization of human immunodeficiency 
virus type-1 protease-resistant variants. Journal of Biological Chemistry 271(30), 
17979-85. 
Pearl, L. (1985). "Aspartic Proteinases and Their Inhibitors." (V. Kostka, Ed.) de Gruyter, 
Berlin. 
Pettit, S. C., Sheng, N., Tritch, R., Erickson-Vitanen, S., and Swanstrom, R. (1998). The 
regulation of sequential processing of HIV-1 Gag by the viral protease. Adv Exp 
Med Biol 436, 15-25. 
Plantier, J. C., Leoz, M., Dickerson, J. E., De Oliveira, F., Cordonnier, F., Lemee, V., 
Damond, F., Robertson, D. L., and Simon, F. (2009). A new human 
immunodeficiency virus derived from gorillas. Nature Medicine 15(8), 871-2. 
Popovic, M., Sarngadharan, M. G., Read, E., and Gallo, R. C. (1984). Detection, 
isolation, and continuous production of cytopathic retroviruses (HTLV-III) from 
patients with AIDS and pre-AIDS. Science 224(4648), 497-500. 
Poveda, E., de Mendoza, C., Martin-Carbonero, L., Corral, A., Briz, V., Gonzalez-Lahoz, 
J., and Soriano, V. (2007). Prevalence of darunavir resistance mutations in HIV-1-
infected patients failing other protease inhibitors. J Antimicrob Chemother 60(4), 
885-8. 
183 
Prabu-Jeyabalan, M., King, N. M., Nalivaika, E., Heilek-Snyder, G., Cammack, N., and 
Schiffer, C. A. (2006a). Substrate Envelope and Drug Resistance: Crystal 
Structure of RO1 in Complex with Wild-Type Human Immunodeficiency Virus 
Type 1 Protease. Antimicrob Agents Chemother 50(4), 1518-1521. 
Prabu-Jeyabalan, M., Nalivaika, E., King, N. M., and Schiffer, C. A. (2004a). Structual 
basis for coevolution of the human immunodeficiency virus type 1 nucleocapsid-
p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 
78(22), 12446-12454. 
Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C. A. (2000a). How does a symmetric 
dimer recognize an asymmetric substrate? A substrate complex of HIV-1 
protease. J Mol Biol 301(5), 1207-20. 
Prabu-Jeyabalan, M., Nalivaika, E., and Schiffer, C. A. (2000b). How does a symmetric 
dimer recognize an asymmetric substrate? A substrate complex of HIV-1 
protease. J Mol Biol 301(5), 1207-20. 
Prabu-Jeyabalan, M., Nalivaika, E. A., King, N. M., and Schiffer, C. A. (2004b). 
Structural basis for coevolution of a human immunodeficiency virus type 1 
nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral 
protease. J Virol 78(22), 12446-54. 
Prabu-Jeyabalan, M., Nalivaika, E. A., Romano, K., and Schiffer, C. A. (2006b). 
Mechanism of substrate recognition by drug-resistant human immunodeficiency 
virus type 1 protease variants revealed by a novel structural intermediate. J Virol 
80(7), 3607-16. 
Prabu-Jeyabalan, M., Nalivaika, E. A., and Schiffer, C. A. (2002). Substrate shape 
determines specificity of recognition for HIV-1 protease: Analysis of crystal 
structures of six substrate complexes. Structure 10(3), 369-381. 
Preston, B. D., Poiesz, B. J., and Loeb, L. A. (1988). Fidelity of HIV-1 reverse 
transcriptase. Science 242(4882), 1168-71. 
Rekharsky, M., and Inoue, Y. (1998). Complexation Thermodynamics of Cyclodextrins. . 
Chem Rev. 98, 1875-1918. 
Renjifo, B., Gilbert, P., Chaplin, B., Msamanga, G., Mwakagile, D., Fawzi, W., and 
Essex, M. (2004). Preferential in-utero transmission of HIV-1 subtype C as 
compared to HIV-1 subtype A or D. AIDS 18(12), 1629-36. 
Robbins, A. H., Coman, R. M., Bracho-Sanchez, E., Fernandez, M. A., Gilliland, C. T., 
Li, M., Agbandje-McKenna, M., Wlodawer, A., Dunn, B. M., and McKenna, R. 
(2010). Structure of the unbound form of HIV-1 subtype A protease: comparison 
with unbound forms of proteases from other HIV subtypes. Acta 
Crystallographica. Section D: Biological Crystallography 66(Pt 3), 233-42. 
Roberts, J. D., Bebenek, K., and Kunkel, T. A. (1988). The accuracy of reverse 
transcriptase from HIV-1. Science 242(4882), 1171-3. 
Roberts, N. A. (1995). Drug-resistance patterns of saquinavir and other HIV proteinase 
inhibitors. AIDS 9 (supplement 2), S27-S32. 
Roberts, N. A., Martin , J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. 
B., Galpin, S. A., Handa, B. K., Kay, J., Krohn, A., and et al. (1990). Rational 
design of peptide-based HIV proteinase inhibitors. Science 248(4953), 358-61. 
184 
Robertson, D. L., Anderson, J. P., Bradac, J. A., Carr, J. K., Foley, B., Funkhouser, R. K., 
Gao, F., Hahn, B. H., Kalish, M. L., Kuiken, C., Learn, G. H., Leitner, T., 
McCutchan, F., Osmanov, S., Peeters, M., Pieniazek, D., Salminen, M., Sharp, P. 
M., Wolinsky, S., and Korber, B. (2000). HIV-1 nomenclature proposal. Science 
288(5463), 55-6. 
Robinson, B. S., Riccardi, K. A., Gong, Y. F., Guo, Q., Stock, D. A., Blair, W. S., Terry, 
B. J., Deminie, C. A., Djang, F., Colonno, R. J., and Lin, P. F. (2000). BMS-
232632, a highly potent human immunodeficiency virus protease inhibitor that 
can be used in combination with other available antiretroviral agents. 
Antimicrobial Agents and Chemotherapy 44(8), 2093-9. 
Rose, J. R., Salto, R., and Craik, C. S. (1993a). Regulation of autoproteolysis of the HIV-
1 and HIV-2 proteases with engineered amino acid substitutions. J Biol Chem 
268, 11939-11945. 
Rose, J. R., Salto, R., and Craik, C. S. (1993b). Regulation of HIV-1 and HIV-2 proteases 
with engineered amino acid substitutions. J Biol Chem 268(16), 11939-11945. 
Rose, R. B., Craik, C. S., and Stroud, R. M. (1998a). Domain flexibility in retroviral 
proteases:  structural implications for drug resistant mutations. Biochemistry 37, 
2607-2621. 
Rose, R. B., Craik, C. S., and Stroud, R. M. (1998b). Domain flexibility in retroviral 
proteases: structural implications for drug resistant mutations. Biochemistry 37(8), 
2607-21. 
Sadler, B. M., and Stein, D. S. (2002). Clinical pharmacology and pharmacokinetics of 
amprenavir. Annals of Pharmacotherapy 36(1), 102-18. 
Sanches, M., Krauchenco, S., Martins, N. H., Gustchina, A., Wlodawer, A., and 
Polikarpov, I. (2007a). Structural characterization of B and non-B subtypes of 
HIV-protease: insights into the natural susceptibility to drug resistance 
development. Journal of Molecular Biology 369(4), 1029-40. 
Sanches, M., Krauchenco, S., Martins, N. H., Gustchina, A., Wlodawer, A., and 
Polikarpov, I. (2007b). Structural characterization of B and non-B subtypes of 
HIV-protease: insights into the natural susceptibility to drug resistance 
development. J Mol Biol 369(4), 1029-40. 
Scott, W. R., and Schiffer, C. A. (2000). Curling of flap tips in HIV-1 protease as a 
mechanism for substrate entry and tolerance of drug resistance. Structure 8(12), 
1259-65. 
Shafer, R. W., Stevenson, D., and Chan, B. (1999). Human immunodeficiency virus 
reverse transcriptase and protease sequence database. Nucleic Acids Res 27(1), 
348-352. 
Shafer, R. W., and Vuitton, D. A. (1999). Highly active antiretroviral therapy (HAART) 
for the treatment of infection with human immunodeficiency virus type 1. 
Biomedicine and Pharmacotherapy 53(2), 73-86. 
Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C. M., Kati, 
W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanonda, 
S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, 
V., Grabowski, B., Granneman, G. R., Sun, E., Japour, A. J., Leonard, J. M., 
185 
Plattner, J. J., and Norbeck, D. W. (1998). ABT-378, a highly potent inhibitor of 
the human immunodeficiency virus protease. Antimicrobial Agents and 
Chemotherapy 42(12), 3218-24. 
Sharp, K. (2001). Entropy—enthalpy compensation: Fact or artifact? Prot. Sci. 10, 661-
667. 
Sharp, P. M., Robertson, D. L., and Hahn, B. H. (1995). Cross-species transmission and 
recombination of 'AIDS' viruses. Philosophical Transactions of the Royal Society 
of London. Series B: Biological Sciences 349(1327), 41-7. 
Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002). Isolation of a human 
gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. 
Nature 418(6898), 646-50. 
Sigurskjold, B. (2000). Exact analysis of competition ligand binding by displacement 
isothermal titration calorimetry. Anal Biochem 277(2), 260-266. 
Silva, A. M., Cachau, R. E., Sham, H. L., and Erickson, J. W. (1996). Inhibition and 
catalytic mechanism of HIV-1 aspartic protease. J Mol Biol 255(2), 321-46. 
Spira, S., Wainberg, M. A., Loemba, H., Turner, D., and Brenner, B. G. (2003a). Impact 
of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug 
resistance. J Antimicrob Chemother 51(2), 229-40. 
Spira, S., Wainberg, M. A., Loemba, H., Turner, D., and Brenner, B. G. (2003b). Impact 
of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug 
resistance. Journal of Antimicrobial Chemotherapy 51(2), 229-40. 
Steuber, H., Heine, A., and Klebe, G. (2007). Structural and thermodynamic study on 
aldose reductase: nitro-substituted inhibitors with strong enthalpic binding 
contribution. J Mol Biol 368(3). 
Stoica, I., Sadiq, S. K., and Coveney, P. V. (2008). Rapid and accurate prediction of 
binding free energies for saquinavir-bound HIV-1 proteases. J Am Chem Soc 130, 
2639-2648. 
Subbramanian, R. A., and Cohen, E. A. (1994). Molecular biology of the human 
immunodeficiency virus accessory proteins. Journal of Virology 68(11), 6831-5. 
Suguna, K., Padlan, E. A., Smith, C. W., Carlson, W. D., and Davies, D. R. (1987). 
Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus 
chinensis: implications for a mechanism of action. Proc Natl Acad Sci U S A 
84(20), 7009-13. 
Surleraux, D. L., de Kock, H. A., Verschueren, W. G., Pille, G. M., Maes, L. J., Peeters, 
A., Vendeville, S., De Meyer, S., Azijn, H., Pauwels, R., de Bethune, M. P., King, 
N. M., Prabu-Jeyabalan, M., Schiffer, C. A., and Wigerinck, P. B. (2005a). 
Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J Med 
Chem 48(6), 1965-73. 
Surleraux, D. L., Tahri, A., Verschueren, W. G., Pille, G. M., de Kock, H. A., Jonckers, 
T. H., Peeters, A., De Meyer, S., Azijn, H., Pauwels, R., de Bethune, M. P., King, 
N. M., Prabu-Jeyabalan, M., Schiffer, C. A., and Wigerinck, P. B. (2005b). 
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. 
J Med Chem 48(6), 1813-22. 
186 
Takeuchi, Y., Nagumo, T., and Hoshino, H. (1988). Low fidelity of cell-free DNA 
synthesis by reverse transcriptase of human immunodeficiency virus. Journal of 
Virology 62(10), 3900-2. 
Tisdale, M., Myers, R. E., Ait-Khaled, M., and Snowden, W. A. (1999). HIV drug 
resistance analysis during clinical studies with the protease inhibitor amprenavir. 
In "Sixth Conference on Retroviruses and Opportunistic Infections", Chicago, IL. 
Todd, M. J., and Freire, E. (1999a). The effect of inhibitor binding on the structural 
stability and cooperativity of the HIV-1 protease. Proteins 36(2), 147-56. 
Todd, M. J., and Freire, E. (1999b). The effect of inhibitor binding on the structural 
stability and cooperativity of the HIV-1 protease. Proteins 36(2), 147-56. 
Todd, M. J., Luque, I., Velazquez-Campoy, A., and Freire, E. (2000). Thermodynamic 
basis of resistance to HIV-1 protease inhibition:  calorimetric analysis of the 
V82F/I84V active site resistant mutant. Biochemistry 39, 11876-11883. 
Turner, S. R., Strohbach, J. W., Tommasi, R. A., Aristoff, P. A., Johnson, P. D., 
Skulnick, H. I., Dolak, L. A., Seest, E. P., Tomich, P. K., Bohanon, M. J., Horng, 
M. M., Lynn, J. C., Chong, K. T., Hinshaw, R. R., Watenpaugh, K. D., 
Janakiraman, M. N., and Thaisrivongs, S. (1998). Tipranavir (PNU-140690): a 
potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-
4-hydroxy-2-pyrone sulfonamide class. Journal of Medicinal Chemistry 41(18), 
3467-76. 
UNAIDS (2009). AIDS Epidemic Update 2009. UNAIDS. 
Valzaquez-Campoy, A., Luque, I., Todd, M. J., Milutinovich, M., Kiso, Y., and Freire, E. 
(2000). Thermodynamic dissection of the binding energetics of KNI-272, a potent 
HIV-1 protease inhibitor. Protein Sci 9(9), 1801-1809. 
Valzaquez-Campoy, A., Todd, M. J., and Freire, E. (2000). HIV-1 protease inhibitors: 
enthalpic versus entropic optimization of the binding affinity. Biochemistry 39, 
2201-7. 
Valzaquez-Campoy, A., Todd, M. J., Vega, S., and Freire, E. (2001). Catalytic efficiency 
and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U 
S A 98(11), 6062-7. 
Van Marck, H., Dierynck, I., Kraus, G., Hallenberger, S., Pattery, T., Muyldermans, G., 
Van Vijmen, H., Hertogs, K., and Bethune, M. (2007). Unraveling the complex 
resistance pathways of darunavir using the bioinformatics resistance 
determination (BIRD). In "XVI International HIV Drug Resistance Workshop", 
Barbados. 
Veerapandian, B., Cooper, J. B., Sali, A., Blundell, T. L., Rosati, R. L., Dominy, B. W., 
Damon, D. B., and Hoover, D. J. (1992). Direct observation by X-ray analysis of 
the tetrahedral "intermediate" of aspartic proteinases. Protein Sci 1(3), 322-8. 
Velazquez-Campoy, A., Todd, M. J., Vega, S., and Freire, E. (2001). Catalytic efficiency 
and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U 
S A 98(11), 6062-7. 
Velazquez-Campoy, A., Vega, S., Fleming, E., Bacha, U., Sayed, Y., Dirr, H. W., and 
Freire, E. (2003). Protease inhibition in African subtypes of HIV-1. AIDS Rev 
5(3), 165-71. 
187 
Velazquez-Campoy, A., Vega, S., and Freire, E. (2002). Amplification of the effects of 
drug resistance mutations by background polymorphisms in HIV-1 protease from 
African subtypes. Biochemistry 41(27), 8613-9. 
Vermeiren, H., Van Craenenbroeck, E., Alen, P., Bacheler, L., Picchio, G., and Lecocq, 
P. (2007). Prediction of HIV-1 drug susceptibility phenotype from the viral 
genotype using linear regression modeling. Journal of Virological Methods 
145(1), 47-55. 
Vondrasek, J., and Wlodawer, A. (2002). HIVdb: a database of the structures of human 
immunodeficiency virus protease. Proteins 47, 429-431. 
Wainberg, M. A. (2004). HIV-1 subtype distribution and the problem of drug resistance. 
AIDS 18 Suppl 3, S63-8. 
Wainberg, M. A., Martinez-Cajas, J. L., and Brenner, B. G. (2007). Strategies for the 
optimal sequencing of antiretroviral drugs toward overcoming and preventing 
drug resistance. Future HIV Therapy 1(3), 291-313. 
Wang, W. K., Chen, M. Y., Chuang, C. Y., Jeang, K. T., and Huang, L. M. (2000). 
Molecular biology of human immunodeficiency virus type 1. J Microbiol 
Immunol Infect 33(3), 131-40. 
Williams, T., and Kelley, C. (1998a). GNUPLOT. gnuplot 1986-1993.  
Williams, T., and Kelly, C. (1998). gnuplot 1986-1993, 1998, 2004. 
http://www.gnuplot.info. 
Wlodawer, A., and Erickson, J. W. (1993). Structure-based inhibitors of HIV-1 protease. 
Annu Rev Biochem 62, 543-585. 
Wyatt, R., and Sodroski, J. (1998). The HIV-1 envelope glycoproteins: fusogens, 
antigens, and immunogens. Science 280(5371), 1884-8. 
Yanchunas, J., Jr., Langley, D. R., Tao, L., Rose, R. E., Friborg, J., Colonno, R. J., and 
Doyle, M. L. (2005). Molecular basis for increased susceptibility of isolates with 
atazanavir resistance-conferring substitution I50L to other protease inhibitors. 
Antimicrobial Agents and Chemotherapy 49(9), 3825-32. 
Zheng, Y. H., Lovsin, N., and Peterlin, B. M. (2005). Newly identified host factors 
modulate HIV replication. Immunology Letters 97(2), 225-34. 
Zhou, P., Tian, F., Lv, F., and Shang, Z. (2009). Geometric characteristics of hydrogen 
bonds involving sulfur atoms in proteins. Proteins 76(1), 151-63. 
Ziermann, R., Limoli, K., Das, K., Arnold, E., Petropoulos, C. J., and Parkin, N. T. 
(2000). A mutation in human immunodeficiency virus type 1 protease, N88S, that 
causes in vitro hypersensitivity to amprenavir. J Virol 74(9), 4414-9. 
 
 
